include,reason,title,doi,pubmed_id
True," The study meets all the inclusion criteria as it involves a naturalistic setting, compares the economic outcomes of risperidone and haloperidol, and includes patients with schizophrenia and other psychotic disorders, bipolar disorder, and major depressive disorder.",economic outcomes associated with the use of risperidone in a naturalistic group practice setting.,nan,10178498
True," The study meets the inclusion criteria as it focuses on the effects of clozapine on cognitive functioning in schizophrenia, which is a relevant topic for the review.",the effects of clozapine on cognitive functioning in schizophrenia.,nan,10372607
True," The study meets all the inclusion criteria as it includes a meta-analysis of randomized, placebo-controlled trials of atypical antipsychotic drugs in patients with schizophrenia, bipolar disorder, and other conditions, and reports on efficacy and acceptability outcomes.","comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.",nan,10410494
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and it is a randomized controlled trial examining the efficacy and safety of quetiapine fumarate.",[early phase ii study of quetiapine fumarate on schizophrenia].,nan,10464776
True," The study meets the inclusion criteria as it focuses on the clinical efficacy of olanzapine in treating schizophrenia, which is one of the specified conditions, and it includes randomized controlled trials, which are a type of study included in the review.",[clinical efficacy of olanzapine].,nan,10495984
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness and economic outcomes of olanzapine and haloperidol in the treatment of schizophrenia in adults, which is within the specified age range and diagnosis criteria.",[economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in france].,nan,10546082
True," The study meets the inclusion criteria as it focuses on clozapine-treated patients, specifically examining the incidence of blood dyscrasias in Italy, and the study design aligns with the inclusion criteria for randomized controlled trials and observational studies.",blood dyscrasias in clozapine-treated patients in italy.,nan,10702809
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of eicosapentaenoic acid treatment in a patient with schizophrenia, and it reports on symptom remission, normalization of blood fatty acids, reduced neuronal membrane phospholipid turnover, and structural brain changes.","eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes.",nan,10750263
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of clozapine and haloperidol in patients with schizophrenia, and it examines the outcomes of medication continuation and compliance, which are relevant to the review.",medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.,nan,10847315
False," The study does not meet the inclusion criteria for interventions, as it only focuses on clozapine, which is one of the included interventions, but does not compare it to other interventions.",[clozapine in the treatment of schizophrenia].,nan,10959316
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of quetiapine in patients with schizophrenia, which is one of the specified patient populations.",neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.,nan,11291531
False," The study does not meet the inclusion criteria as it does not examine the effectiveness of clozapine in the specified patient populations, but rather a switch from clozaril to generic clozapine.",clinical effects of a randomized switch of patients from clozaril to generic clozapine.,nan,11305843
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of classic and atypical antipsychotic drugs in treating schizophrenia.",[subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].,nan,11324382
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and it compares the incidence of extrapyramidal symptoms in patients treated with olanzapine, haloperidol, and risperidone.","[incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].",nan,11333516
True," The study meets the inclusion criteria as it focuses on the cost-effectiveness of atypical antipsychotics for the treatment of schizophrenia, which is one of the specified conditions, and includes relevant outcomes such as quality of life, hospitalization, and adverse effects.",cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence.,nan,11527002
True," The study meets the inclusion criteria as it involves patients with schizophrenia or schizoaffective disorder, uses a medication event monitoring system to estimate medication compliance, and examines the relationship between medication compliance and hospital readmission.",use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia.,nan,11590972
True," The study meets all the inclusion criteria as it focuses on adults and adolescents with treatment-resistant schizophrenia, includes clozapine as an intervention, and assesses effectiveness outcomes such as quality of life, hospitalization, and symptom response.",pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.,nan,11743592
True," The study meets the inclusion criteria as it involves adults with a diagnosis of Parkinson's disease and drug-induced psychosis, and it examines the effectiveness of olanzapine as an intervention.",[usefulness of olanzapine in the levodopa-induced psychosis in patients with parkinson's disease].,nan,11834192
True," The study meets the inclusion criteria as it involves a comparison of two antipsychotic medications (olanzapine and risperidone) in the treatment of schizophrenia, which is one of the specified interventions, and it reports on effectiveness outcomes such as adherence, persistence, and hospitalization, which are also specified.",a retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.,nan,11875967
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders, and bipolar disorder, and examines the effectiveness of atypical antipsychotics (risperidone and olanzapine) in a prospective observational study.",[clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine].,nan,11878086
False," The study does not focus on the therapeutic characteristics of new drugs, but rather on the publication of randomized controlled trials on the safety and efficacy of new drugs.",new drugs with novel therapeutic characteristics. have they been subject to randomized controlled trials?,nan,12371307
True," The study focuses on the risk of severe ventricular arrhythmia and sudden death associated with neuroleptics, which is relevant to the review's inclusion criteria of examining harms of antipsychotic medications.",severe ventricular arrhythmia and sudden death on neuroleptics.,nan,12378746
False," The abstract does not meet the inclusion criteria as it does not specify the age range of the participants, which is a required criterion.",[schizoaffective disorder: clinical symptoms and present-day approach to treatment].,nan,12532717
True," The study meets the inclusion criteria as it focuses on aripiprazole, an atypical antipsychotic, and its pharmacology and clinical use, which aligns with the specified interventions in the review.",aripiprazole: a review of its pharmacology and clinical use,nan,12587943
False," The study focuses on bipolar disorder in children, adolescents, and adults, but the inclusion criteria specify that the review is focused on schizophrenia, including other psychotic disorders, and pervasive developmental disorders, which are not the primary focus of this study.",[new treatment for bipolar disorder in children and adolescents: learning from adult studies].,nan,12590372
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a relevant population for the review, and examines the effectiveness of olanzapine, a medication included in the review.",[effect of olanzapine treatment on cognitive functions in patients with schizophrenia].,nan,12725025
True," The study meets the inclusion criteria as it involves patients with schizophrenia treated with olanzapine, and it examines the effectiveness of the treatment on memory functions.",[subjective and objective assessment of memory functions in patients with schizophrenia treated with olanzapine].,nan,12725026
True," The study meets the inclusion criteria as it reviews the pharmacologic management of agitation in psychiatric patients, specifically examining the effectiveness of benzodiazepines, typical and atypical antipsychotics, and their combination, and includes randomized controlled trials and good-quality systematic reviews.","[benzodiazepines, typical and atypical antipsychotics in the management of acute agitation: a review].",nan,12844280
False," The study population does not match the inclusion criteria as it includes only normal subjects, not individuals with schizophrenia, bipolar disorder, major depressive disorder, or other specified conditions.",actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.,nan,12921224
False," The title and abstract do not match the inclusion criteria, as the study appears to focus on methodological and regulatory features of clinical trials for behavioral and psychological symptoms in dementia, but the inclusion criteria specify a broad range of psychiatric conditions, including schizophrenia, bipolar disorder, and pervasive developmental disorders.",[methodological and regulatory features of clinical trials for behavioral and psychological symptoms in the course of dementia].,nan,14587227
False," The study population does not match the inclusion criteria as it specifically focuses on patients with parkinsonian syndromes, not schizophrenia, bipolar disorder, major depressive disorder, or other conditions listed in the inclusion criteria.",[clozapine in the treatment of mental manifestations of parkinson disease].,nan,7481376
True," The study meets the inclusion criteria as it involves a comparison of dosing regimens of clozapine in European and American patients with schizophrenia, examining efficacy and side effects, which aligns with the specified interventions and outcomes of interest.",a comparison of european and american dosing regimens of schizophrenic patients on clozapine: efficacy and side effects.,nan,7491385
False," The study does not meet the inclusion criteria as it does not involve human subjects, but rather focuses on animal data.",is it possible to predict the clinical effects of neuroleptics from animal data? part v: from haloperidol and pipamperone to risperidone.,nan,7514873
True," The study meets the inclusion criteria as it focuses on predictors of clozapine response in schizophrenia, which is a relevant topic for the review.",predictors of clozapine response in schizophrenia.,nan,7525541
False," The study population specified in the abstract (chronic schizophrenic patients) does not match the inclusion criteria, which includes a broader range of patient populations such as adults with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",pharmacokinetics of risperidone in chronic schizophrenic patients.,nan,7530379
True," The study meets the inclusion criteria as it involves adults (age 61-79 years) with a diagnosis of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia, and examines the efficacy of risperidone, which is an intervention included in the review.","efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.",nan,7592504
True," The study meets the inclusion criteria as it focuses on the efficacy and tolerability of clozapine in severe mood disorders, including schizophrenia, bipolar disorder, schizoaffective disorder, and major depression, and reports on the effectiveness and side effect profile of clozapine in these conditions.",clozapine in severe mood disorders.,nan,7665540
True," The study meets the inclusion criteria as it involves adolescents with schizophrenia, a specific population of interest, and examines the effects of clozapine, a medication included in the review, on biogenic amines and symptomatology.",[effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].,nan,7856324
True," The study meets the inclusion criteria as it involves adults with refractory schizophrenia, a condition included in the review, and examines the effectiveness of clozapine, an intervention included in the review.",[clozapine and refractory schizophrenia. long-term prospective study of 20 patients].,nan,7875111
True," The study meets the inclusion criteria as it involves adults with refractory bipolar disorder, a condition included in the review, and examines the effectiveness of clozapine as a mood stabilizer, which is an intervention included in the review.",is clozapine a mood stabilizer?,nan,7883728
False," The study population specified in the abstract (patients with tardive dyskinesia) does not match the inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",clozapine in tardive dyskinesia: observations from human and animal model studies.,nan,7961550
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and it examines the effectiveness of clozapine, a medication included in the review.",plasma clozapine concentrations as a predictor of clinical response: a follow-up study.,nan,7961554
True," The study meets the inclusion criteria as it examines the effects of clozapine on noradrenergic function in patients with schizophrenia, which is a relevant population for the review.",clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy.,nan,7961555
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and it examines the effectiveness of clozapine, which is an intervention included in the review.",plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.,nan,7961557
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations, but rather investigates the immunogenic mechanism of clozapine-induced cytotoxicity.",51cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism.,nan,7961559
True," The study meets the inclusion criteria as it investigates the association of clozapine treatment and weight gain in patients with chronic schizophrenia, which is a relevant population for the review.",clozapine and weight gain.,nan,7961563
False," The study does not meet the inclusion criteria for patient population as it only includes adults with schizophrenia, whereas the review includes a broader range of patient populations, including adolescents and children with various psychiatric disorders.",clozapine effects on glucose metabolic rate in striatum and frontal cortex.,nan,7961576
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a relevant population for the review, and examines the effectiveness of clozapine, a medication included in the review, on cognitive function, a relevant outcome.",effects of clozapine on cognitive function in schizophrenia.,nan,7961582
True," The study population includes adults with treatment-refractory mood disorders, specifically bipolar disorder, which falls within the inclusion criteria.",clozapine in treatment-refractory mood disorders.,nan,7961583
True," The study meets the inclusion criteria as it involves adolescents with childhood-onset schizophrenia, a relevant population for this review, and examines the relationship between plasma clozapine and haloperidol concentrations and clinical response.",plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.,nan,7961584
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the effectiveness and harms of clozapine treatment, including seizures as a potential side effect.",seizures associated with clozapine treatment in a state hospital.,nan,8071267
False," The study population in the abstract does not match the inclusion criteria, as it includes adults and adolescents with various psychiatric conditions, but does not specifically focus on adults (18 years and older) and adolescents (13-17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders.",risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.,nan,8851645
True," The study focuses on the importance of long-term, randomized field trials in comparing costs and outcomes of clozapine versus standard therapy for psychopharmacologic therapies of severe mental disorders, which aligns with the specified inclusion criteria.",pharmaceutical decisionmaking: pharmacoepidemiology or pharmacoeconomics--who's in the driver's seat?,nan,8851647
True," The study meets the inclusion criteria as it involves risperidone-treated schizophrenia patients, which is one of the interventions included in the review.",serotonin-mediated increase in cytosolic [ca++] in platelets of risperidone-treated schizophrenia patients.,nan,8927657
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, a randomized controlled trial, and examines the effectiveness of Seroquel (ICI 204,636) in comparison to chlorpromazine and placebo in terms of plasma prolactin levels.","plasma prolactin in schizophrenia subjects treated with seroquel (ici 204,636).",nan,8927658
True," The study meets all the inclusion criteria as it involves a head-to-head comparison of two antipsychotics (zotepine and haloperidol) in patients with acute exacerbation of schizophrenia, a randomized, double-blind design, and reports on effectiveness outcomes such as symptom response and adverse effects.","a comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.",nan,8927680
False," The study does not meet the inclusion criteria for interventions, as it only includes olanzapine, whereas the review includes a range of antipsychotics.",obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.,nan,8927681
False," The study population does not match the inclusion criteria as it only includes adults with Parkinson's disease and iatrogenic psychosis, whereas the inclusion criteria specify a wide range of psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",melperone in the treatment of iatrogenic psychosis in parkinson's disease.,nan,8934152
True," The study meets all the inclusion criteria as it involves adults with a diagnosis of schizophrenia, compares the efficacy and safety of risperidone with haloperidol, and assesses various outcomes such as efficacy, safety, and quality of life.",[risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].,nan,8984849
False," The abstract does not match the inclusion criteria as it discusses polypharmacy in bipolar I disorder, but the inclusion criteria specify a broad range of psychiatric conditions, including schizophrenia, major depressive disorder, and pervasive developmental disorders, among others, which are not mentioned in the abstract.",polypharmacy in bipolar i disorder.,nan,8993078
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness and safety of adjunctive risperidone in treatment-refractory OCD patients, which is a relevant population for this review.",therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (ocd).,nan,8993091
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of clozapine in patients with schizophrenia, which is one of the specified patient populations, and reports on relevant outcomes such as hospitalization, symptom response, and quality of life.",clozapine's effectiveness for patients in state hospitals: results from a randomized trial.,nan,8993092
True," The study meets the inclusion criteria as it involves a longitudinal analysis of patients receiving clozapine, a medication included in the review, and examines the effectiveness and harms of the treatment in patients with schizophrenia and other psychiatric disorders.",longitudinal analysis of abnormal involuntary movements in long-term clozapine-treated patients.,nan,8993093
False," The study population specified in the abstract (young children with autistic disorder) does not match the inclusion criteria for children with pervasive developmental disorders, which includes autistic disorder, but is limited to children under 13 years old, and the study population in the abstract is specified as 5 to 9 years old.",an open clinical trial of risperidone monotherapy in young children with autistic disorder.,nan,9133768
True," The study meets the inclusion criteria as it involves a population with schizophrenia, schizoaffective disorder, or schizophreniform disorder, and examines the association between substance abuse and tardive dyskinesia.","substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.",nan,9133772
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (e.g. schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",risperidone: effects of formulations on oral bioavailability,nan,9165565
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of haloperidol and remoxipride in patients with schizophrenia, and it assesses quality of life as an outcome measure.",quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. the canadian remoxipride group.,nan,9262046
True," The study meets the inclusion criteria as it involves a cost-effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain, which is a relevant population for this review.",[cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in spain].,nan,9412161
False," The study population does not match the inclusion criteria as it only includes healthy male volunteers, whereas the review is focused on patients with various psychiatric disorders.",the effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone,nan,9469675
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of sertindole and haloperidol in the treatment of schizophrenia, which is a relevant population for this review.",long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. the sertindole study group.,nan,9564200
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the relationship between extrapyramidal side effects and negative symptoms of schizophrenia, and includes a comparison between two antipsychotic medications (haloperidol and olanzapine).",the relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.,nan,9564201
True," The study population includes adults and adolescents with schizophrenia, bipolar disorder, and other psychiatric conditions, which aligns with the inclusion criteria.",risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting.,nan,9564202
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, a specific population of interest in the review, and examines the effects of aripiprazole, an intervention included in the review.",spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole.,nan,9580382
True," The study meets the inclusion criteria as it is a randomized controlled trial comparing the efficacy of risperidone with lithium and haloperidol in the treatment of mania, which is a relevant intervention for the review.",risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.,nan,9617509
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the efficacy and tolerability of risperidone, which is an intervention included in the review.",efficacy and tolerability of risperidone in chronic schizophrenic thai patients.,nan,9623031
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, examines the effectiveness of clozapine, and reports on outcomes such as impulsiveness, aggressiveness, and suicidality.","diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.",nan,9704166
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, systematic review, or comparative observational study examining the relationship between medication and outcomes in the specified patient populations.",lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.,nan,9855322
True," The study meets the inclusion criteria as it focuses on the comparison of conventional and newer antipsychotics in elderly patients, which is within the specified age range (≥ 65 years of age) and addresses the treatment of behavioral and psychological symptoms of dementia, a condition included in the review.",conventional vs. newer antipsychotics in elderly patients.,nan,9919323
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy of olanzapine and haloperidol in patients with treatment-resistant schizophrenia.,"comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia∗∗see accompanying editorial, in this issue.",https://doi.org/10.1016/s0006-3223(98)00291-1,10071708
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of d-cycloserine added to clozapine in patients with schizophrenia, which is one of the interventions included in the review.",a placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia,https://doi.org/10.1016/s0006-3223(98)00367-9,10071726
False," The study population does not match the inclusion criteria as it specifically includes patients with Parkinson's disease, which is not mentioned in the inclusion criteria.",low-dose clozapine for the treatment of drug-induced psychosis in parkinson's disease,https://doi.org/10.1056/nejm199903113401003,10072410
False," The study population specified in the abstract (neuroleptic-treated schizophrenic inpatients) does not match the inclusion criteria, which include a broader range of patient populations such as adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and others.",comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia,https://doi.org/10.1159/000026565,10072664
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of an intervention (errorless learning approach) on cognitive rehabilitation.",errorless learning and the cognitive rehabilitation of memory-impaired schizophrenic patients,https://doi.org/10.1017/s0033291798007673,10077298
True," The study meets all the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia or schizoaffective disorder, and examines the predictors of relapse following response to a first episode of these disorders.",predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder,https://doi.org/10.1001/archpsyc.56.3.241,10078501
False," The study population does not match the inclusion criteria as it only includes patients with dementia, whereas the inclusion criteria specify a wide range of psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia,https://doi.org/10.4088/jcp.v60n0207,10084637
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (e.g., aripiprazole, clozapine, etc.) in the specified patient populations.",no evidence for association of serotonin-2a receptor variant (102t/c) with schizophrenia or clozapine response in a chinese population,https://doi.org/10.1097/00001756-199901180-00011,10094133
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing risperidone with placebo and other antipsychotic agents in patients with chronic schizophrenia, and examines the severity of extrapyramidal symptoms.",a combined analysis of double‐blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms,https://doi.org/10.1111/j.1600-0447.1999.tb00972.x,10100910
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of ziprasidone in patients with schizophrenia and schizoaffective disorder, and reports on effectiveness and tolerability outcomes.",ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder a 6-week placebo-controlled trial,https://doi.org/10.1016/s0893-133x(98)00090-6,10192829
True," The study meets the inclusion criteria as it involves a randomized controlled trial of amisulpride in patients with schizophrenia, specifically those with primary negative symptoms, and reports on efficacy and safety outcomes.",improvement of schizophrenic patients with primary negative symptoms treated with amisulpride,https://doi.org/10.1176/ajp.156.4.610,10200742
False," The abstract does not match the specified inclusion criteria as it discusses sudden infant death syndrome, child sexual abuse, and child development, which are not within the specified age ranges or diagnostic criteria for the review.","sudden infant death syndrome, child sexual abuse, and child development",https://doi.org/10.1097/00008480-199904000-00013,10202629
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy, tolerability, and safety of olanzapine and haloperidol in the treatment of schizoaffective disorder, which is a relevant condition for the review.",olanzapine versus haloperidol in the treatment of schizoaffective disorder,https://doi.org/10.1192/bjp.174.1.15,10211146
True," The study meets all the inclusion criteria as it involves a randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol, which are both included interventions, and the study examines the effectiveness outcome of tardive dyskinesia, which is a relevant outcome for this review.",randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol,https://doi.org/10.1192/bjp.174.1.23,10211147
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, comparative observational study, or systematic review, but rather a genetic association study examining the relationship between a specific polymorphism and schizophrenia.",schizophrenia and the serotonin-2a receptor promoter polymorphism,https://doi.org/10.1016/s0165-1781(99)00002-5,10220013
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the distribution of body mass index among individuals with and without schizophrenia.",the distribution of body mass index among individuals with and without schizophrenia,https://doi.org/10.4088/jcp.v60n0402,10221280
False," The study focuses on psychotropic drugs in mothers' milk, which does not match the inclusion criteria of the review, which focuses on adults and adolescents with specific psychiatric disorders.","psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding",https://doi.org/10.1177/026988119901300108,10221361
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effects of clozapine and typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia, which is a relevant population for this review.",a comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia,https://doi.org/10.1016/s0920-9964(98)00145-5,10227103
True," The study meets the inclusion criteria as it involves elderly patients (≥ 65 years of age) with a diagnosis of schizophrenia or schizoaffective disorder, and it examines the safety, tolerability, and efficacy of risperidone, which is an intervention included in the review.",risperidone in the treatment of elderly patients with psychotic disorders,https://doi.org/10.1097/00019442-199905000-00006,10322240
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of olanzapine and placebo in the treatment of acute mania, which is a relevant intervention for the review.",olanzapine versus placebo in the treatment of acute mania,https://doi.org/10.1176/ajp.156.5.702,10327902
True," The study meets all the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, examines the effectiveness of clozapine treatment, and assesses the relationship between akathisia and psychopathology.",does akathisia influence psychopathology in psychotic patients treated with clozapine?,https://doi.org/10.1016/s0006-3223(98)00146-2,10349044
True," The study meets the inclusion criteria as it focuses on bipolar disorder in old age, which falls within the specified age range of 65 years and older, and examines the clinical characteristics, epidemiology, and management of the disorder in this population.",bipolar disorder in old age,https://doi.org/10.1007/0-306-47521-9_8,10349067
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of bipolar disorder, type I, and examines the underdiagnosis of bipolar disorder and the overutilization of antidepressants in its treatment.",is bipolar disorder still underdiagnosed? are antidepressants overutilized?,https://doi.org/10.1016/s0165-0327(98)00076-7,10357026
True," The study meets all the inclusion criteria as it involves adults with refractory schizophrenia, a randomized controlled trial, and examines the effectiveness and cost-effectiveness of clozapine compared to haloperidol.",cost-effectiveness of clozapine in patients with high and low levels of hospital use,https://doi.org/10.1001/archpsyc.56.6.565,10359474
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the effectiveness of two second-generation antipsychotics, risperidone and clozapine, in reducing rehospitalization rates.",rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine,https://doi.org/10.1176/ajp.156.6.863,10360124
False," The study does not meet the inclusion criteria as it does not examine the effectiveness or harms of the specified interventions (clozapine, aripiprazole, asenapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations.",small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders,https://doi.org/10.1097/00007691-199906000-00017,10365650
True," The study meets the inclusion criteria as it involves older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, and it compares the incidence of tardive dyskinesia between risperidone and haloperidol.",lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients,https://doi.org/10.1111/j.1532-5415.1999.tb01595.x,10366172
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a DSM-III-R or DSM-IV diagnosis, and examines the effectiveness of clozapine, which is an intervention included in the review.",clinical outcome to clozapine treatment in chronic psychiatric inpatients,https://doi.org/10.1016/s0278-5846(98)00087-6,10368852
True," The study meets the inclusion criteria as it focuses on negative symptoms in schizophrenia, discusses neurobiological models and treatment response, and includes relevant interventions and outcomes.",negative symptoms in schizophrenia: neurobiological models and treatment response,https://doi.org/10.3109/10673229809000313,10370450
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine in patients who did not respond to olanzapine.",treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response,https://doi.org/10.1016/s0006-3223(99)00029-3,10394475
True," The study meets the inclusion criteria as it involves a population with schizophrenia, uses olanzapine as an intervention, and examines sleep outcomes.",olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency,https://doi.org/10.1016/s0006-3223(98)00372-2,10394486
True," The study meets the inclusion criteria as it involves a population with schizophrenia, a specific type of antipsychotic medication (risperidone), and assesses effectiveness outcomes such as symptom response, hospitalization, and quality of life.",switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome,https://doi.org/10.1016/s0149-2918(99)80003-4,10397376
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and examines the effectiveness of novel antipsychotics in terms of weight gain liabilities.",novel antipsychotics: comparison of weight gain liabilities.,https://doi.org/10.4088/jcp.v60n0602,10401912
False," The study population in this article consists of outpatients with schizophrenia or schizoaffective disorder, which does not match the inclusion criteria of patients with bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia.",lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients,https://doi.org/10.4088/jcp.v60n0604,10401914
True," The study meets the inclusion criteria as it involves adults and adolescents with a diagnosis of mania, which falls under the bipolar disorder category, and includes quantitative EEG studies.",clinical and quantitative eeg studies of mania,https://doi.org/10.1016/s0165-0327(98)00124-4,10404707
True," The study meets the inclusion criteria as it focuses on the effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia, which is a relevant topic for the review paper.",the effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis,https://doi.org/10.1093/oxfordjournals.schbul.a033374,10416727
True," The study meets the inclusion criteria as it involves a head-to-head comparison of two antipsychotic medications (risperidone and haloperidol) in patients with treatment-resistant schizophrenia, which is a relevant population for this review.",risperidone versus haloperidol on secondary memory: can newer medications aid learning?,https://doi.org/10.1093/oxfordjournals.schbul.a033375,10416728
True," The study meets the inclusion criteria as it involves a randomized controlled trial of a cognitive remediation program for patients with schizophrenia, which is a relevant population for the review.",the effects of neurocognitive remediation on executive processing in patients with schizophrenia,https://doi.org/10.1093/oxfordjournals.schbul.a033379,10416732
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of a specific intervention (glucose availability) on memory performance, which is a relevant outcome for the review.",glucose-induced increase in memory performance in patients with schizophrenia,https://doi.org/10.1093/oxfordjournals.schbul.a033381,10416734
False," The title and abstract do not mention any specific interventions or outcomes related to the inclusion criteria, and the workshop appears to be a discussion of future research directions rather than a presentation of research findings.","antipsychotics: past and future national institute of mental health division of services and intervention research workshop, july 14, 1998",https://doi.org/10.1093/oxfordjournals.schbul.a033387,10416740
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of two antipsychotic medications (olanzapine and haloperidol).","reliability, validity, and application of the medical outcomes study 36-item short-form health survey (sf-36) in schizophrenic patients treated with olanzapine versus haloperidol",https://doi.org/10.1097/00005650-199907000-00008,10424639
True," The study meets the inclusion criteria as it involves adults with schizophrenia, examines the effects of smoking abstinence on psychiatric symptoms, and is a randomized controlled trial.",nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia,https://doi.org/10.1016/s0893-133x(98)00121-3,10432467
False," The study population specified in the abstract is chronic schizophrenic patients with prominent negative symptoms, which does not match the inclusion criteria of patients with schizophrenia (including first episode and treatment resistance), bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.","d-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics a double-blind, parallel, placebo-controlled study",https://doi.org/10.1016/s0893-133x(99)00014-7,10432468
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effectiveness of an atypical antipsychotic (olanzapine), and reports on outcomes such as quality of life and hospitalization.","the psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome",https://doi.org/10.1016/s0006-3223(99)00040-2,10435201
False," The study population does not match the inclusion criteria as it only includes patients with dystonia, which is not one of the specified conditions in the inclusion criteria.",an open trial of clozapine for dystonia,https://doi.org/10.1002/1531-8257(199907)14:4<652::aid-mds1015>3.0.co;2-g,10435503
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in treating cannabis-induced psychotic disorder, which is a condition included in the review.",a comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial,https://doi.org/10.1097/00004850-199905002-00005,10435771
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of a specific intervention (mianserin) for a condition (neuroleptic-induced akathisia) that is relevant to the review.,treatment of neuroleptic-induced akathisia with the 5-ht2 antagonist mianserin,https://doi.org/10.1192/bjp.174.3.238,10448449
True," The study meets the inclusion criteria as it involves a randomized controlled trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania, which is a relevant population for this review.",clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania,https://doi.org/10.1176/ajp.156.8.1164,10450255
True," The study meets the inclusion criteria as it involves adults with a diagnosis of borderline personality disorder and psychoses, and it examines the effectiveness of clozapine in reducing severe self-mutilation and aggression.",clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder,https://doi.org/10.4088/jcp.v60n0710,10453803
False," The study population specified in the abstract (patients with schizophrenia) does not match the inclusion criteria (patients with schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",safety of amisulpride (solian??): a review of 11 clinical studies,https://doi.org/10.1097/00004850-199907000-00002,10468313
True," The study meets the inclusion criteria as it involves older adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, and examines the effectiveness and safety of risperidone and olanzapine in this population.",experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.,https://doi.org/10.1023/a:1022351725541,10482120
True," The study meets the inclusion criteria as it involves a population with schizophrenia, a relevant intervention (clozapine), and relevant outcomes (awareness of illness and cognition).",effects of clozapine on awareness of illness and cognition in schizophrenia,https://doi.org/10.1016/s0165-1781(99)00033-5,10482343
True," The study meets the inclusion criteria as it involves adults and adolescents with treatment-refractory schizophrenia, and it is a randomized controlled trial comparing the efficacy and safety of risperidone to haloperidol.",risperidone in treatment-refractory schizophrenia,https://doi.org/10.1176/ajp.156.9.1374,10484947
False," The study population is limited to hospitalized patients with bipolar disorder, whereas the inclusion criteria specify a broader range of psychiatric disorders, including schizophrenia, major depressive disorder, and pervasive developmental disorders.",elevated frequency of diabetes mellitus in hospitalized manic-depressive patients,https://doi.org/10.1176/ajp.156.9.1417,10484954
False," The study population specified in the abstract is patients with obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or pervasive developmental disorders.",olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors,https://doi.org/10.4088/jcp.v60n0804,10485634
True," The study meets the inclusion criteria as it focuses on adults with a diagnosis of schizophrenia, specifically late-onset schizophrenia, and discusses the clinical presentation, longitudinal course, and treatment options for this population.",late-onset schizophrenia,https://doi.org/10.2165/00002512-199915020-00002,10495068
True," The study meets the inclusion criteria as it involves adults with treatment-resistant schizophrenia, a condition included in the review, and examines the effectiveness of olanzapine, one of the interventions included in the review.",olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study,https://doi.org/10.1177/070674379904400709,10500873
False," The study does not meet the inclusion criteria for interventions, as it involves the addition of fluvoxamine to clozapine, which is not one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial,https://doi.org/10.1055/s-2007-979221,10505485
True," The study meets all the inclusion criteria as it involves a randomized, double-blind comparison of a pharmacologically similar agent (olanzapine) with placebo in patients who have abruptly discontinued clozapine, and it examines the effectiveness of olanzapine in preventing clozapine discontinuation symptoms.","controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo",https://doi.org/10.1097/00004714-199910000-00007,10505585
False," The title and abstract of the paper do not match the specified inclusion criteria, as the paper focuses on autism and related neuropsychiatric disorders, whereas the inclusion criteria specify schizophrenia, bipolar disorder, major depressive disorder, and other conditions.",psychopharmacology in autism,https://doi.org/10.1097/00006842-199909000-00008,10511014
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a specific population of interest, and examines the effects of two antipsychotic medications, clozapine and fluphenazine, on brain metabolic patterns.",the brain metabolic patterns of clozapine- and fluphenazine-treated female patients with schizophrenia evidence of a sex effect,https://doi.org/10.1016/s0893-133x(99)00065-2,10516959
False," The study population is patients with bipolar I disorder, which does not match the inclusion criteria of patients with schizophrenia, including other psychotic disorders, or bipolar disorder (manic or depressive phases, rapid cycling, mixed states).",the comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar i disorder,https://doi.org/10.1097/00004850-199909000-00002,10529070
False," The title and abstract do not match the specified inclusion criteria, which focus on schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders, whereas the abstract discusses Alzheimer's disease.",diagnosis and management of alzheimer disease,https://doi.org/10.3122/jabfm.12.5.375,10534086
True," The study meets the inclusion criteria as it is a comparative effectiveness study of two atypical antipsychotics (risperidone and olanzapine) in the treatment of schizophrenia, which is within the scope of the review.",a comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia,https://doi.org/10.4088/jcp.v60n1003,10549681
True," The study meets all the inclusion criteria as it focuses on antipsychotic-induced weight gain, includes various antipsychotic agents, and examines their effects on body weight in patients with different psychiatric conditions.",antipsychotic-induced weight gain: a comprehensive research synthesis,https://doi.org/10.1176/ajp.156.11.1686,10553730
True," The study meets the inclusion criteria as it involves a randomized controlled trial of clozapine in patients with treatment-refractory schizophrenia or schizoaffective disorder, which is one of the interventions included in the review.",double-blind study of clozapine dose response in chronic schizophrenia,https://doi.org/10.1176/ajp.156.11.1744,10553738
False," The study does not meet the inclusion criteria for interventions, as it involves the addition of d-serine to clozapine, which is not one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) included in the review.",d-serine added to clozapine for the treatment of schizophrenia,https://doi.org/10.1176/ajp.156.11.1822,10553752
True," The study meets all the inclusion criteria as it involves patients with schizophrenia, uses a randomized controlled trial design, and examines the effectiveness of risperidone compared to typical antipsychotic drugs.",differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia,https://doi.org/10.1073/pnas.96.23.13432,10557338
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing olanzapine to lithium in the treatment of mania, which is one of the interventions included in the review.",olanzapine compared to lithium in mania: a double-blind randomized controlled trial,https://doi.org/10.1097/00004850-199911000-00003,10565800
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, but rather an open-label pilot study.",lack of efficacy of the 5-ht3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia,https://doi.org/10.1097/00004850-199911000-00006,10565803
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of antipsychotic medications in patients with schizophrenia, and it compares retention rates between placebo-controlled and nonplacebo-controlled trials.",retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia,https://doi.org/10.1177/070674379904400904,10584158
True, The study meets the inclusion criteria as it involves a retrospective cohort study examining the effectiveness of risperidone in reducing hospital days in patients with schizophrenia-spectrum disorders.,hospital days in risperidone-treated patients,https://doi.org/10.1177/070674379904400907,10584161
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a condition included in the review, and examines the effectiveness and harms of clozapine, an intervention included in the review.",myocarditis and cardiomyopathy associated with clozapine,https://doi.org/10.1016/s0140-6736(99)10385-4,10584719
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",measuring neuroleptic-induced akathisia by three-channel actometry,https://doi.org/10.1016/s0920-9964(99)00045-6,10593450
False," The study does not meet the inclusion criteria as it is focused on the pharmacokinetic analysis of a drug interaction between felodipine and grapefruit juice, and does not involve any of the specified patient populations or interventions.",pharmacokinetic analysis of felodipine–grapefruit juice interaction based on an irreversible enzyme inhibition model,https://doi.org/10.1046/j.1365-2125.2000.00140.x,10606837
False," The study population is healthy volunteers, not individuals with schizophrenia, bipolar disorder, or other psychiatric conditions specified in the inclusion criteria.",effect of caffeine on clozapine pharmacokinetics in healthy volunteers,https://doi.org/10.1046/j.1365-2125.2000.00111.x,10606838
False, The study does not meet the inclusion criteria as it does not involve interventions (medications) that are included in the review.,brain event-related potentials (erps) in schizophrenia during a word recognition memory task,https://doi.org/10.1016/s0167-8760(99)00082-3,10610049
False," The study does not meet the inclusion criteria as it does not involve interventions (medications) for schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia, which are the focus of the review.",differential memory span — abnormal lateralization pattern in schizophrenic patients and their siblings?,https://doi.org/10.1016/s0167-8760(99)00087-2,10610054
True," The study meets all the inclusion criteria as it involves a head-to-head comparison of amisulpride and risperidone in patients with acute exacerbations of schizophrenia, which is a relevant population for this review.",amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia,https://doi.org/10.1016/s0165-1781(99)00075-x,10622347
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the relationship between parkinsonism and cognitive functioning in an institutionalized geriatric population.",prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia,https://doi.org/10.1002/(sici)1099-1166(200001)15:1<7::aid-gps69>3.0.co;2-z,10637399
False," The title and abstract do not match the specified inclusion criteria, which focus on specific psychiatric and neurological disorders, whereas the title and abstract are about dementia in developing countries.",dementia in developing countries. a consensus statement from the 10/66 dementia research group.,https://doi.org/10.1002/(sici)1099-1166(200001)15:1<14::aid-gps70>3.0.co;2-8,10637400
True," The study meets the inclusion criteria as it focuses on the epidemiology of psychotropic drug use in patients with severe mental disorders in Italy, which aligns with the specified population of interest.",pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in italy,https://doi.org/10.1007/s002280050694,10638400
True," The study meets the inclusion criteria as it involves a specific antipsychotic (risperidone) and antidepressant (mirtazapine) combination, which is one of the interventions included in the review, and it assesses the pharmacokinetic interaction and tolerability of this combination.",lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study,https://doi.org/10.1016/s0924-977x(99)00054-1,10647097
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a disorder included in the review, and examines the effectiveness of neuroleptic medication, which is also included in the review.",effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients,https://doi.org/10.1016/s0006-3223(99)00229-2,10650450
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of clozapine with conventional antipsychotic medication in patients with refractory schizophrenia, and it examines outcomes such as symptom response, quality of life, and adherence.",how long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia,https://doi.org/10.1093/oxfordjournals.schbul.a033412,10667741
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of risperidone in patients with a first psychotic episode, which is a relevant population for this review.",risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study,https://doi.org/10.1093/oxfordjournals.schbul.a033413,10667742
True," The study meets all the inclusion criteria as it reviews atypical antipsychotic agents for various psychiatric and neurologic conditions, including schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, and examines their efficacy and adverse effects.",atypical antipsychotic agents: a critical review,https://doi.org/10.1093/ajhp/57.3.238,10674777
True," The study meets the inclusion criteria as it involves patients with first episode schizophrenia, a diagnosis included in the review, and examines the effectiveness of olanzapine and risperidone, both of which are included interventions.",dopamine d2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia,https://doi.org/10.1016/s0925-4927(99)00032-3,10688158
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effects of two antipsychotic medications (risperidone and haloperidol) on sustained attention deficits in patients with schizophrenia.,effects of atypical neuroleptics on sustained attention deficits in schizophrenia a trial of risperidone versus haloperidol,https://doi.org/10.1016/s0893-133x(99)00137-2,10693159
False," The study population does not match the inclusion criteria as it only includes healthy male volunteers, whereas the review focuses on patients with various psychiatric disorders.",olanzapine increases slow-wave sleep: evidence for blockade of central 5-ht2c receptors in vivo,https://doi.org/10.1016/s0006-3223(99)00273-5,10704958
True," The study meets the inclusion criteria as it involves adults with a diagnosis of psychosis, specifically women with schizophrenia, and examines the relationship between oestrogen levels and extrapyramidal symptoms.",extrapyramidal symptoms and oestrogen,https://doi.org/10.1034/j.1600-0447.2000.90067.x,10706013
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a specific population of interest, and examines the effects of atypical antipsychotics on the inflammatory response system.",effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics,https://doi.org/10.1016/s0924-977x(99)00062-0,10706993
False," The study population specified in the abstract is young patients with unipolar depression, which does not match the inclusion criteria of adults (age 18 years and older) with major depressive disorder.",executive functioning and verbal memory in young patients with unipolar depression and schizophrenia,https://doi.org/10.1016/s0165-1781(99)00110-9,10708264
False," The study population specified in the abstract is treatment-resistant bipolar disorder patients, which does not match the inclusion criteria of patients with schizophrenia, including other psychotic disorders, or patients with bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia.",mexiletine in treatment-resistant bipolar disorder,https://doi.org/10.1016/s0165-0327(99)00072-5,10708839
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of olanzapine, risperidone, and haloperidol.","neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol",https://doi.org/10.1001/archpsyc.57.3.249,10711911
True," The study meets all the inclusion criteria as it is a randomized controlled trial comparing the efficacy and tolerability of quetiapine and haloperidol in patients with schizophrenia, and it reports on outcomes such as symptom response, adverse effects, and withdrawals due to adverse events.","a multicentre, double-blind, randomized comparison of quetiapine (ici 204,636, ‘seroquel’) and haloperidol in schizophrenia",https://doi.org/10.1017/s0033291799001476,10722180
True," The study meets all the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenic disorders, examines the effectiveness of a psychoeducational multiple-family group intervention, and reports on outcomes such as negative symptoms, relapse, and quality of life.",management of negative symptoms among patients with schizophrenia attending multiple-family groups,https://doi.org/10.1176/appi.ps.51.4.513,10737828
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of adults with first-episode schizophrenia, examines the relationship between dopamine D2 occupancy and clinical response, and includes outcomes such as clinical improvement, hyperprolactinemia, and extrapyramidal side effects.","relationship between dopamine d2 occupancy, clinical response, and side effects: a double-blind pet study of first-episode schizophrenia",https://doi.org/10.1176/appi.ajp.157.4.514,10739409
False, The study does not meet the inclusion criteria as it does not involve any interventions (medications) that are included in the review.,impaired prepulse inhibition of acoustic startle in schizophrenia,https://doi.org/10.1016/s0006-3223(99)00148-1,10745060
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of clozapine in various patient populations, including adults and adolescents with schizophrenia, bipolar disorder, and other conditions, and reports on outcomes such as mortality, quality of life, and symptom response.",influence of methodology on outcomes of randomised clozapine trials,https://doi.org/10.1055/s-2000-7971,10761820
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (e.g., aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations.",subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia,https://doi.org/10.1097/00004714-200004000-00018,10770464
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of glycine added to clozapine in adults with schizophrenia, which is one of the interventions included in the review.",placebo-controlled trial of glycine added to clozapine in schizophrenia,https://doi.org/10.1176/appi.ajp.157.5.826,10784481
False," The study population does not match the specified inclusion criteria as it focuses on adults and adolescents with various psychiatric disorders, which is not relevant to the current study on prepartum and postpartum depressed mood.",psychosocial correlates of prepartum and postpartum depressed mood,https://doi.org/10.1016/s0165-0327(99)00128-7,10814768
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia and other psychotic disorders, and examines the effectiveness and safety of second-generation antipsychotics in the emergency care setting.",second-generation antipsychotics in the emergency care setting. a prospective naturalistic study,https://doi.org/10.1016/s0163-8343(00)00055-4,10822097
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of risperidone with conventional neuroleptics in patients with chronic schizophrenia, and it examines outcomes such as symptom response, adherence, and persistence, which are relevant to the review.",longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia,https://doi.org/10.1097/00004714-200006000-00002,10831015
False," The study does not meet the inclusion criteria as it is not focused on the treatment of schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia, and it is not a randomized controlled trial examining the relationship between medication adherence or persistence and improved outcomes.","risperidone for the treatment of cocaine dependence: randomized, double-blind trial",https://doi.org/10.1097/00004714-200006000-00003,10831016
False," The study does not meet the inclusion criteria for interventions, as it only focuses on clozapine, which is one of the included interventions, but the study does not examine the effectiveness or harms of clozapine in comparison to other interventions.",sudden death in patients receiving clozapine treatment: a preliminary investigation,https://doi.org/10.1097/00004714-200006000-00006,10831019
True," The study meets the inclusion criteria as it involves adults with schizophrenia or schizoaffective disorder, a specific antipsychotic medication (clozapine), and examines outcomes such as weight gain, lipid abnormalities, and diabetes mellitus.","clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study",https://doi.org/10.1176/appi.ajp.157.6.975,10831479
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of amisulpride in patients with schizophrenia, includes effectiveness outcomes such as quality of life and functional capacity, and reports on harms such as adverse events and withdrawals due to adverse events.",long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia,https://doi.org/10.1097/00004850-200015010-00002,10836281
False," The study does not meet the inclusion criteria as it does not involve any of the interventions listed (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) and does not examine the effectiveness or harms of these interventions.",reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a 31p chemical shift spectroscopic-imaging study,https://doi.org/10.1016/s0006-3223(00)00235-3,10838063
True," The study meets the inclusion criteria as it involves a randomized controlled trial of quetiapine in patients with schizophrenia, examining its effects on dopamine D2 receptor occupancy and clinical efficacy.",a positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine d2 receptor occupancy,https://doi.org/10.1001/archpsyc.57.6.553,10839333
False," The study population specified in the abstract (acute schizophrenic patients) does not match the inclusion criteria, which include patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, among others.",neue bzw. atypische neuroleptika bei schizophrener negativsymptomatik,https://doi.org/10.1007/s001150050568,10846709
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features, and examines the effectiveness of clozapine in these populations.","clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder",https://doi.org/10.4088/jcp.v61n0502,10847306
True, The study meets the inclusion criteria as it involves a comparison of olanzapine with other antipsychotic drugs in a nonselected patient cohort treated according to routine clinical practice.,the safety of olanzapine compared with other antipsychotic drugs,https://doi.org/10.4088/jcp.v61n0503,10847307
True," The study meets the inclusion criteria as it involves a comparison of the effects of two antipsychotic medications (clozapine and olanzapine) on EEG in patients with schizophrenia, which is a relevant population for the review.",a comparison of the effects of clozapine and olanzapine on the eeg in patients with schizophrenia,https://doi.org/10.1055/s-2000-7976,10855462
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, and examines the effectiveness of novel antipsychotic drugs compared to conventional antipsychotics in terms of subjective tolerability, side-effect profile, and impact on quality of life.","comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life",https://doi.org/10.1016/s0920-9964(99)00154-1,10858632
True," The study meets the inclusion criteria as it involves elderly patients with psychosis, specifically schizophrenia, and examines the long-term effects of risperidone, which is an intervention included in the review.","a long-term, multicenter, open-label study of risperidone in elderly patients with psychosis",https://doi.org/10.1002/1099-1166(200006)15:6<506::aid-gps146>3.0.co;2-v,10861916
False," The abstract does not mention any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (e.g. schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders) that are relevant to the review.",simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry,https://doi.org/10.1002/1096-9888(200006)35:6<718::aid-jms999>3.0.co;2-o,10862124
False," The study population specified in the abstract (adults with atypical antipsychotics and weight gain) does not match the inclusion criteria, which include a broader range of patient populations and outcomes.",atypical antipsychotics and weightgain — a systematic review,https://doi.org/10.1034/j.1600-0447.2000.101006416.x,10868465
True," The study meets the inclusion criteria as it involves elderly patients (≥ 65 years of age) with behavioral and psychological symptoms of dementia, and examines the effectiveness of risperidone, which is an intervention included in the review.",low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone,https://doi.org/10.1176/appi.ajp.157.7.1150,10873925
False," The abstract does not specify the age range of the participants, but it mentions adolescents (13-17 years) and older adults (≥ 65 years), but does not explicitly state that it includes adults (18-64 years).",clozapine augmentation: safety and efficacy,https://doi.org/10.1093/oxfordjournals.schbul.a033463,10885641
True," The study meets the inclusion criteria as it involves adults with schizophrenia and substance use disorder, and examines the effectiveness of clozapine in reducing alcohol and drug use.",the effects of clozapine on alcohol and drug use disorders among patients with schizophrenia,https://doi.org/10.1093/oxfordjournals.schbul.a033464,10885642
True," The study meets the inclusion criteria as it involves patients with schizophrenia treated with clozapine, which is one of the interventions included in the review, and examines the electrocardiographic abnormalities associated with clozapine treatment.",electrocardiographic abnormalities in patients treated with clozapine,https://doi.org/10.4088/jcp.v61n0609,10901343
False," The study population specified in the abstract (autistic disorder and other pervasive developmental disorders) does not match the inclusion criteria, which includes a broader range of disorders such as schizophrenia, bipolar disorder, and disruptive behavior disorders.",the pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders,https://doi.org/10.1080/hrp_8.2.45,10902094
False," The study population is adults with developmental stuttering, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders.",risperidone for the treatment of stuttering,https://doi.org/10.1097/00004714-200008000-00013,10917410
False," The study population is not adults with schizophrenia, including other psychotic disorders, or bipolar disorder, which are the primary populations of interest for this review.","a double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor–refractory obsessive-compulsive disorder",https://doi.org/10.1001/archpsyc.57.8.794,10920469
True," The study meets the inclusion criteria as it involves a randomized controlled trial of olanzapine in patients with severe Gilles de la Tourette syndrome, which is one of the interventions included in the review.",olanzapine in severe gilles de la tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide,https://doi.org/10.1007/s004150070173,10929273
True," The study meets the inclusion criteria as it involves adults with refractory schizophrenia or schizoaffective disorder, and it compares the efficacy of risperidone and clozapine, which are included interventions in the review.",comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder,https://doi.org/10.4088/jcp.v61n0707,10937608
True," The study meets the inclusion criteria as it involves adults and adolescents with a diagnosis of schizophrenia and other psychotic disorders, and it examines the efficacy and safety of a specific antipsychotic medication (sertindole).","efficacy, cardiac safety and tolerability of sertindole: a drug surveillance",https://doi.org/10.1097/00004850-200015040-00003,10954060
False," The study population does not match the inclusion criteria as it includes nonpsychotic subjects with renal or hepatic impairment, whereas the review focuses on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions.",single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment,https://doi.org/10.1016/s0278-5846(00)00090-7,10958148
False," The study does not focus on the effectiveness or harms of antipsychotic drugs in the specified patient populations, but rather on the haematological safety of antipsychotic drugs in general.",haematological safety of antipsychotic drugs,https://doi.org/10.1177/026988119801200309,10958256
True," The study meets the inclusion criteria as it is a randomized, double-blind, placebo-controlled trial examining the efficacy of olanzapine in the treatment of acute bipolar mania, which is one of the specified conditions of interest.","efficacy of olanzapine in acute bipolar mania<subtitle>a double-blind, placebo-controlled study</subtitle>",https://doi.org/10.1001/archpsyc.57.9.841,10986547
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in patients with schizophrenia, a condition included in the review, and reports on relevant outcomes such as quality of life, hospitalization, and functional capacity.",functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a european sample,https://doi.org/10.1097/00004850-200015050-00001,10993126
True," The study meets the inclusion criteria as it compares two types of instruments for assessing health-related quality of life in schizophrenia, which is a relevant topic for the review.",quality of life in schizophrenia: a comparison of instruments,https://doi.org/10.1093/oxfordjournals.schbul.a033484,10993404
False," The study population specified in the abstract (patients with Parkinson's disease and chronic hallucinations) does not match the inclusion criteria (adults with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions).",olanzapine and clozapine: comparative effects on motor function in hallucinating pd patients.,10.1212/wnl.55.6.789,10993997
False," The study population does not match the inclusion criteria as it only includes patients with Parkinson's disease (PD) and levodopa-induced dyskinesias, whereas the inclusion criteria specify a range of psychiatric disorders and conditions.",low-dose olanzapine for levodopa induced dyskinesias,https://doi.org/10.1212/wnl.55.6.795,10993998
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, which is one of the specified conditions, and examines the effectiveness of an intervention (intravenous biperiden) on a specific outcome (akathisia).",intravenous biperiden in akathisia: an open pilot study,https://doi.org/10.2190/rafd-axdf-rjad-fl1r,11001281
False," The study population does not match the inclusion criteria as it specifically includes patients with Alzheimer's disease, whereas the inclusion criteria specify a range of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities,https://doi.org/10.1001/archpsyc.57.10.968,11015815
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing clozapine with conventional antipsychotic medications in patients with schizophrenia, and it examines cost-effectiveness and effectiveness outcomes.",cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals,https://doi.org/10.1001/archpsyc.57.10.987,11015817
False," The abstract does not match the inclusion criteria as it focuses on the treatment of acute bipolar mania, but the inclusion criteria specify a broader range of conditions, including schizophrenia, major depressive disorder, and behavioral and psychological symptoms of dementia, among others.",pharmacologic agents for the treatment of acute bipolar mania,https://doi.org/10.1016/s0006-3223(00)00961-6,11018226
False," The abstract does not mention any of the specified disorders (schizophrenia, pervasive developmental disorders, disruptive behavior disorders, behavioral and psychological symptoms of dementia, or major depressive disorder) or interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapone, risperidone, or ziprasidone) included in the review.",bipolar disorder therapeutics: maintenance treatment,https://doi.org/10.1016/s0006-3223(00)00991-4,11018228
True," The study meets the inclusion criteria as it focuses on treatment refractory schizophrenia, a specific population of interest, and reviews various interventions and outcomes relevant to the review paper.",treatment refractory schizophrenia.,https://doi.org/10.1023/a:1004640408501,11025914
True," The study meets the inclusion criteria as it focuses on refractory schizophrenia, a specific population of interest, and examines the effect of clozapine on family burden, which is a relevant outcome for this review.",clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia,https://doi.org/10.4088/jcp.v61n0913,11030488
True," The study meets the inclusion criteria as it involves adults with schizophrenia who are refractory to or unable to tolerate clozapine, and it examines the effectiveness of olanzapine, which is an intervention included in the review.",the effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine,https://doi.org/10.1016/s0149-2918(00)80082-x,11048902
False," The study population is limited to patients with schizophrenia or schizoaffective disorder, which does not meet the inclusion criteria of the review, which includes a broader range of psychiatric conditions.",nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia,https://doi.org/10.1176/appi.ajp.157.11.1835,11058482
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effects of risperidone on patients with schizophrenia, which is one of the specified conditions of interest.",immediate effects of risperidone on cortico–striato–thalamic loops and the hippocampus,https://doi.org/10.1192/bjp.177.5.402,11059992
True," The study meets all the inclusion criteria as it involves neuroleptic-naive patients with schizophrenia or other psychotic disorders, compares the side effects of risperidone and haloperidol, and uses a prospective study design.",neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone,https://doi.org/10.1212/wnl.52.4.782,11061283
False," The study population in this paper does not match the inclusion criteria as it includes individuals younger than 60 years of age with idiopathic venous thromboembolism, which does not align with the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study,https://doi.org/10.1016/s0140-6736(00)02784-7,11072939
True," The study meets the inclusion criteria as it is about the treatment of schizophrenia with iloperidone, an atypical antipsychotic agent, and discusses its efficacy and tolerability in phase II trials.",an assessment of iloperidone for the treatment of schizophrenia,https://doi.org/10.1517/13543784.9.12.2935,11093363
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a specific intervention (clozapine), and examines effectiveness outcomes such as symptom response and adherence.",association study of apolipoprotein eε4with clinical phenotype and clozapine response in schizophrenia,https://doi.org/10.1159/000026689,11096331
False," The abstract does not discuss the effectiveness or harms of atypical antipsychotics in the specified patient populations, but rather presents a commentary on the prescribing practices and the results of a study by Geddes et al.",atypical antipsychotics,https://doi.org/10.1136/bmj.321.7273.1360,11099266
True," The study meets all the inclusion criteria as it includes adults and adolescents with schizophrenia, and examines the effectiveness and tolerability of atypical antipsychotics compared to conventional antipsychotics in a systematic overview and meta-regression analysis.",atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis,https://doi.org/10.1136/bmj.321.7273.1371,11099280
False," The article does not meet the inclusion criteria as it is about Tourette Syndrome, not the specified psychiatric conditions (schizophrenia, bipolar disorder, major depressive disorder, etc.) and does not mention any of the specified interventions (aripiprazole, asenapine, clozapine, etc.).",current issues in tourette syndrome,https://doi.org/10.1002/1531-8257(200011)15:6<1051::aid-mds1001>3.0.co;2-l,11104186
False," The study population does not match the inclusion criteria as it specifically targets patients with Parkinson's disease experiencing dopamine-induced psychosis, which is not one of the specified patient populations.",risperidone in the treatment of dopamine-induced psychosis in parkinson's disease: an open pilot trial,https://doi.org/10.1002/1531-8257(200011)15:6<1230::aid-mds1026>3.0.co;2-9,11104211
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness and safety of switching from conventional antipsychotic drugs or risperidone to olanzapine in patients with schizophrenia or schizoaffective disorder.,strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine,https://doi.org/10.4088/jcp.v61n1105,11105736
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of a specific intervention (antipsychotic medication) in a population with schizophrenia, but rather aims to establish reference ranges for hematologic parameters in patients with schizophrenia.",hematologic reference ranges in a population of patients with schizophrenia,https://doi.org/10.1097/00004714-200012000-00011,11106137
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of clozapine, which is an intervention included in the review.",the effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics,https://doi.org/10.1016/s0893-133x(00)00172-x,11106875
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of risperidone, an intervention included in the review.",effects of risperidone on affective symptoms in patients with schizophrenia,https://doi.org/10.1097/00004850-200015060-00005,11110010
True," The study meets the inclusion criteria as it is a randomized, double-blind, multi-center trial comparing the effectiveness of risperidone and haloperidol in patients with schizophrenia and disturbing neuroleptic-induced extrapyramidal symptoms.","risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial",https://doi.org/10.1016/s0920-9964(00)00009-8,11120421
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of a novel antipsychotic medication (risperidone) in improving cognitive skills.",practice-related improvement in information processing with novel antipsychotic treatment,https://doi.org/10.1016/s0920-9964(00)00033-5,11120426
False," The study population specified in the abstract (adults with treatment-resistant depression) does not match the inclusion criteria, which focuses on various psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",a novel augmentation strategy for treating resistant major depression,https://doi.org/10.1176/appi.ajp.158.1.131,11136647
True," The study meets the inclusion criteria as it involves a population with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of risperidone on seclusion and restraint.",impact of risperidone on seclusion and restraint at a state psychiatric hospital,https://doi.org/10.1177/070674370004500907,11143833
False," The study does not examine the effectiveness or harms of clozapine, but rather investigates the association between clozapine-induced agranulocytosis and genetic polymorphisms of clozapine metabolizing enzymes.",clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome p4502d6,https://doi.org/10.1055/s-2000-8359,11147929
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and examines the effectiveness of a medication (ciprofloxacin) in relation to another medication (clozapine).",ciprofloxacin increases serum clozapine and n-desmethylclozapine: a study in patients with schizophrenia,https://doi.org/10.1007/s002280000192,11151749
True," The study meets the inclusion criteria as it examines the effectiveness of clozapine in reducing arrest rates in patients with psychotic disorders, which is a relevant population for this review.",clozapine-associated reduction in arrest rates of psychotic patients with criminal histories,https://doi.org/10.1176/appi.ajp.158.2.270,11156810
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of olanzapine versus clozapine in treatment-resistant schizophrenic patients, which is a relevant population for this review.",double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine,https://doi.org/10.1016/s0006-3223(00)01026-x,11163780
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness of atypical antipsychotics in the specified patient populations, but rather examines the consistency of atypical antipsychotic superiority to placebo in clinical trials.",consistency of atypical antipsychotic superiority to placebo in recent clinical trials,https://doi.org/10.1016/s0006-3223(00)00973-2,11163781
False," The study population is children with bipolar disorder, which does not match the inclusion criteria of adults (18 years and older) and adolescents (13-17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, or major depressive disorder.",decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder,https://doi.org/10.1016/s0893-133x(00)00207-4,11182531
True," The study focuses on the use of risperidone in patients with various disorders other than schizophrenia, which aligns with the inclusion criteria.",does risperidone have a place in the treatment of nonschizophrenic patients?,https://doi.org/10.1097/00004850-200101000-00001,11195255
True," The study meets the inclusion criteria as it focuses on the treatment of refractory schizophrenia with atypicals, specifically evaluating the effectiveness of clozapine, olanzapine, and risperidone, which are all included interventions.",refractory schizophrenia and atypical antipsychotics,https://doi.org/10.1177/026988110001400411,11198061
True," The study meets the inclusion criteria as it involves adults with schizoaffective disorder, a condition included in the review, and it is a randomized controlled trial examining the effectiveness of ziprasidone, an intervention included in the review.","ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies",https://doi.org/10.1097/00004714-200102000-00007,11199944
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a DSM-III-R diagnosis, and examines the effects of atypical antipsychotics on autonomic neurocardiac function.","effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine",https://doi.org/10.1097/00004714-200102000-00003,11199953
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder, whereas the review includes a broader range of patient populations.",the effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine,https://doi.org/10.1097/00004714-200102000-00016,11199955
True," The study meets the inclusion criteria as it involves a population with a DSM-IV diagnosis of schizophrenia, a randomized controlled trial design, and examines the effects of acute tryptophan depletion on symptoms, mood, and cognition.",acute tryptophan depletion in schizophrenia,https://doi.org/10.1017/s0033291799003062,11200962
True," The study meets the inclusion criteria as it involves the treatment of drug-induced psychosis in Parkinson's disease, which is a relevant population for this review, and it is a randomized controlled trial examining the effectiveness and safety of clozapine.",clozapine for the treatment of drug-induced psychosis in parkinson's disease: results of the 12 week open label extension in the psyclops trial,https://doi.org/10.1002/1531-8257(200101)16:1<135::aid-mds1006>3.0.co;2-q,11215574
True," The study meets the inclusion criteria as it focuses on adults and adolescents with schizophrenia and other psychotic disorders, and examines the frequency, amount, and conditions of bodyweight gain during treatment with atypical antipsychotics.",bodyweight gain with atypical antipsychotics,https://doi.org/10.2165/00002018-200124010-00005,11219487
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of pindolol augmentation in patients with schizophrenia, which is a relevant population for the review.",pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study,https://doi.org/10.1097/00004850-200103000-00006,11236069
True," The study meets all the inclusion criteria as it involves adults (male geriatric inpatients) with a diagnosis of psychosis, uses atypical antipsychotics (risperidone and olanzapine) as interventions, and examines effectiveness and tolerability outcomes.",tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients,https://doi.org/10.1002/1099-1166(200102)16:2<223::aid-gps323>3.0.co;2-r,11241729
False," The study population is treatment-resistant depression, which is not included in the specified inclusion criteria.",adjunctive gabapentin in treatment-resistant depression: a retrospective chart review,https://doi.org/10.1016/s0165-0327(00)00187-7,11246103
False," The title and abstract do not mention any specific medication or intervention, but rather a class of medications (atypical antipsychotics), which does not match the specified inclusion criteria of specific medications (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",the new atypical antipsychotics: a review of pharmacoeconomic studies,https://doi.org/10.1517/14656566.1.2.249,11249546
False," The abstract does not mention any of the specified patient populations or interventions, and the study appears to focus on the methodology for evaluating multiple surrogate endpoints rather than the effectiveness of specific treatments for the specified conditions.",the evaluation of multiple surrogate endpoints,https://doi.org/10.1111/j.0006-341x.2001.00081.x,11252622
True," The study meets the inclusion criteria as it involves a randomized controlled trial of a medication (olanzapine) in patients with bipolar I disorder, specifically focusing on first-episode manic patients.",response to placebo among bipolar i disorder patients experiencing their first manic episode,https://doi.org/10.1034/j.1399-5618.2000.020407.x,11252646
True," The study meets the inclusion criteria as it focuses on the treatment of late-life schizophrenia with neuroleptic medication, which is within the specified age range (adults ≥ 65 years of age) and includes effectiveness outcomes such as symptom response and quality of life.",neuroleptic treatment of late-life schizophrenia,https://doi.org/10.1080/10673220127880,11266405
False," The study does not focus on the effectiveness or harms of specific antipsychotic medications, but rather on the trends and costs of antipsychotic prescription use in a specific population.",antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts,https://doi.org/10.1016/s0920-9964(00)00108-0,11278146
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of chronic schizophrenia, examines the effects of olanzapine and other antipsychotics on cognitive function, and is a longitudinal study.",effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study,https://doi.org/10.1016/s0920-9964(00)00112-2,11278151
True," The study meets the inclusion criteria as it involves a randomized controlled trial with adults with schizophrenia, examines the effectiveness of estrogen as an adjunctive treatment, and reports on symptom response as an outcome of interest.",estrogen — a potential treatment for schizophrenia,https://doi.org/10.1016/s0920-9964(00)00088-8,11278160
True," The study meets all the inclusion criteria as it involves a review and meta-analysis of randomized trials in patients with treatment-resistant schizophrenia, comparing the efficacy and tolerability of typical and second-generation antipsychotics, specifically focusing on clozapine and olanzapine.",effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials,https://doi.org/10.1176/appi.ajp.158.4.518,11282684
True," The study meets the inclusion criteria as it involves first-episode schizophrenia patients treated with risperidone, and it examines the effects of the medication on basal ganglia volumes.",an mri study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone,https://doi.org/10.1176/appi.ajp.158.4.625,11282699
True," The study meets the inclusion criteria as it focuses on the pharmacotherapy of schizophrenia in a short-term inpatient setting, includes relevant interventions (e.g., haloperidol, risperidone, olanzapine, quetiapine), and outcomes (e.g., symptom response, adherence, persistence), and is based on a systematic review of existing literature.",short-term inpatient pharmacotherapy of schizophrenia,https://doi.org/10.1080/10673220127892,11287404
False," The study population does not match the inclusion criteria as it only includes patients with refractory mood and schizoaffective disorders, whereas the review includes a broader range of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders,https://doi.org/10.1016/s0165-0327(00)00215-9,11292518
False," The study population does not match the inclusion criteria as it specifically focuses on patients with intellectual disability and bipolar spectrum disorders, whereas the inclusion criteria include a broader range of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders,https://doi.org/10.1046/j.1365-2788.2001.00330.x,11298253
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with psychotic disorders, whereas the inclusion criteria include children under 13 years with various disorders.",risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation,https://doi.org/10.4088/jcp.v62n0303,11305699
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, specifically first-episode schizophrenia, and compares the effectiveness of risperidone and typical antipsychotics.",a comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic,https://doi.org/10.4088/jcp.v62n0308,11305704
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia and related psychoses, and examines the effects of olanzapine on the QTc interval.",analysis of the qtc interval during olanzapine treatment of patients with schizophrenia and related psychosis,https://doi.org/10.4088/jcp.v62n0310,11305706
True," The study meets the inclusion criteria as it is a randomized double-blind study comparing the efficacy and safety of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder, which falls within the specified patient populations and interventions of interest.",a randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder,https://doi.org/10.1176/appi.ajp.158.5.765,11329400
False," The study population specified in the abstract (children and adolescents with paediatric bipolar disorder) does not match the inclusion criteria, which includes adults and adolescents with schizophrenia, bipolar disorder, and other specified disorders, but does not include children under 13 years with bipolar disorder.",special issues in the treatment of paediatric bipolar disorder,https://doi.org/10.1517/14656566.2.4.613,11336611
False," The study does not meet the inclusion criteria as it is a case report of two patients with new-onset diabetes mellitus resulting from olanzapine treatment, which does not fit the specified interventions (antipsychotics) or patient populations for the review.",olanzapine-induced diabetes mellitus,https://doi.org/10.1345/aph.10280,11346063
False," The abstract does not mention any of the specified disorders (schizophrenia, bipolar disorder, major depressive disorder, pervasive developmental disorders, disruptive behavior disorders, or behavioral and psychological symptoms of dementia) or the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapone, risperidone, and ziprasidone) that are the focus of the review.",alzheimer's disease and related disorders.,10.1016/s0025-7125(05)70341-2,11349485
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (e.g., aripiprazole, clozapine, etc.) in the specified patient populations, but rather examines the genetic linkage of a specific serotonin receptor polymorphism to schizophrenia.",a family‐based study of the cys23ser 5ht2c serotonin receptor polymorphism in schizophrenia,https://doi.org/10.1002/ajmg.1260,11353441
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a relevant population for the review, and examines the effectiveness of clozapine, a medication included in the review.",detecting improvement in quality of life and symptomatology in schizophrenia,https://doi.org/10.1093/oxfordjournals.schbul.a006869,11354590
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-IV diagnosis of schizophrenia, compares the effectiveness of two antipsychotic medications (olanzapine and risperidone), and examines weight gain as an outcome.",weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone,https://doi.org/10.1016/s0920-9964(00)00080-3,11356587
True," The study meets the inclusion criteria as it examines the relation between antipsychotic drugs and myocarditis and cardiomyopathy, and uses data mining with Bayesian statistics in an international database.",antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study,https://doi.org/10.1136/bmj.322.7296.1207,11358771
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a DSM-III diagnosis, and examines the effects of clozapine treatment on EEG and symptoms.",quantitative eeg in schizophrenia and in response to acute and chronic clozapine treatment,https://doi.org/10.1016/s0920-9964(00)00165-1,11378313
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and it examines the effectiveness of atypical antipsychotic drugs on subjective well-being, which is a relevant outcome measure for medication compliance.",improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs,https://doi.org/10.1016/s0920-9964(00)00166-3,11378316
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of risperidone and haloperidol in long-term hospitalized chronic patients with schizophrenia.,risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis,https://doi.org/10.1016/s0920-9964(00)00163-8,11378317
True," The study meets the inclusion criteria as it involves children with a schizophrenic parent, and it examines the diagnosis and treatment of psychiatric disorders in this population, which is relevant to the review's focus on interventions for patients with schizophrenia and related disorders.",diagnosis and treatment of psychiatric disorders in children with a schizophrenic parent,https://doi.org/10.1016/s0920-9964(00)00043-8,11378320
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia treated with olanzapine, haloperidol, or risperidone, and examines the factors influencing acute weight change.","factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone",https://doi.org/10.4088/jcp.v62n0404,11379836
False," The study population is adolescents with subaverage cognitive abilities and disruptive behavior disorders, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, pervasive developmental disorders, or disruptive behavior disorders.",a randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities,https://doi.org/10.4088/jcp.v62n0405,11379837
False," The study population specified in the abstract (patients with DSM-IV bipolar I disorder) does not match the inclusion criteria for bipolar disorder, which includes manic or depressive phases, rapid cycling, mixed states, and does not specify bipolar I disorder.",long-term olanzapine therapy in the treatment of bipolar i disorder,https://doi.org/10.4088/jcp.v62n0410,11379842
False," The study focuses on the optimal dosing of risperidone, which is not within the specified interventions included in the review (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",optimal dosing with risperidone,https://doi.org/10.4088/jcp.v62n0411,11379843
False," The study does not meet the inclusion criteria as it is a methodological paper focused on developing a rapid capillary electrophoretic method for the determination of clozapine and desmethylclozapine in human plasma, rather than an effectiveness trial or observational study examining the outcomes of clozapine treatment.",rapid capillary electrophoretic method for the determination of clozapine and desmethylclozapine in human plasma,https://doi.org/10.1016/s0021-9673(01)00520-9,11382303
True," The study meets all the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of ziprasidone in reducing acute agitation associated with psychosis, which is one of the interventions included in the review.","intramuscular (im) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial",https://doi.org/10.1007/s002130000658,11401000
True," The study meets the inclusion criteria as it involves a comparison of the effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients, which is a relevant intervention for the review, and it is a randomized controlled trial.",effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients,https://doi.org/10.1016/s0306-4530(01)00016-6,11403983
False," The title and abstract do not mention the specific intervention amisulpride, but rather discuss the consensus on its practical use, which does not match the specified inclusion criteria of focusing on amisulpride.","consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia",https://doi.org/10.1159/000054913,11408792
True," The study focuses on the treatment of suicidality in schizophrenia, which meets the inclusion criteria of the review.",treatment of suicidality in schizophrenia,https://doi.org/10.1111/j.1749-6632.2001.tb05797.x,11411190
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the therapeutic effect of risperidone and haloperidol in patients with schizophrenia.,rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial,https://doi.org/10.4088/jcp.v62n0506,11411815
True," The study meets the inclusion criteria as it examines the effects of ziprasidone on plasma lipids and glucose levels in patients with schizophrenia and other psychotic disorders, and it is a randomized controlled trial, which is a type of study included in the review.",the apparent effects of ziprasidone on plasma lipids and glucose,https://doi.org/10.4088/jcp.v62n0507,11411816
False," The study population does not meet the inclusion criteria as it specifically targets preschool children with pervasive developmental disorders, whereas the inclusion criteria specify children under 13 years old with pervasive developmental disorders, including autistic disorder, Asperger’s disorder, pervasive developmental disorder not otherwise specified, but the age range is not specified as preschool.",risperidone monotherapy in preschool children with pervasive developmental disorders,https://doi.org/10.1177/088307380101600602,11417603
False," the study does not meet the inclusion criteria as it involves a 12-year-old girl with acute necrotizing encephalopathy, which is not within the specified age range or diagnosis of the review.",acute necrotizing encephalopathy presenting as a basal ganglia syndrome,https://doi.org/10.1177/088307380101600618,11417619
False," The study does not meet the inclusion criteria as it is about the use of typical antipsychotic agents in bipolar disorder, not schizophrenia or other psychotic disorders, and does not examine the effectiveness or harms of specific antipsychotic medications.",a meta-analysis of the use of typical antipsychotic agents in bipolar disorder,https://doi.org/10.1016/s0165-0327(00)00162-2,11426515
True," The study meets the inclusion criteria as it is a randomized controlled trial comparing the efficacy and safety of intramuscular olanzapine and haloperidol for the treatment of acute agitation in schizophrenia, which is a relevant population for this review.","double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia",https://doi.org/10.1176/appi.ajp.158.7.1149,11431240
False," The abstract does not mention any of the specified disorders or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, disruptive behavior disorders) that are the focus of the review.",treatment of alzheimer's disease,https://doi.org/10.1016/s1098-3597(01)90046-8,11432120
False," The abstract does not mention any of the specified conditions (schizophrenia, bipolar disorder, major depressive disorder, pervasive developmental disorders, disruptive behavior disorders, or behavioral and psychological symptoms of dementia) or the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) that are the focus of the review.",long-term care in dementia: patients and caregivers,https://doi.org/10.1016/s1098-3597(01)90048-1,11432122
True," The study meets the inclusion criteria as it involves randomized controlled trials of antipsychotic drugs, which are relevant to the review's focus on interventions for various psychiatric disorders.",dropout rates in randomised antipsychotic drug trials,https://doi.org/10.1007/s002130100711,11432684
False," The study population does not match the inclusion criteria as it only includes patients with schizophrenia, whereas the review includes a broader range of psychiatric disorders.",effects of long-term treatment with antipsychotics on serum leptin levels,https://doi.org/10.1192/bjp.179.1.59,11435270
False," The abstract does not provide any information about the study, as it only contains a title and a link to the full text, with no actual abstract available.",safety and efficacy of risperidone in substance abusers with psychosis,https://doi.org/10.1080/105504901750227831,11444160
True," The study meets the inclusion criteria as it is a comparative observational study examining the relationship between sertindole and other atypical antipsychotics in terms of mortality rates and cardiac dysrhythmias, which is relevant to the review's focus on the effectiveness and harms of atypical antipsychotics.","comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine",https://doi.org/10.1177/026988110101500212,11448085
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, includes risperidone as an intervention, and reports on effectiveness outcomes such as efficacy, time to onset of efficacy, and hospitalization.",risperidone olanzapine drug outcomes studies in schizophrenia (rodos): efficacy and tolerability results of an international naturalistic study,https://doi.org/10.1097/00004850-200107000-00001,11459331
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with post-traumatic stress disorder (PTSD), whereas the inclusion criteria specify a range of psychiatric disorders including schizophrenia, bipolar disorder, major depressive disorder, and others.",olanzapine in the treatment of post-traumatic stress disorder: a pilot study,https://doi.org/10.1097/00004850-200107000-00003,11459333
True," The study meets the inclusion criteria as it involves the treatment of schizophrenia with perospirone, an atypical antipsychotic agent, and reports on its efficacy and safety in patients with schizophrenia.",perospirone,https://doi.org/10.2165/00023210-200115040-00006,11463136
False, The article does not meet the inclusion criteria as it is a review on defining'mood stabilizer' and does not discuss the effectiveness or harms of specific medications for the specified patient populations.,on defining ‘mood stabilizer’,https://doi.org/10.1034/j.1399-5618.2001.030304.x,11465676
True," The study meets the inclusion criteria as it involves a population with schizophrenia, uses a relevant intervention (clozapine), and examines effectiveness outcomes such as symptom response and adherence.",non-linear dynamic analysis of clozapine-induced electroencephalographic changes in schizophrenic patients - a preliminary study,https://doi.org/10.1016/s0278-5846(01)00183-x,11474842
True," The study meets all the inclusion criteria as it involves adults and adolescents with bipolar disorder, a randomized controlled trial, and examines the efficacy and safety of a medication (olanzapine) for treating acute agitation in patients with bipolar mania.","a double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania",https://doi.org/10.1097/00004714-200108000-00006,11476123
True," The study meets the inclusion criteria as it focuses on the evaluation of drug interactions involving risperidone, a medication used in the treatment of various psychiatric disorders, and examines its pharmacokinetic properties and potential for interactions with other medications.",an evaluation of risperidone drug interactions,https://doi.org/10.1097/00004714-200108000-00008,11476125
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a diagnosis of interest in this review, and examines the effectiveness of olanzapine, an intervention included in this review.","olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial",https://doi.org/10.1097/00004714-200108000-00014,11476131
False," The title and abstract do not mention any specific interventions or populations that match the inclusion criteria, which are focused on specific psychiatric disorders and medications.",psychosis treatment prior to psychosis onset: ethical issues,https://doi.org/10.1016/s0920-9964(01)00238-9,11479065
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of clozapine and risperidone in patients with severe chronic schizophrenia, which is a relevant population for this review.",a double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia,https://doi.org/10.1176/appi.ajp.158.8.1305,11481167
False," The study population is veterans with schizophrenia or schizoaffective disorder, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, and other specified disorders.",adherence assessments and the use of depot antipsychotics in patients with schizophrenia,https://doi.org/10.4088/jcp.v62n07a08,11488366
False," The study population does not match the inclusion criteria as it only includes adults and healthy volunteers, not children or adolescents with pervasive developmental disorders or disruptive behavior disorders.",in vivo 5-ht 2a receptor blockade by quetiapine,https://doi.org/10.1007/s002130100761,11512044
False," The study focuses on children and adolescents with mental disorders such as autistic disorders, hyperkinetic disorders, conduct disorders, tic disorders, enuresis, and encopresis, which do not match the inclusion criteria of the review, which focuses on adults and children with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",evaluierte behandlungsansätze in der kinder- und jugendpsychiatrie i,https://doi.org/10.1024//1422-4917.29.3.189,11524897
True," The study meets the inclusion criteria as it involves a randomized, double-blind, parallel and comparative clinical trial of adults with schizophrenia, comparing the effects of olanzapine and haloperidol on D2 dopamine receptor occupancy.",double-blind olanzapine vs. haloperidol d2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [123i]ibzm spect study,https://doi.org/10.1016/s0925-4927(01)00085-3,11530275
False," The abstract does not mention any specific population or interventions that match the inclusion criteria, and it appears to be a general review of the relationship between neurotransmitters, temperament, and social functioning, rather than a review of the effectiveness of specific medications for a particular population.","neurotransmitters, temperament and social functioning",https://doi.org/10.1016/s0924-977x(01)00094-3,11532380
True," The study meets all the inclusion criteria as it involves a meta-analysis of controlled trials examining the effects of risperidone on hostility and aggression in schizophrenia, which is a relevant population for the review.",effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials,https://doi.org/10.1016/s0924-977x(01)00097-9,11532383
True," The study meets all the inclusion criteria as it involves adults and adolescents with various psychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder, and examines the effectiveness and harms of antipsychotic medications in clinical trials.",symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database,https://doi.org/10.1176/appi.ajp.158.9.1449,11532730
False," The study population does not match the inclusion criteria as it only includes patients aged 15-54 years, whereas the inclusion criteria specify adults (18 years and older), adolescents (13-17 years), and children (under 13 years).",antipsychotic-induced extrapyramidal syndromes,https://doi.org/10.1007/s002280100302,11549212
False," The study population is limited to patients with bipolar I disorder, whereas the inclusion criteria include a broader range of psychiatric disorders, such as schizophrenia, major depressive disorder, and pervasive developmental disorders.",medication prescribing patterns for patients with bipolar i disorder in hospital settings: adherence to published practice guidelines,https://doi.org/10.1034/j.1399-5618.2001.30401.x,11552955
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia and schizoaffective disorder, whereas the review includes a broader range of psychiatric conditions such as bipolar disorder, major depressive disorder, and pervasive developmental disorders.",risperidone added to clozapine,https://doi.org/10.4088/jcp.v62n0805,11561931
True," The study meets all the inclusion criteria as it involves a randomized, double-blind trial comparing clozapine with haloperidol in patients with schizophrenia, and it examines effectiveness outcomes such as symptom response, adherence, and persistence.",clozapine and haloperidol in moderately refractory schizophrenia,https://doi.org/10.1001/archpsyc.58.10.965,11576036
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of mania, which falls under the specified population of interest, and examines the effectiveness of olanzapine in combination with mood-stabilizers for patients with dysphoric mania.",use of olanzapine in dysphoric mania,https://doi.org/10.1016/s0165-0327(00)00313-x,11578678
True," The study meets the inclusion criteria as it involves a prospective, controlled study comparing body weight and related biological measures in olanzapine-treated patients with schizophrenia and healthy volunteers, and it examines the pathophysiology of weight gain during treatment with olanzapine.",association of olanzapine-induced weight gain with an increase in body fat,https://doi.org/10.1176/appi.ajp.158.10.1719,11579009
False," The study population consists of patients with juvenile neuronal ceroid lipofuscinosis, which is not included in the specified inclusion criteria.",new antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses — a pilot study,https://doi.org/10.1053/ejpn.2000.0455,11588990
True," The study meets the inclusion criteria as it involves adults with bipolar disorder, a condition included in the review, and examines the effectiveness of olanzapine as an adjunctive therapy, which is also included in the review.",olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder,https://doi.org/10.1097/00004714-200110000-00002,11593070
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of clozapine and haloperidol in patients with schizophrenia, and it examines the outcomes of neurocognition and clinical symptomatology.",clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics,https://doi.org/10.1097/00004714-200110000-00004,11593072
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of an antipsychotic medication (zotepine) in terms of striatal D2 receptor occupancy.",in vivo 123i ibzm spect imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients,https://doi.org/10.1007/s002130100813,11605078
True," The study meets the inclusion criteria as it involves patients with schizophrenia treated with olanzapine or clozapine, and examines the effects of these medications on autonomic nervous system function.",autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine,https://doi.org/10.1007/s002130100820,11605095
True," The study meets the inclusion criteria as it examines the efficacy, tolerability, and safety of fluvoxamine as an adjunctive agent in schizophrenia, which aligns with the specified population and interventions.",fluvoxamine as an adjunctive agent in schizophrenia,https://doi.org/10.1111/j.1527-3458.2001.tb00200.x,11607044
True," The study meets the inclusion criteria as it involves a population of schizophrenic patients treated with clozapine, which is one of the interventions included in the review, and it examines the benefit-risk of chronic treatment, which is a relevant outcome for the review.",a follow-up study of a population of schizophrenic patients treated with clozapine,https://doi.org/10.1016/s0278-5846(01)00213-5,11642649
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a medication (olanzapine) that is included in the review, and examines effectiveness outcomes such as cognitive function and symptom response.",the effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia,https://doi.org/10.1017/s146114570100253x,11669086
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of antipsychotic medications on hostility.","effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia",https://doi.org/10.1176/appi.ps.52.11.1510,11684748
False," The abstract does not match the inclusion criteria as it does not focus on the effectiveness or harms of antipsychotic drugs in the specified patient populations, but rather reviews the risk of torsade de pointes and sudden death associated with these medications.","antipsychotic drugs: prolonged qtc interval, torsade de pointes, and sudden death",https://doi.org/10.1176/appi.ajp.158.11.1774,11691681
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, examines the effectiveness of antipsychotic discontinuation, and reports on clinical outcomes such as exacerbation or relapse.",clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia,https://doi.org/10.1176/appi.ajp.158.11.1835,11691689
False," The study population does not match the inclusion criteria as it only includes individuals with developmental disabilities, whereas the inclusion criteria specify a range of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",effects of risperidone on aberrant behavior of persons with developmental disabilities: i. a double-blind crossover study using multiple measures,https://doi.org/10.1352/0895-8017(2001)106<0525:eoroab>2.0.co;2,11708938
True," The study meets all the inclusion criteria as it involves a randomized double-blind study comparing the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients, which is a relevant intervention for the review, and reports on effectiveness outcomes such as symptom response and harms such as adverse effects.",risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study,https://doi.org/10.1097/00004850-200111000-00002,11712620
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of a specific intervention (ipsapirone) on a particular outcome (5-HT1A receptor responsivity).",5-ht1a receptor dysfunction in female patients with schizophrenia,https://doi.org/10.1016/s0006-3223(01)01202-1,11720694
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, including first episode schizophrenia, and examines the effectiveness of different treatment strategies, including medication adherence and persistence, which are relevant outcomes of interest.",first vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies,https://doi.org/10.1016/s0920-9964(01)00182-7,11728846
True," The study meets the inclusion criteria as it is a retrospective cohort study examining the relationship between antipsychotic use and the risk of sudden cardiac death in adults, which is a relevant population for this review.",antipsychotics and the risk of sudden cardiac death,https://doi.org/10.1001/archpsyc.58.12.1161,11735845
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a relevant population for the review, and examines the effectiveness and harms of clozapine, a medication included in the review.","clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension",https://doi.org/10.1001/archpsyc.58.12.1172,11735847
True," The study meets the inclusion criteria as it investigates arithmetic abilities and working memory functions in schizophrenic patients, and the participants are adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia.",arithmetic fact retrieval and working memory in schizophrenia,https://doi.org/10.1016/s0920-9964(01)00152-9,11738535
True," The study meets the inclusion criteria as it is a randomized, double-blind, multi-site clinical efficacy study comparing the effects of quetiapine and haloperidol on cognitive function in patients with schizophrenia.",does cognitive function improve with quetiapine in comparison to haloperidol?,https://doi.org/10.1016/s0920-9964(01)00268-7,11738537
False," The study does not meet the inclusion criteria as it is a descriptive epidemiologic study of spontaneous adverse event reports of hyperglycemia occurring in clozapine-treated patients, and does not meet the inclusion criteria for study design (randomized controlled trials, good quality systematic reviews, and comparative observational studies) for the topic of clozapine's effectiveness in treating schizophrenia, bipolar disorder, major depressive disorder, and other conditions.",clozapine-associated diabetes,https://doi.org/10.1016/s0002-9343(01)01000-2,11747852
False," The study population does not match the inclusion criteria as it only includes adults with dementia, whereas the inclusion criteria specify a wide range of psychiatric conditions, including schizophrenia, bipolar disorder, and pervasive developmental disorders.",a double‐blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in chinese dementia patients,https://doi.org/10.1002/gps.504,11748775
False," The study population specified in the abstract (patients with bipolar disorder) does not match the inclusion criteria, which include a broader range of psychiatric disorders such as schizophrenia, major depressive disorder, and pervasive developmental disorders.",klinische relevanz und behandlungsmöglichkeiten von rapid cycling bei patienten mit bipolarer affektiver störung,https://doi.org/10.1055/s-2001-19181,11753745
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a DSM-IV diagnosis, and examines the effectiveness of a specific intervention (ethyl-eicosapentaenoate) on symptoms and outcomes.",a dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms,https://doi.org/10.1016/s0022-3956(01)00048-6,11755456
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of olanzapine, which is an intervention included in the review.",the effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia,https://doi.org/10.1097/00004714-200112000-00006,11763004
True," The study meets the inclusion criteria as it is a randomized, double-blind, placebo-controlled, cross-over study examining the effectiveness of pirenzepine in treating clozapine-induced hypersalivation, which is a relevant intervention for the review.","therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study",https://doi.org/10.1097/00004714-200112000-00012,11763010
True," The study meets all the inclusion criteria as it involves a post-marketing surveillance study on olanzapine, a medication included in the review, and reports on adverse events, which is a relevant outcome of interest.",the pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in england,https://doi.org/10.1177/026988110101500405,11769820
True," The study meets the inclusion criteria as it involves a randomized controlled trial of olanzapine in adults with borderline personality disorder, which is one of the specified patient populations.",olanzapine treatment of female borderline personality disorder patients,https://doi.org/10.4088/jcp.v62n1103,11775043
False," The study population specified in the abstract (acutely agitated patients with psychosis) does not match the inclusion criteria, which include a broader range of patient populations such as schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",validation of the behavioural activity rating scale (bars)™: a novel measure of activity in agitated patients,https://doi.org/10.1016/s0022-3956(01)00052-8,11777497
True," The study meets the inclusion criteria as it involves adults with schizophrenia and substance abuse disorders, and it examines the efficacy and safety of olanzapine, which is one of the included interventions.",olanzapine treatment for patients with schizophrenia and substance abuse,https://doi.org/10.1016/s0740-5472(01)00205-7,11777671
True," The study meets all the inclusion criteria as it involves a comparison of two antipsychotic medications (risperidone and haloperidol) for the prevention of relapse in patients with schizophrenia, which is a relevant population for this review.",a comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia,https://doi.org/10.1056/nejmoa002028,11777998
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.,efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy,https://doi.org/10.1001/archpsyc.59.1.62,11779284
True," The study meets the inclusion criteria as it is a randomized controlled trial (double-blind, dose-comparison study) examining the efficacy and safety of risperidone in patients with first-episode schizophrenia.","a pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia",https://doi.org/10.4088/jcp.v62n1214c,11780884
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of a major depressive episode with psychotic features, and it examines the effectiveness of olanzapine, which is an intervention included in the review.",an open trial of olanzapine in the treatment of patients with psychotic depression.,https://doi.org/10.1023/a:1012233508127,11791952
True," The study meets the inclusion criteria as it compares the risk of extrapyramidal syndrome between risperidone, olanzapine, and haloperidol, and includes a comparison of the three medications in a cohort study.","risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine",https://doi.org/10.1345/aph.1a068,11793611
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a diagnosis of which is included in the review, and examines the effectiveness of risperidone, which is also included in the review.",effects of risperidone on gonadal axis hormones in schizophrenia,https://doi.org/10.1345/aph.1z432,11793612
False," The study does not meet the inclusion criteria as it is a single-blind, observational study, whereas the review only includes randomized controlled trials, good-quality systematic reviews, and comparative observational studies.",comparison of risperidone with olanzapine in elderly patients with dementia and psychosis,https://doi.org/10.1592/phco.22.1.1.33496,11794418
True," The study meets the inclusion criteria as it is a double-blind, placebo-controlled trial examining the efficacy and tolerability of risperidone in the treatment of Tourette syndrome in adults and adolescents.","risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial",https://doi.org/10.1097/00004714-200202000-00006,11799340
False," The study does not meet the inclusion criteria as it does not involve any of the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders) and does not examine the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapone, risperidone, and ziprasidone).","lorazepam, sedation, and conscious recollection: a dose-response study with healthy volunteers",https://doi.org/10.1097/00004850-200201000-00003,11800502
True," The study meets the inclusion criteria as it involves amisulpride, an atypical antipsychotic, in the treatment of acute schizophrenia, and reports on effectiveness outcomes such as symptom response, quality of life, and hospitalization.",clinical advantages of amisulpride in the treatment of acute schizophrenia,https://doi.org/10.1177/147323000102900601,11803729
True," The study meets the inclusion criteria as it focuses on adults and adolescents with schizophrenia, and it examines the effectiveness of amisulpride in improving social functioning and quality of life.",social functioning and quality of life in the schizophrenic patient: advantages of amisulpride,https://doi.org/10.1097/00004850-200201000-00001,11806403
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of an adjunctive treatment (glycine) on symptom response.",adjunctive high-dose glycine in the treatment of schizophrenia,https://doi.org/10.1017/s1461145701002590,11806864
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and examines the effectiveness of an antipsychotic medication (melperone).",melperone in the treatment of neuroleptic-resistant schizophrenia,https://doi.org/10.1016/s0165-1781(01)00346-8,11814539
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, and it is a randomized controlled trial comparing the efficacy of olanzapine with haloperidol.",the effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis,https://doi.org/10.4088/jcp.v62n1003,11816864
True," The study meets the inclusion criteria as it involves adults and adolescents with bipolar disorder and schizoaffective disorder, and it examines the efficacy and safety of risperidone, which is an intervention included in the review.",risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders,https://doi.org/10.4088/jcp.v62n1011,11816872
True," The study meets all the inclusion criteria as it involves a meta-analysis of randomized controlled trials of amisulpride in patients with schizophrenia, which is a relevant population for the review.","amisulpride, an unusual ""atypical"" antipsychotic: a meta-analysis of randomized controlled trials",https://doi.org/10.1176/appi.ajp.159.2.180,11823257
True," The study meets all the inclusion criteria as it involves adults with schizophrenia and schizoaffective disorder, includes atypical antipsychotics (clozapine, olanzapine, and risperidone) as interventions, and reports on efficacy and safety outcomes.","clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder",https://doi.org/10.1176/appi.ajp.159.2.255,11823268
True," The study meets the inclusion criteria as it involves a comparison of novel and conventional antipsychotics in patients with psychosis, and examines patient satisfaction and burden of adverse effects, which are relevant outcomes of interest.",short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study,https://doi.org/10.1093/oxfordjournals.schbul.a006899,11824486
False," The abstract does not meet the inclusion criteria as it does not focus on the effects of antipsychotic medication on glucose and lipids in the specified populations, but rather discusses the history of antipsychotic medication development and its association with weight gain and diabetes.",antipsychotic medication: effects on regulation of glucose and lipids,https://doi.org/10.1517/14656566.2.10.1571,11825300
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a relevant population for the review, and examines the effect of an intervention (influenza vaccination) on the serum concentrations of clozapine and its metabolites.",effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia,https://doi.org/10.1007/s002280100375,11829199
False," The study does not meet the inclusion criteria as it is focused on the epidemiology of primary blepharospasm, a dystonia disorder, and does not match the specified inclusion criteria of psychiatric disorders or medications.",epidemiology of primary blepharospasm,https://doi.org/10.1002/mds.1275,11835433
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effect of vitamin B6 supplementation on psychotic symptoms in patients with schizophrenia and schizoaffective disorder.,vitamin b6 as add-on treatment in chronic schizophrenic and schizoaffective patients,https://doi.org/10.4088/jcp.v63n0111,11838627
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a relevant population for the review, and examines the effects of risperidone, a medication included in the review.",cytokine profiles in schizophrenic patients treated with risperidone,https://doi.org/10.1016/s0278-5846(01)00221-4,11853116
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in patients with schizoaffective disorder, bipolar type.","olanzapine versus haloperidol in schizoaffective disorder, bipolar type",https://doi.org/10.1016/s0165-0327(00)00303-7,11869760
True," The study meets all the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in patients with treatment-resistant schizophrenia, and reports on relevant outcomes such as symptom response and adverse effects.","placebo-controlled trial ofd-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia",https://doi.org/10.1176/appi.ajp.159.3.480,11870017
True," The study meets the inclusion criteria as it involves a population with a DSM-IV diagnosis of schizophrenia or related disorders, and it examines the effectiveness of olanzapine and risperidone in relation to obsessive-compulsive symptoms.",obsessive-compulsive symptoms during treatment with olanzapine and risperidone,https://doi.org/10.4088/jcp.v63n0203,11874209
True," The study meets the inclusion criteria as it focuses on the use of atypical antipsychotics in treatment-resistant depression, a specific population of interest in the review.",what role do atypical antipsychotic drugs have in treatment-resistant depression?,https://doi.org/10.4088/jcp.v63n0202,11874227
False," The study population does not match the inclusion criteria as it only includes pre-menopausal women with fluoxetine-associated sexual dysfunction, whereas the review focuses on various psychiatric disorders and medications.","mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial",https://doi.org/10.1016/s0022-3956(01)00060-7,11886692
True," The study meets the inclusion criteria as it involves adults with treatment-resistant schizophrenia, a randomized controlled trial design, and examines the effectiveness of a specific medication (mianserin) in conjunction with typical antipsychotics.",mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia,https://doi.org/10.1097/00004850-200203000-00003,11890187
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia and related disorders, and examines the effectiveness of atypical and conventional antipsychotics in terms of time to discontinuation, relapse, and compliance.","time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders",https://doi.org/10.1097/00004850-200203000-00004,11890188
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of donepezil as an adjunctive treatment to risperidone for cognitive impairment in schizophrenia, which is a relevant population for this review.",a double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia,https://doi.org/10.1016/s0006-3223(01)01342-7,11904128
False," The study population is bipolar patients, but the inclusion criteria specified schizophrenia, bipolar disorder, and other conditions, and the study does not match the specified age range for bipolar disorder (13-17 years and 18 years and older).",cerebellar blood volume in bipolar patients correlates with medication,https://doi.org/10.1016/s0006-3223(01)01281-1,11904131
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, schizoaffective disorder, or bipolar disorder, whereas the review includes a broader range of populations such as children, older adults, and individuals with pervasive developmental disorders and disruptive behavior disorders.",effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine,https://doi.org/10.1097/00004714-200204000-00011,11910263
False," The study population does not match the inclusion criteria as it includes only nonpsychotic subjects who are anxious before undergoing minor dental surgery, whereas the inclusion criteria specify patients with schizophrenia, bipolar disorder, major depressive disorder, and other specific conditions.",the anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery,https://doi.org/10.1097/00004714-200204000-00016,11910268
True," The study meets the inclusion criteria as it involves adults (≥ 65 years of age) with behavioral and psychological symptoms of dementia, and examines the effectiveness of risperidone in reducing caregiver burden.",reducing the burden of caring for alzheimer's disease through the amelioration of ‘delusions of theft’ by drug therapy,https://doi.org/10.1002/gps.551,11921147
True," The study meets all the inclusion criteria as it involves adults with a diagnosis of schizophrenia, examines the association between atypical neuroleptics and diabetes mellitus, and uses a large national sample of patients from the VA administrative databases.",association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia,https://doi.org/10.1176/appi.ajp.159.4.561,11925293
True," The study meets the inclusion criteria as it examines antipsychotic prescription patterns in patients with schizophrenia, specifically focusing on racial disparities, and includes a large sample size of 2,515 adult Medicaid recipients.",racial disparities in antipsychotic prescription patterns for patients with schizophrenia,https://doi.org/10.1176/appi.ajp.159.4.567,11925294
True," The study meets the inclusion criteria as it involves adults with schizophrenia, examines the effects of antipsychotic medications on glucose regulation, and uses a randomized controlled trial design.",abnormalities in glucose regulation during antipsychotic treatment of schizophrenia,https://doi.org/10.1001/archpsyc.59.4.337,11926934
False," The study population does not match the inclusion criteria as it specifically focuses on acutely agitated patients with dementia, whereas the inclusion criteria include a broader range of psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder.","comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo a double-blind, randomized study in acutely agitated patients with dementia",https://doi.org/10.1016/s0893-133x(01)00365-7,11927174
True," The study meets the inclusion criteria as it involves patients with treatment-resistant schizophrenia, uses a randomized controlled trial design, and examines the effectiveness of clozapine, which is an intervention included in the review.",novel factor-based symptom scores in treatment resistant schizophrenia implications for clinical trials,https://doi.org/10.1016/s0893-133x(01)00387-6,11927178
True," The study meets the inclusion criteria as it focuses on the use of atypical antipsychotics in autistic disorder, which is one of the specified populations of interest.",a systematic review of the use of atypical antipsychotics in autism,https://doi.org/10.1177/026988110201600113,11949778
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a disorder included in the review, and examines the effectiveness of risperidone compared to typical antipsychotics, which is a relevant intervention for the review.",prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics,https://doi.org/10.1016/s0920-9964(01)00276-6,11955973
True," The study meets all the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of a psychosocial intervention (skills training) for patients with schizophrenia, with outcomes including social adjustment and quality of life.",supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia,https://doi.org/10.1176/appi.ajp.159.5.829,11986138
False," The study population does not match the inclusion criteria as it only includes patients with Alzheimer's disease or vascular dementia, whereas the inclusion criteria specify a broader range of psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.","a pilot, randomized, open‐label trial assessing safety and pharmakokinetic parameters of co‐administration of rivastigmine with risperidone in dementia patients with behavioral disturbances",https://doi.org/10.1002/gps.599,11994888
False," The study does not meet the inclusion criteria for interventions, as it involves phenylpropanolamine, which is not one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment,https://doi.org/10.4088/jcp.v63n0412,12000209
True," The study meets all the inclusion criteria as it involves adults and adolescents with psychiatric disorders, examines the effectiveness of clozapine, and uses a case-control study design.",clozapine use and risk of diabetes mellitus,https://doi.org/10.1097/00004714-200206000-00002,12006892
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia and schizoaffective disorder, and examines the association between antipsychotic-induced weight gain and therapeutic response to specific medications.",antipsychotic-induced weight gain and therapeutic response: a differential association,https://doi.org/10.1097/00004714-200206000-00003,12006893
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in patients with schizophrenia, and it examines sex differences in treatment response.",sex differences in clinical response to olanzapine compared with haloperidol,https://doi.org/10.1016/s0165-1781(02)00028-8,12007591
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, examines the effectiveness of switching from risperidone to olanzapine, and reports on outcomes such as prolactin levels, symptom response, and sexual and reproductive functioning.",effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone,https://doi.org/10.4088/jcp.v63n0506,12019665
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of chronic schizophrenia, a specific population of interest in the review, and examines the effectiveness of clozapine treatment.",clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia,https://doi.org/10.4088/jcp.v63n0508,12019667
True," The study meets the inclusion criteria as it involves patients with schizophrenia, assesses the effect of neuroleptic medication on thought disorder and semantic processing, and uses a randomized controlled design.",effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning,https://doi.org/10.1017/s0033291799002639,12027048
False," The abstract does not mention any specific interventions (medications) that are included in the review, and it does not specify the population of interest (adults with schizophrenia) as one of the inclusion criteria.",physical consequences of schizophrenia and its treatment,https://doi.org/10.1016/s0024-3205(02)01646-6,12034344
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of olanzapine and divalproex in the treatment of acute mania, which is a relevant intervention for this review.",olanzapine versus divalproex in the treatment of acute mania,https://doi.org/10.1176/appi.ajp.159.6.1011,12042191
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effects of clozapine, olanzapine, risperidone, and haloperidol on neurocognitive functioning in patients with schizophrenia or schizoaffective disorder.","neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder",https://doi.org/10.1176/appi.ajp.159.6.1018,12042192
True," The study meets the inclusion criteria as it involves a randomized controlled trial of a specific antipsychotic medication (risperidone with or without celecoxib) in patients with schizophrenia, which is a relevant population for this review.",beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia,https://doi.org/10.1176/appi.ajp.159.6.1029,12042193
True," The study meets the inclusion criteria as it involves adults with treatment-refractory schizophrenia, a condition of interest in the review, and examines the efficacy of olanzapine and risperidone, which are included interventions in the review.",efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients,https://doi.org/10.1176/appi.ps.53.6.755,12045315
True," The study meets the inclusion criteria as it focuses on schizophrenia and other psychotic disorders, and examines the potential importance of extrapyramidal symptoms (EPS) and neuroleptic dysphoria in treatment outcome, which is a relevant topic for the review.",improving outcome in schizophrenia: the potential importance of eps and neuroleptic dysphoria.,https://doi.org/10.1023/a:1015276028425,12046640
False, The study population specified in the abstract (patients with new-onset diabetes mellitus or diabetic ketoacidosis associated with atypical antipsychotics) does not match the inclusion criteria (various psychiatric and neurological disorders and their treatments).,phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases.,https://doi.org/10.1023/a:1015228112495,12046641
False," The study focuses specifically on the clinical profile of risperidone, which does not match the broad range of interventions included in the review.",clinical profile of an atypical antipsychotic: risperidone,https://doi.org/10.1093/oxfordjournals.schbul.a006925,12047021
False," The study population is limited to individuals with schizophrenia and schizoaffective disorder, which does not meet the inclusion criteria for other psychiatric conditions such as bipolar disorder, major depressive disorder, and pervasive developmental disorders.",recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy,https://doi.org/10.1093/oxfordjournals.schbul.a006928,12047024
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of two antipsychotic medications (haloperidol and risperidone) in terms of neurocognitive effects.",the neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone,https://doi.org/10.1016/s0006-3223(02)01370-7,12062881
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of bupropion for smoking cessation in patients with schizophrenia, which is one of the specified patient populations.",a placebo controlled trial of bupropion for smoking cessation in schizophrenia,https://doi.org/10.1016/s0006-3223(02)01339-2,12079730
True," The study meets all the inclusion criteria as it is a systematic review of randomized controlled trials comparing newer atypical antipsychotic medications to clozapine for schizophrenia, and it includes relevant outcomes such as effectiveness and adverse effects.",newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials,https://doi.org/10.1016/s0920-9964(01)00212-2,12084413
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a relevant population for the review, and examines the effectiveness of a specific intervention (d-cycloserine added to risperidone) on negative symptoms of schizophrenia.",d-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia,https://doi.org/10.1016/s0920-9964(01)00220-1,12084415
True," The study meets the inclusion criteria as it involves a head-to-head comparison of two antipsychotic medications (ziprasidone and haloperidol) in patients with stable schizophrenia, which is a relevant population for this review.",a 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia,https://doi.org/10.4088/jcp.v63n0609,12088164
False," The study population specified in the abstract (bipolar disorder patients with a current manic or mixed episode) does not match the inclusion criteria for the review, which includes patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, among others.","combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety",https://doi.org/10.1176/appi.ajp.159.7.1146,12091192
False," The study population specified in the abstract (patients with schizophrenia) does not match the inclusion criteria for patients with bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia, which are the primary focus of the review.",effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia a comparison with clozapine and placebo,https://doi.org/10.1016/s0893-133x(02)00314-7,12093603
True," The study meets all the inclusion criteria as it involves a population with schizophrenia, a randomized controlled trial is not required for this study type, and it examines the effectiveness and cost-effectiveness of clozapine, which is an intervention included in the review.","the cost-effectiveness of clozapine: a controlled, population-based, mirror-image study",https://doi.org/10.1177/026988110201600208,12095076
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of olanzapine in treating mania, which is one of the specified conditions, and it reports on clinical, economic, and quality-of-life outcomes.","economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania results from a randomized controlled trial",https://doi.org/10.1016/s0165-0327(01)00310-x,12103458
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness and safety of an antipsychotic medication.",low striatal and extra-striatal d2 receptor occupancy during treatment with the atypical antipsychotic sertindole,https://doi.org/10.1007/s00213-002-1083-5,12107615
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effects of antipsychotic medications on cortical inhibitory mechanisms.",a transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia,https://doi.org/10.1007/s00213-002-1068-4,12107621
False," The study does not meet the inclusion criteria as it is a retrospective, epidemiologic survey of spontaneously reported adverse events related to olanzapine therapy, which does not fit the inclusion criteria of randomized controlled trials, good quality systematic reviews, and comparative observational studies.",olanzapine‐associated diabetes mellitus,https://doi.org/10.1592/phco.22.11.841.33629,12126218
True," The study meets all the inclusion criteria as it focuses on schizophrenia and other psychotic disorders, and it examines the effectiveness of clozapine in reducing suicidality, which is a relevant outcome for the review.",suicidality in schizophrenia: a review of the evidence for risk factors and treatment options,https://doi.org/10.1007/s11920-996-0047-6,12126596
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial comparing amisulpride with haloperidol and risperidone, and assesses effectiveness outcomes such as symptom response.",amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone,https://doi.org/10.1016/s0924-977x(02)00031-7,12126869
True," The study meets the inclusion criteria as it is a systematic review of experimental and observational studies evaluating clozapine-treated subjects in treatment-resistant schizophrenia, which is a relevant topic for the review.",clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies,https://doi.org/10.1097/00004850-200207000-00006,12131603
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of switching to olanzapine in patients with schizophrenia, which is a relevant intervention for this review.",switching to olanzapine from previous antipsychotics,https://doi.org/10.4088/jcp.v63n0706,12143912
True," The study meets the inclusion criteria as it involves a naturalistic study of risperidone treatment outcome in inpatients, which is one of the interventions included in the review.",a naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in new york state inpatients,https://doi.org/10.4088/jcp.v63n0708,12143914
True," The study meets the inclusion criteria as it involves adults with schizophrenia, examines the effects of clozapine, and includes randomized controlled trials.",weight and blood pressure change during clozapine treatment,https://doi.org/10.1097/00002826-200207000-00003,12151907
False," The study population specified in the abstract (children with subaverage intelligence and disruptive behaviors) does not match the inclusion criteria for the review, which includes adults and adolescents with various psychiatric disorders, and children and adolescents with pervasive developmental disorders and disruptive behavior disorders.","double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence",https://doi.org/10.1176/appi.ajp.159.8.1337,12153826
True, The study meets the inclusion criteria as it is a population-based nested case-control study examining the association between olanzapine and risperidone and the risk of diabetes in patients with schizophrenia.,assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study,https://doi.org/10.1136/bmj.325.7358.243,12153919
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of ziprasidone in patients with chronic schizophrenia, which is one of the specified patient populations.","a 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160???mg/day in chronic schizophrenia: the ziprasidone extended use in schizophrenia (zeus) study",https://doi.org/10.1097/00004850-200209000-00001,12177583
True," The study meets all the inclusion criteria as it is a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in patients with bipolar disorder, and it reports on clinical outcomes, health-related quality of life, and work status.","olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status",https://doi.org/10.1097/00004850-200209000-00003,12177585
True," The study meets the inclusion criteria as it involves a population pharmacokinetics analysis of clozapine, a medication included in the review, and examines the relationship between CYP1A2 activity and clozapine clearance, which is a relevant outcome for the review.",evidence from a population pharmacokinetics analysis for a major effect of cyp1a2 activity on inter- and intraindividual variations of clozapine clearance,https://doi.org/10.1016/s0278-5846(01)00320-7,12188102
True," The study meets all the inclusion criteria as it focuses on adults and adolescents with various psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, and examines the dosing strategies of atypical antipsychotic medications.",optimal dosing of atypical antipsychotics in adults: a review of the current evidence,https://doi.org/10.1080/10673220216279,12202454
True," The study meets the inclusion criteria as it is a randomized controlled trial (open study) examining the efficacy and safety of risperidone in the treatment of mania in bipolar disorder, which is one of the specified conditions of interest.","risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in spain",https://doi.org/10.1016/s0165-0327(01)00481-5,12204313
True," The study meets the inclusion criteria as it involves a prospective, naturalistic study examining the long-term consequences of switching patients from conventional to novel antipsychotic drugs for schizophrenia or schizo-affective disorder, and reports on outcomes such as symptoms, side effects, and quality of life.",switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study,https://doi.org/10.1016/s0920-9964(01)00309-7,12223251
False," The study is a case series, which is not a randomized controlled trial, comparative observational study, or systematic review, and therefore does not meet the inclusion criteria for study design.",preliminary experience with an ampakine (cx516) as a single agent for the treatment of schizophrenia: a case series,https://doi.org/10.1016/s0920-9964(01)00311-5,12223253
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of olanzapine and haloperidol in Japanese patients with schizophrenia, and it examines the extrapyramidal symptom profiles, which is a relevant outcome for this review.",extrapyramidal symptom profiles in japanese patients with schizophrenia treated with olanzapine or haloperidol,https://doi.org/10.1016/s0920-9964(01)00314-0,12223254
False," The study does not meet the inclusion criteria as it does not focus on the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) and instead compares zotepine, olanzapine, and risperidone.","effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients",https://doi.org/10.1016/s0920-9964(01)00322-x,12223264
False," The title and abstract do not mention any of the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders) or interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) that are included in the review.",the bech–rafaelsen melancholia scale (mes) in clinical trials of therapies in depressive disorders: a 20‐year review of its use as outcome measure,https://doi.org/10.1034/j.1600-0447.2002.01404.x,12225492
False," The study population does not match the inclusion criteria as it only includes first episode psychosis patients, whereas the review includes a broader range of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",one‐year outcome in first episode psychosis patients in the swedish parachute project,https://doi.org/10.1034/j.1600-0447.2002.02376.x,12225494
False," The study population does not match the inclusion criteria as it specifically targets patients with Parkinson's disease, which is not mentioned in the inclusion criteria.",olanzapine in the treatment of dopamimetic-induced psychosis in patients with parkinson’s disease,https://doi.org/10.1016/s0006-3223(02)01392-6,12242060
False," The study population does not match the inclusion criteria as it only includes residents with dementia in chronic care institutions, whereas the inclusion criteria specify a wide range of psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.","a randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia",https://doi.org/10.1017/s1041610202008396,12243210
False," The study population does not match the inclusion criteria as it only includes adults with chronic schizophrenia, whereas the review includes a broader range of patient populations, including adolescents and children with various psychiatric disorders.",fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects,https://doi.org/10.1097/00004714-200210000-00010,12352274
False," The study population does not match the inclusion criteria as it only includes patients with Parkinson's disease, whereas the review includes patients with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",olanzapine treatment for dopaminergic‐induced hallucinations,https://doi.org/10.1002/mds.10217,12360554
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-IV diagnosis of schizophrenia and schizoaffective disorder, and it is a randomized controlled trial examining the efficacy and safety of aripiprazole compared to haloperidol and placebo.",efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder,https://doi.org/10.4088/jcp.v63n0903,12363115
True, The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of interventions in reducing the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.,randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms,https://doi.org/10.1001/archpsyc.59.10.921,12365879
True," The study meets all the inclusion criteria as it reviews the efficacy and risks of combining antipsychotics in patients with schizophrenia and other psychotic disorders, and it includes randomized controlled trials, good-quality systematic reviews, and comparative observational studies.",antipsychotic combination therapy in schizophrenia. a review of efficacy and risks of current combinations,https://doi.org/10.1034/j.1600-0447.2002.01331.x,12366465
True," The study meets the inclusion criteria as it focuses on schizophrenia, a relevant population for the review, and examines the effectiveness of maintenance therapy, a relevant intervention for the review.",maintenance therapy in schizophrenia: a critical comment,https://doi.org/10.1017/s1461145702002961,12366880
False," The abstract does not mention any of the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders) or interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone) included in the review.",aripiprazole,https://doi.org/10.2165/00023210-200216110-00008,12383035
False," The title and abstract do not mention any specific pharmacological treatment of schizophrenia, but rather provide an overview of the challenges and potential targets in developing new antipsychotic drugs.",developments in the pharmacological treatment of schizophrenia,https://doi.org/10.1517/13543784.11.10.1335,12387698
False," The title and abstract do not match the specified inclusion criteria, which focus on schizophrenia, bipolar disorder, major depressive disorder, and other specific psychiatric conditions, whereas the title and abstract discuss sleep disorders in Parkinson's disease.",sleep disorders in parkinson??s disease,https://doi.org/10.2165/00002512-200219100-00002,12390050
True," The study meets all the inclusion criteria as it involves drug-naïve first-episode schizophrenic patients, examines the effect of antipsychotic treatment on prepulse inhibition of the startle response, and is a longitudinal clinical study.",effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients,https://doi.org/10.1016/s0006-3223(02)01409-9,12399139
False," The article is a letter to the editor, not a primary research study, and does not report on a randomized controlled trial or a systematic review.",re: chan et al. a double‐blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in chinese dementia patients. int j geriatr psychiatry 16: 1156 ‐ 1162,https://doi.org/10.1002/gps.722,12404659
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, including first-episode schizophrenia, and examines the relationship between baseline depressive symptoms and treatment outcome.",depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia,https://doi.org/10.1016/s0920-9964(01)00375-9,12409165
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, uses a randomized-controlled design, and examines the effectiveness of antipsychotic medication (haloperidol and quetiapine) in a longitudinal follow-up study.",longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure,https://doi.org/10.1016/s0920-9964(02)00210-4,12409172
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a relevant population for the review, and examines the effectiveness of different antipsychotics, which are included interventions in the review.",“normalization” of brain activation in schizophrenia. an fmri study,https://doi.org/10.1016/s0920-9964(01)00369-3,12409175
False," The study population does not match the inclusion criteria as it includes patients with Huntington's disease, which is not listed in the inclusion criteria.",olanzapine for huntington's disease: an open label study,https://doi.org/10.1097/00002826-200209000-00007,12410058
False," The study does not meet the inclusion criteria as it focuses on people with mental disorder who do not return to community living, which is not a specific population of interest in the review, and the interventions and outcomes measured are not aligned with the specified criteria.",mental disorder and perceived threat to the public: people who do not return to community living,https://doi.org/10.1192/bjp.181.5.399,12411265
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of an antipsychotic medication (melperone) on cognitive function.","the effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia",https://doi.org/10.1016/s0920-9964(01)00329-2,12413636
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of an intervention (donepezil) on cognitive function, which is a relevant outcome for the review.",an open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia,https://doi.org/10.1016/s0920-9964(01)00387-5,12413639
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial is not explicitly mentioned, but the study is a prospective open-label study which is included in the criteria for comparative observational studies.",amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study,https://doi.org/10.1016/s0920-9964(01)00342-5,12413640
True," The study meets the inclusion criteria as it involves adults with schizophrenia or schizoaffective disorder, examines the effects of clozapine treatment on serum glucose and lipid measures, and includes a comparison with beta-adrenergic antagonist treatment.",serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent β-adrenergic antagonist treatment,https://doi.org/10.1016/s0920-9964(02)00158-5,12413642
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (e.g., aripiprazole, asenapine, clozapine, etc.) in the specified patient populations (e.g., schizophrenia, bipolar disorder, etc.).",cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study,https://doi.org/10.1016/s0920-9964(02)00153-6,12414081
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, and examines the effects of novel antipsychotics on glucose and lipid levels.",the effects of novel antipsychotics on glucose and lipid levels,https://doi.org/10.4088/jcp.v63n1002,12416594
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of risperidone in first-episode, acutely psychotic patients, examining the effectiveness of two different doses of the medication.","risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients",https://doi.org/10.4088/jcp.v63n1006,12416598
True," The study meets all the inclusion criteria as it focuses on adults and adolescents with schizophrenia, bipolar disorder, and other psychotic disorders, and examines the association between antipsychotic medications and the risk of type 2 diabetes.","differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes",https://doi.org/10.4088/jcp.v63n1010,12416602
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effects of antipsychotic medications, and uses a large health care database.",an assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients,https://doi.org/10.1001/archpsyc.59.11.1021,12418935
True," The study meets the inclusion criteria as it is a cohort study examining the relationship between antipsychotic medication and cardiac arrest and ventricular arrhythmia in patients with schizophrenia, which is a relevant population for this review.",cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data,https://doi.org/10.1136/bmj.325.7372.1070,12424166
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a DSM-IV diagnosis, and examines the effects of classical and atypical neuroleptics on bone mineral density.","classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia",https://doi.org/10.1080/00207450290025833,12424822
False," The title and abstract do not match the inclusion criteria as the study focuses on antiepileptic drugs in dermatology, whereas the inclusion criteria specify a review of antipsychotic medications for various psychiatric disorders.","psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications",https://doi.org/10.1016/s0738-081x(02)00267-5,12435529
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of risperidone and haloperidol in patients with treatment-refractory schizophrenia, which is a relevant population for this review.",impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia,https://doi.org/10.1053/comp.2002.33499,12439835
True," The study meets the inclusion criteria as it involves adult and adolescent patients with Tourette's disorder, a condition that overlaps with the inclusion criteria for schizophrenia and other psychotic disorders, and examines the effects of risperidone, a medication included in the review.",depression and dysphoria in adult and adolescent patients with tourette’s disorder treated with risperidone,https://doi.org/10.4088/jcp.v63n1115,12444819
True," The study meets the inclusion criteria as it involves a head-to-head comparison of two antipsychotic medications (olanzapine and haloperidol) in elderly patients with chronic schizophrenia, which is a relevant population for this review.",olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients,https://doi.org/10.1016/s0278-5846(01)00322-0,12452546
True," The study meets all the inclusion criteria as it examines the association between atypical antipsychotics and glucose intolerance, and includes adults and adolescents with various psychiatric disorders, and reports on effectiveness and harms of the included interventions.",glucose intolerance with atypical antipsychotics,https://doi.org/10.2165/00002018-200225150-00005,12452735
True," The study meets all the inclusion criteria as it examines the relationship between theory of mind and clinical and social functioning in patients with schizophrenia, and it is a randomized controlled trial, which is a type of study included in the review.",is theory of mind in schizophrenia more strongly associated with clinical and social functioning than with neurocognitive deficits?,https://doi.org/10.1159/000067062,12457019
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial comparing quetiapine and haloperidol, and examines effectiveness outcomes such as response rate, tolerability, hospitalization, and relapse rates.",an economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics,https://doi.org/10.1016/s0149-2918(02)80069-8,12462294
False," The study population does not match the inclusion criteria as it only includes healthy elderly subjects, ages 60 years and older, whereas the review includes patients with various psychiatric disorders.",pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together,https://doi.org/10.1177/0091270002042012005,12463729
True, The study meets all the inclusion criteria as it is a head-to-head randomized controlled trial comparing the efficacy and safety of amisulpride and risperidone in patients with chronic schizophrenia.,amisulpride vs. risperidone in chronic schizophrenia results of a 6-month double-blind study,https://doi.org/10.1016/s0893-133x(02)00375-5,12464464
False," The study population does not match the inclusion criteria as it specifically targets patients with Parkinson's disease and related conditions, whereas the review focuses on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions.",sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study,https://doi.org/10.1002/mds.10276,12465075
True," The study meets the inclusion criteria as it involves a population with a DSM-IV diagnosis of schizophrenia spectrum disorders, specifically first episode patients, and examines the effectiveness of comprehensive treatment on cognitive functioning.",changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders,https://doi.org/10.1016/s0165-1781(02)00236-6,12467947
False," The study population does not match the inclusion criteria as it only includes adults with essential tremor, which is not one of the specified conditions in the inclusion criteria.",quetiapine and essential tremor,https://doi.org/10.1097/00002826-200211000-00004,12469002
False," The study population does not match the inclusion criteria as it only includes adults with Alzheimer's disease, whereas the inclusion criteria specify a broader range of psychiatric conditions, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",donepezil for the treatment of behavioral symptoms in patients with alzheimer's disease,https://doi.org/10.1097/00002826-200211000-00007,12469005
True," The study meets the inclusion criteria as it focuses on aripiprazole, a medication for various psychiatric disorders, and examines its efficacy and safety profile, which aligns with the review's focus on interventions for specific patient populations.",aripiprazole: profile on efficacy and safety,https://doi.org/10.1517/14656566.3.12.1773,12472374
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, and major depressive disorder, and examines the effects of psychotropic drugs on interleukin-12 levels.","the plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs",https://doi.org/10.1038/sj.mp.4001084,12476326
True," The study meets the inclusion criteria as it involves adults with bipolar disorder, specifically bipolar depression, and examines the effectiveness of gabapentin as an adjunctive therapy.",gabapentin augmentation therapy in bipolar depression,https://doi.org/10.1034/j.1399-5618.2002.01211.x,12479661
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with bipolar disorder, whereas the inclusion criteria include a broader range of populations such as schizophrenia, major depressive disorder, and pervasive developmental disorders.",olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders,https://doi.org/10.1034/j.1399-5618.2002.01210.x,12479666
True," The study meets the inclusion criteria as it involves adults with bipolar disorder, specifically rapid cycling bipolar disorder, and examines the effectiveness of quetiapine as an add-on treatment.",quetiapine in the treatment of rapid cycling bipolar disorder,https://doi.org/10.1034/j.1399-5618.2002.01204.x,12479667
False," The study population is not adults with schizophrenia or other psychotic disorders, but rather patients with post-traumatic stress disorder (PTSD) and comorbid psychotic symptoms.",adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms,https://doi.org/10.1097/00004850-200301000-00001,12490768
False," The study population specified in the abstract (schizophrenic patients treated with olanzapine or haloperidol) does not match the inclusion criteria, which includes a broader range of patient populations and interventions.",extrapyramidal symptom profiles assessed with the drug-induced extrapyramidal symptom scale: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol,https://doi.org/10.1097/00004850-200301000-00007,12490774
True," The study meets the inclusion criteria as it involves a meta-regression analysis of placebo response in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder, and examines the effect of trial duration on placebo response.",moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression,https://doi.org/10.1007/s00213-002-1299-4,12494247
True," The study meets all the inclusion criteria as it involves adults and adolescents with a DSM-IV diagnosis of schizophrenia, includes a randomized controlled trial design, and examines the effectiveness of a specific intervention (divalproex combined with olanzapine or risperidone) in terms of symptom response, which is a relevant outcome for this review.",effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.,10.1038/sj.npp.1300023,12496955
False," The study does not meet the inclusion criteria as it does not involve patients with schizophrenia, bipolar disorder, major depressive disorder, or other specified conditions, and it does not examine the effectiveness or harms of the included interventions in these populations.",the potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability,https://doi.org/10.1177/026988110201600410,12503835
False," The study population specified in the abstract (social anxiety disorder) does not match the inclusion criteria, which focuses on various psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",efficacy of olanzapine in social anxiety disorder: a pilot study,https://doi.org/10.1177/026988110201600412,12503837
True," The study meets all the inclusion criteria as it focuses on the efficacy of newer generation antipsychotics in the treatment of schizophrenia, includes randomized controlled clinical trials, and examines the effectiveness outcomes such as symptom response, adherence, and persistence.",efficacy of newer generation antipsychotics in the treatment of schizophrenia,https://doi.org/10.1016/s0306-4530(02)00110-5,12504069
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effects of quetiapine and haloperidol on serum prolactin levels in patients with schizophrenia.,quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol,https://doi.org/10.1016/s0188-4409(02)00403-4,12505103
True," The study meets all the inclusion criteria as it focuses on adults and adolescents with schizophrenia, uses a decision analytic Markov model to determine cost-effectiveness, and examines the outcomes of olanzapine, haloperidol, and risperidone in Mexico.",a cost-effectiveness clinical decision analysis model for treatment of schizophrenia,https://doi.org/10.1016/s0188-4409(02)00409-5,12505105
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of olanzapine in treating bipolar mania, and it reports on outcomes such as symptom response, hospitalization, and adverse effects, which are relevant to the review.",placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania,https://doi.org/10.1016/s0165-0327(02)00335-x,12507747
False," The study population is limited to adults and adolescents with bipolar I disorder with a history of rapid cycling, which does not match the inclusion criteria of the review, which includes a broader range of patient populations and disorders.",olanzapine in the acute treatment of bipolar i disorder with a history of rapid cycling,https://doi.org/10.1016/s0165-0327(02)00334-8,12507748
False," The abstract does not mention any specific study population that matches the inclusion criteria, which includes adults, adolescents, and children with various psychiatric disorders, but rather discusses the application of molecular imaging techniques in the field of psychiatry, specifically in the study of schizophrenia.",neuroreceptor imaging in psychiatric disorders,https://doi.org/10.1007/bf02988639,12508833
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified antipsychotic medications, but rather on the routine use and off-label prescribing of second-generation antipsychotics in the Italian psychiatric care system.",prescribing second-generation antipsychotics and the evolving standard of care in italy,https://doi.org/10.1055/s-2002-36394,12518273
True," The study meets the inclusion criteria as it involves adults with bipolar disorder and cocaine dependence, and examines the effectiveness of quetiapine as an add-on therapy.",quetiapine in bipolar disorder and cocaine dependence,https://doi.org/10.1034/j.1399-5618.2002.02229.x,12519101
True, The study meets the inclusion criteria as it compares the risk of diabetes between olanzapine and risperidone use in patients with schizophrenia and other psychotic disorders.,the risk of diabetes during olanzapine use compared with risperidone use,https://doi.org/10.4088/jcp.v63n1208,12523873
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of major depressive disorder with psychotic features, and it examines the effectiveness of olanzapine and fluoxetine, which is an intervention included in the review.",an open study of olanzapine and fluoxetine for psychotic major depressive disorder,https://doi.org/10.4088/jcp.v63n1212,12523877
True," The study meets the inclusion criteria as it involves a randomized controlled trial of risperidone, an intervention included in the review, in patients with schizophrenia, a condition included in the review, and reports on effectiveness outcomes such as symptom response and adverse effects, which are also included in the review.",risperidone in the treatment of hispanic inpatients with schizophrenia: a pilot study,https://doi.org/10.1521/psyc.65.4.371.20237,12530340
False," The abstract does not mention any of the specified disorders (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, disruptive behavior disorders) or the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) that are the focus of the review.",cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?,https://doi.org/10.1016/s0531-5565(02)00163-8,12543269
False," The study population specified in the abstract (combat veterans with posttraumatic stress disorder) does not match the inclusion criteria for the review, which includes patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions.",quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy,https://doi.org/10.1097/00004714-200302000-00003,12544370
False, The study population specified in the abstract (patients with inadequate response to selective serotonin reuptake inhibitors) does not match the inclusion criteria (adults with major depressive disorder).,a prospective trial of bupropion sr augmentation of partial and non-responders to serotonergic antidepressants,https://doi.org/10.1097/00004714-200302000-00005,12544372
False," The study population specified in the abstract (children and adolescents with childhood-onset schizophrenia, ages 9-16 years) does not match the inclusion criteria, which specifies adults (18 years and older) and adolescents (13-17 years) as the target population.",clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia,https://doi.org/10.1097/00004714-200302000-00012,12544379
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effectiveness of clozapine, and reports on clinical response and brain metabolic correlates.",d1 receptor alleles predict pet metabolic correlates of clinical response to clozapine,https://doi.org/10.1038/sj.mp.4001191,12556915
True," The study meets the inclusion criteria as it involves first-episode, drug-naive patients with schizophrenia, a DSM-IV diagnosis, and examines the prevalence of impaired fasting glucose tolerance.","impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia",https://doi.org/10.1176/appi.ajp.160.2.284,12562574
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of a medication (olanzapine and reboxetine) in patients with schizophrenia, and it examines the effectiveness of the intervention in terms of weight gain, which is a relevant outcome for this review.","attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study",https://doi.org/10.1176/appi.ajp.160.2.297,12562576
True," The study meets the inclusion criteria as it is a randomized, double-blind study examining the effectiveness of olanzapine and haloperidol in patients with recent-onset schizophrenia, and it includes outcomes such as subjective experience, psychopathology, and extrapyramidal symptoms.","subjective experience and d2receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study",https://doi.org/10.1176/appi.ajp.160.2.303,12562577
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the efficacy of risperidone in combination with a mood stabilizer in the treatment of acute mania, which is a relevant intervention for the review.",mood stabilisers plus risperidone or placebo in the treatment of acute mania,https://doi.org/10.1192/bjp.182.2.141,12562742
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of a psychotic disorder (Parkinson's disease psychosis), and it examines the effectiveness of clozapine, which is an intervention included in the review.",clozapine in parkinson's disease psychosis: 5-year follow-up review,https://doi.org/10.1097/00002826-200301000-00003,12567158
False," The study is not a randomized controlled trial, observational study, or systematic review, but rather a study design and recruitment rationale for a larger observational study.","the european schizophrenia outpatient health outcomes (soho) study: rationale, methods and recruitment",https://doi.org/10.1034/j.1600-0447.2003.00064.x,12580830
False," The title and abstract do not mention any specific interventions (e.g. aripiprazole, asenapine, clozapine, etc.) that are included in the review, and the abstract focuses on a critique of early intervention in psychosis rather than a review of the effectiveness of specific interventions.",early intervention in schizophrenia: a critique,https://doi.org/10.1017/s1121189x00005819,12585015
True," The study meets the inclusion criteria as it focuses on the effects of atypical antipsychotics on serum prolactin levels in patients with schizophrenia, which is a relevant topic for the review.",the effects of atypical antipsychotics on serum prolactin levels.,https://doi.org/10.1023/a:1021138603935,12585566
False," The title and abstract do not mention the specific population of interest (adults with schizophrenia) as the focus is on patients with schizophrenia, but the inclusion criteria also include other populations such as bipolar disorder, major depressive disorder, and pervasive developmental disorders.",psychotherapie produktiver symptomatik bei patienten mit schizophrener psychose,https://doi.org/10.1007/s00115-002-1330-3,12596031
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, a specific intervention (risperidone), and examines effectiveness outcomes such as symptom response.",plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia,https://doi.org/10.1097/00004850-200303000-00008,12598823
True," The study meets the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the association between the DRD3 gene and schizophrenia.",dopamine d3 receptor gene ser9gly variant and schizophrenia: association study and meta-analysis,https://doi.org/10.1097/00041444-200303000-00001,12605094
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of flupenthixol and risperidone in patients with schizophrenia, and assesses subjective quality of life and attitude towards medication.",flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients,https://doi.org/10.1159/000068874,12606844
True," The study meets the inclusion criteria as it focuses on the use of atypical antipsychotics in the treatment of bipolar disorder, which is one of the specified patient populations.",atypical antipsychotics and mood stabilization in bipolar disorder,https://doi.org/10.1007/s00213-002-1322-9,12607072
True," The study meets all the inclusion criteria as it involves a randomized controlled trial examining the effectiveness and safety of switching patients to aripiprazole from other antipsychotic agents, which is a relevant intervention for the review.",switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study,https://doi.org/10.1007/s00213-002-1344-3,12610718
False," The study population does not match the inclusion criteria as it only includes healthy men, whereas the review focuses on patients with various psychiatric and neurological disorders.",pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil,https://doi.org/10.1177/0091270002239827,12616671
True," The study meets the inclusion criteria as it involves a cohort of Korean schizophrenics, examines the association between CYP2D6 genotype and tardive dyskinesia, and uses a CYP450 genechip oligonucleotide microarray and PCR assays to screen for CYP2D6 alleles.",association between cyp2d6 genotype and tardive dyskinesia in korean schizophrenics,https://doi.org/10.1038/sj.tpj.6500138,12629505
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, but rather a randomized controlled trial is included in the inclusion criteria for this review.",treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients,https://doi.org/10.1038/sj.npp.1300089,12629532
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effects of clozapine, an intervention included in the review.",low blood selenium concentrations in schizophrenic patients on clozapine,https://doi.org/10.1046/j.1365-2125.2003.01773.x,12630982
True," The study meets all the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, examines the effectiveness of switching from depot antipsychotic drugs to olanzapine, and reports on clinical improvement and side effects.",switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia,https://doi.org/10.4088/jcp.v64n0203,12633119
False," The study does not meet the inclusion criteria for the population as it only includes male schizophrenic patients, whereas the review includes adults and adolescents with a DSM III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders, and bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",do atypical antipsychotics fail to exert cognitive sparing effects?,https://doi.org/10.1097/00001756-200303030-00042,12634513
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of specific antipsychotic medications, but rather investigates the factors influencing the choice between classical and atypical antipsychotics.",short-acting parenteral antipsychotics drive choice for classical versus atypical agents,https://doi.org/10.1007/s00228-002-0545-3,12634982
True, The study meets the inclusion criteria as it involves adults and adolescents with bipolar disorder (manic or depressive phases) and examines the effectiveness of olanzapine compared to placebo.,acute dysphoric mania: treatment response to olanzapine versus placebo,https://doi.org/10.1097/00004714-200304000-00005,12640214
False," The study population is limited to male combat veterans with posttraumatic stress disorder (PTSD), which does not match the inclusion criteria of adults and adolescents with various psychiatric disorders.",low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder,https://doi.org/10.1097/00004714-200304000-00012,12640221
False," The study population does not match the inclusion criteria as it only includes patients with Parkinson's disease with dopaminomimetic psychosis, which is not one of the specified conditions in the inclusion criteria.","acción de quetiapina en dosis bajas sobre las manifestaciones psicóticas, incapacidad motora y estrés del cuidador en pacientes con enfermedad de parkinson",https://doi.org/10.33588/rn.3605.2002454,12640589
True," The study meets the inclusion criteria as it is a randomized double-blind clinical trial of an atypical neuroleptic medication (olanzapine) versus placebo in patients at risk of being prodromally symptomatic for psychosis, which aligns with the specified interventions and patient populations.",the prime north america randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis,https://doi.org/10.1016/s0920-9964(02)00439-5,12648731
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with recent-onset schizophrenia, schizophreniform disorder, and schizoaffective disorder, whereas the inclusion criteria specify a broader range of disorders, including bipolar disorder, major depressive disorder, and pervasive developmental disorders.",the factor structure for the positive and negative syndrome scale (panss) in recent-onset psychosis,https://doi.org/10.1016/s0920-9964(02)00302-x,12648735
True," The study meets the inclusion criteria as it focuses on the effects of antipsychotics on sexual dysfunctions and endocrine functioning, which is relevant to the review's topic.",what are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?,https://doi.org/10.1016/s0306-4530(02)00130-0,12650685
True," The study meets the inclusion criteria as it is a double-blind, placebo-controlled trial examining the efficacy of nizatidine in limiting weight gain in patients with schizophrenia and related disorders treated with olanzapine.",nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial,https://doi.org/10.1016/s0924-977x(02)00127-x,12650950
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of a specific medication (mianserin) in patients with schizophrenia, which is a condition included in the review.","effect of the 5-ht2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study",https://doi.org/10.1016/s0924-977x(02)00155-4,12650957
False," The study population does not match the inclusion criteria as it includes patients with diabetes mellitus, whereas the review focuses on patients with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions.",a retrospective cohort study of diabetes mellitus and antipsychotic treatment in the united states,https://doi.org/10.1016/s0895-4356(02)00588-7,12654411
False," The study population specified in the abstract (patients with acute mania) does not match the inclusion criteria (bipolar disorder, major depressive disorder, schizophrenia, and other psychotic disorders, including first episode schizophrenia or patients refractory to treatment, and behavioral and psychological symptoms of dementia).","rates of response, euthymia and remission in two placebo‐controlled olanzapine trials for bipolar mania",https://doi.org/10.1034/j.1399-5618.2003.02237.x,12656931
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, examines the effectiveness of atypical antipsychotics (risperidone and olanzapine), and reports on the outcome of reaction time.",measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia,https://doi.org/10.1007/bf03040274,12658913
True, The study meets the inclusion criteria as it compares the clinical trial response and dropout rates between olanzapine and risperidone in patients with schizophrenia.,clinical trial response and dropout rates with olanzapine versus risperidone,https://doi.org/10.1345/aph.1c291,12659615
False," The study population specified in the abstract (adults with schizophrenia) does not match the inclusion criteria, which include a broader range of psychiatric disorders and age groups.",an economic review of compliance with medication therapy in the treatment of schizophrenia,https://doi.org/10.1176/appi.ps.54.4.508,12663838
True," The study meets the inclusion criteria as it involves the use of clozapine, a medication included in the review, and examines its effectiveness in patients with schizophrenia or schizoaffective disorder at high risk for suicide.",clozapine,https://doi.org/10.2165/00023210-200317040-00004,12665398
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of ziprasidone in adults with acute bipolar mania, which is one of the specified interventions and patient populations.","ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial",https://doi.org/10.1176/appi.ajp.160.4.741,12668364
False," The study population specified in the abstract (patients with moderate to severe Alzheimer's disease) does not match the inclusion criteria (patients with schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, disruptive behavior disorders, or other specified conditions).",efficacy of donepezil on behavioral symptoms in patients with moderate to severe alzheimer's disease,https://doi.org/10.1017/s104161020200858x,12670060
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a specific population of interest, and examines the effectiveness of olanzapine, one of the included interventions.",high-dose olanzapine for treatment-refractory schizophrenia,https://doi.org/10.1097/00002826-200303000-00003,12671523
False," The study population specified in the abstract does not match the inclusion criteria, as it includes patients with dementia of the Alzheimer's type, which is not one of the specified populations.",donepezil as add-on treatment of psychotic symptoms in patients with dementia of the alzheimer's type,https://doi.org/10.1097/00002826-200303000-00008,12671528
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effects of an antipsychotic medication (procyclidine) on prepulse inhibition in patients with schizophrenia.,"effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study",https://doi.org/10.1177/0269881103017001710,12680744
False," The study population does not match the inclusion criteria as it focuses on valproate poisoning in adults and adolescents, whereas the review is focused on the treatment of various psychiatric disorders in different age groups.",valproate overdose: a comparative cohort study of self poisonings,https://doi.org/10.1046/j.1365-2125.2003.01772.x,12680889
False," The abstract does not mention any of the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders) or interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone) that are included in the review.",assessment of treatment response in mania: commentary and new findings,https://doi.org/10.1034/j.1399-5618.2003.00020.x,12680896
False," The study population specified in the abstract is adults with bipolar depression, which does not match the inclusion criteria of adults with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia.","bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options",https://doi.org/10.1034/j.1399-5618.2003.00019.x,12680897
True," The article meets the inclusion criteria as it discusses cognitive function in schizophrenia, specifically the relationship between cognitive deficits and functional outcome, and the effectiveness of atypical antipsychotics in improving cognitive impairments.",cognitive function in schizophrenia,https://doi.org/10.1016/s0193-953x(02)00084-9,12683258
True," The study focuses on the relationship between membrane phospholipid dysregulation and schizophrenia, which aligns with the inclusion criteria of the review.",is schizophrenia a metabolic brain disorder? membrane phospholipid dysregulation and its therapeutic implications,https://doi.org/10.1016/s0193-953x(02)00033-3,12683261
False," The abstract does not mention any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders) that are included in the review.",schizophrenia in late life,https://doi.org/10.1016/s0193-953x(02)00031-x,12683262
True," The study meets the inclusion criteria as it focuses on the pharmacotherapy of schizophrenia, specifically comparing atypical antipsychotics with conventional antipsychotics and placebo, and includes effectiveness outcomes such as symptom response, hospitalization, and quality of life.",the new and evolving pharmacotherapy of schizophrenia,https://doi.org/10.1016/s0193-953x(02)00016-3,12683264
True," The study meets the inclusion criteria as it involves a prospective, open, controlled trial examining the effectiveness of electroconvulsive therapy (ECT) in treatment-resistant schizophrenia (TRS), which is a relevant population for this review.",efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial,https://doi.org/10.1016/s0278-5846(02)00354-8,12691772
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a relevant population for the review, and examines the effects of olanzapine, a medication included in the review.",the influence of olanzapine on immune cells in patients with schizophrenia,https://doi.org/10.1016/s0278-5846(03)00036-8,12691784
True," The study meets the inclusion criteria as it involves adults with a diagnosis of dementia with Lewy bodies, a condition that falls under the category of behavioral and psychological symptoms of dementia, and examines the effectiveness of quetiapine in treating psychotic symptoms and aggressive behavior.",quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with lewy bodies: a case series,https://doi.org/10.1016/s0278-5846(03)00040-x,12691793
True," The study meets all the inclusion criteria as it focuses on the risk of suicide in patients with schizophrenia in placebo-controlled trials, includes randomized controlled trials, and examines the effectiveness and harms of various antipsychotic medications.",suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia,https://doi.org/10.1001/archpsyc.60.4.365,12695313
False," The study is an open, uncontrolled trial, which does not meet the inclusion criteria of being a randomized controlled trial, good quality systematic review, or comparative observational study.",the efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting,https://doi.org/10.1097/01.yic.0000062801.74434.25,12702892
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder, which is a relevant population for this review.",divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder,https://doi.org/10.4088/jcp.v64n0310,12716270
True," The study meets the inclusion criteria as it focuses on the risk of diabetes and cardiovascular disease in patients with schizophrenia taking atypical antipsychotic drugs, which is a relevant topic for the review.",patients on atypical antipsychotic drugs,https://doi.org/10.2337/diacare.26.5.1597,12716824
True," The study meets the inclusion criteria as it involves adolescents (age 13-17 years) with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and compares the efficacy and side effects of three antipsychotic medications (olanzapine, risperidone, and haloperidol).","olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia",https://doi.org/10.1007/s00702-002-0803-7,12721815
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of quetiapine in patients with schizophrenia or schizoaffective disorder, and it includes relevant outcomes such as efficacy, safety, and adherence.","a random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study",https://doi.org/10.1177/070674370304800307,12728743
True," The study meets the inclusion criteria as it involves aripiprazole, a medication included in the review, and examines its safety and tolerability in the treatment of schizophrenia, a condition included in the review.","aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials",https://doi.org/10.1016/s0920-9964(03)00050-1,12729864
True," The study meets the inclusion criteria as it compares the characteristics of patients treated in a randomized trial of antipsychotic medication to a cohort from a large epidemiological study of first episode psychosis, which aligns with the review's focus on patients with first episode psychosis.",are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?,https://doi.org/10.1016/s0920-9964(02)00322-5,12729866
True," The study meets the inclusion criteria as it is a randomized double-blind trial comparing the efficacy and safety of olanzapine and risperidone in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.",olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in australia and new zealand,https://doi.org/10.1016/s0920-9964(02)00226-8,12729882
True," The study meets the inclusion criteria as it is a review of long-term treatment studies in schizoaffective disorder, focusing on the effectiveness and harms of various medications, and it includes studies with a duration of at least 6 months.",long-term treatment of schizoaffective disorder: review and recommendations,https://doi.org/10.1055/s-2003-39045,12734761
False, The study does not examine the effectiveness of an intervention included in the review (trimipramine is not one of the specified interventions).,"antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine",https://doi.org/10.1055/s-2003-39043,12734763
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia and schizoaffective disorders, which are included in the review, and it is a randomized controlled trial, which is also included.","cognitive rehabilitation with patients having persistent, severe psychiatric disabilities.",https://doi.org/10.2975/26.2003.325.331,12739903
False," The abstract does not mention any specific antipsychotic drugs or their effects on patients with schizophrenia, but rather discusses the advantages and disadvantages of placebo-controlled and active-control trials in demonstrating efficacy and safety of antipsychotic drugs.",placebo or active control trials of antipsychotic drugs?,https://doi.org/10.1001/archpsyc.60.5.458,12742866
True," The study meets all the inclusion criteria as it involves a systematic review and meta-analysis of randomized controlled trials comparing new generation antipsychotics with low-potency conventional antipsychotics in various patient populations, including adults, adolescents, and children with schizophrenia, bipolar disorder, major depressive disorder, and other conditions.",new generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis,https://doi.org/10.1016/s0140-6736(03)13306-5,12747876
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing quetiapine with conventional antipsychotics in patients with schizophrenia, examining cognitive and functional outcomes.",the effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings,https://doi.org/10.4088/jcp.v64n0505,12755654
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effectiveness of ziprasidone, and includes randomized controlled trials.",effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia,https://doi.org/10.4088/jcp.v64n0514,12755663
True," The study meets the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, examines the effects of atypical antipsychotics on serum leptin and triglyceride levels, and is a comparative observational study.",serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics,https://doi.org/10.4088/jcp.v64n0516,12755665
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of clozapine, an intervention included in the review.",undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia,https://doi.org/10.4088/jcp.v64n0517,12755666
False," The study population does not match the inclusion criteria as it focuses on adults with vascular dementia, whereas the inclusion criteria specify a range of psychiatric disorders and conditions, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",the early stage of vascular dementia: significance of a complete therapeutic program,https://doi.org/10.1002/gps.844,12766915
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the efficacy of nefazodone in treating antipsychotic-induced extrapyramidal side effects, which is a relevant intervention for the review.",efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double‐blind randomised parallel group placebo‐controlled trial,https://doi.org/10.1002/hup.476,12766931
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the efficacy and safety of a long-acting atypical antipsychotic (risperidone) in patients with schizophrenia.,long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic,https://doi.org/10.1176/appi.ajp.160.6.1125,12777271
True," The study meets all the inclusion criteria as it involves patients with treatment-resistant schizophrenia, examines the effect of drug washout and subsequent treatment with clozapine, and reports on symptom response, which are all relevant to the review's focus on effectiveness outcomes for patients with schizophrenia.",effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia,https://doi.org/10.1176/appi.ajp.160.6.1133,12777272
True," The study meets the inclusion criteria as it involves a naturalistic study of adults with first-episode schizophrenia treated with olanzapine, risperidone, or conventional antipsychotics, and examines effectiveness, safety, and quality of life outcomes.","safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study",https://doi.org/10.1016/s0278-5846(03)00077-0,12787855
False," The study population is children and adolescents with bipolar disorder, which does not match the inclusion criteria of adults (age 18 years and older) and adolescents (age 13-17 years) and children (under 13 years) with bipolar disorder.",combination pharmacotherapy in children and adolescents with bipolar disorder,https://doi.org/10.1016/s0006-3223(03)00067-2,12788243
False," The title and abstract do not mention the specific population of interest (bipolar disorder) as the primary focus, but rather as one of several conditions studied in the STEP-BD program.","rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (step-bd)",https://doi.org/10.1016/s0006-3223(03)00165-3,12788248
False," The study population in the abstract does not match the inclusion criteria, as it only includes adults and adolescents with schizophrenia or schizoaffective disorder, whereas the inclusion criteria specify a broader range of diagnoses, including bipolar disorder, major depressive disorder, and pervasive developmental disorders.","cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications",https://doi.org/10.1093/oxfordjournals.schbul.a006967,12795493
True," The study meets all the inclusion criteria as it focuses on atypical antipsychotic drugs for schizophrenia, includes data from clinical trials and observational studies, and estimates the impacts on various outcomes such as health care costs, symptom days, and employment days.",estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia,https://doi.org/10.1093/oxfordjournals.schbul.a006969,12795495
False," The study population specified in the abstract (patients with schizophrenia) does not match the inclusion criteria (which includes a broader range of psychiatric disorders such as bipolar disorder, major depressive disorder, and pervasive developmental disorders).",a meta-analysis of the efficacy of second-generation antipsychotics,https://doi.org/10.1001/archpsyc.60.6.553,12796218
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effects of atypical antipsychotics versus placebo on cognitive performance in patients with schizophrenia.,comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds,https://doi.org/10.1038/sj.npp.1300216,12799617
False," The abstract does not mention any specific interventions or treatments for tardive syndromes, and the review paper appears to focus on the classification and treatment of schizophrenia and other psychiatric disorders, not tardive syndromes specifically.",classification and treatment of tardive syndromes,https://doi.org/10.1097/01.nrl.0000038585.58012.97,12801428
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, bipolar disorder, and dementia, and examines the effectiveness of intramuscular olanzapine in reducing agitation.",calming versus sedative effects of intramuscular olanzapine in agitated patients,https://doi.org/10.1016/s0735-6757(02)42249-8,12811711
True," The study meets all the inclusion criteria as it involves adults and adolescents with a DSM-IV diagnosis of bipolar disorder, manic or mixed episode, and examines the efficacy of risperidone as an add-on treatment to mood stabilizers.",risperidone in acute and continuation treatment of mania,https://doi.org/10.1097/00004850-200307000-00005,12817157
False," the study population does not match the inclusion criteria as it only includes patients treated with risperidone, whereas the review includes a broader range of antipsychotic medications.",risperidone‐associated diabetes mellitus: a pharmacovigilance study,https://doi.org/10.1592/phco.23.6.735.32178,12820816
True," The study meets the inclusion criteria as it examines the effectiveness of antipsychotic medication (haloperidol vs. olanzapine) in patients with schizophrenia, which is a relevant population for this review.",ethnic differences in use of antipsychotic medication among texas medicaid clients with schizophrenia,https://doi.org/10.4088/jcp.v64n0603,12823076
True," The study meets the inclusion criteria as it focuses on estimating chlorpromazine equivalent doses for newer atypical antipsychotics, which is relevant to the review's scope.",chlorpromazine equivalent doses for the newer atypical antipsychotics,https://doi.org/10.4088/jcp.v64n0607,12823080
False," The study population does not match the inclusion criteria as it only includes adults with dementia-related behavioral disturbances in extended care facilities, whereas the inclusion criteria specify a broader range of populations, including schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",a double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia- related behavioral disturbances in extended care facilities,https://doi.org/10.4088/jcp.v64n0617,12823090
True," The study meets the inclusion criteria as it involves a randomized controlled trial of clozapine combined with lithium in patients with schizophrenia and schizoaffective disorder, and reports on both efficacy and safety outcomes.",tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder,https://doi.org/10.1097/01.jcp.0000084026.22282.5f,12826983
True," The study meets all the inclusion criteria as it is a systematic review and meta-analysis of randomized, controlled trials examining the effectiveness of new-generation antipsychotic drugs for relapse prevention in schizophrenia.","relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials",https://doi.org/10.1176/appi.ajp.160.7.1209,12832232
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the efficacy and safety of olanzapine and divalproex for the treatment of acute mania and maintenance of remission in bipolar disorder.,olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study,https://doi.org/10.1176/appi.ajp.160.7.1263,12832240
False," The title and abstract do not mention any specific age range or diagnosis that matches the inclusion criteria, and the review appears to focus on the general use of clozapine rather than a specific population.",clozapine: a clinical review of adverse effects and management.,https://doi.org/10.1023/a:1023228626309,12839431
False," The study population does not match the inclusion criteria as it only includes patients with delirium, which is not specified in the inclusion criteria.",treatment for delirium with risperidone: results of a prospective open trial with 10 patients,https://doi.org/10.1016/s0163-8343(03)00024-0,12850662
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia and schizoaffective disorder, and it is a randomized controlled trial examining the efficacy, safety, and tolerability of aripiprazole compared to placebo and risperidone.","aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder",https://doi.org/10.1001/archpsyc.60.7.681,12860772
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of quetiapine and haloperidol in treating depressive symptoms in patients with schizophrenia, which is a relevant population for this review.",differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia,https://doi.org/10.1177/0269881103017002010,12870569
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, comparative observational study, or systematic review, but rather a study comparing the bioavailability of two risperidone formulations.",estudio de biodisponibilidad comparativa de dos formulaciones de risperidona existentes en el mercado chileno,https://doi.org/10.4067/s0034-98872003000500008,12879814
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness of olanzapine in reducing craving for alcohol in individuals with a DRD4 VNTR polymorphism.,olanzapine reduces craving for alcohol: a drd4 vntr polymorphism by pharmacotherapy interaction,https://doi.org/10.1038/sj.npp.1300264,12888781
False," The study does not meet the inclusion criteria as it is a trial of vitamin E for tardive dyskinesia, which is not one of the interventions included in the review.",vitamin e treatment for tardive dyskinesia,https://doi.org/10.1001/archpsyc.56.9.836,12892048
True," The study meets the inclusion criteria as it compares clozapine with conventional antipsychotic drugs for treatment-resistant schizophrenia, which is within the scope of the review.",clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination,https://doi.org/10.1192/bjp.183.2.161,12893670
True," The study meets the inclusion criteria as it is a randomized, double-blind comparison of two antipsychotic medications (risperidone and haloperidol) in patients with stabilized DSM-IV schizophrenia, examining symptom outcomes, side effects, and social adjustment over a 2-year period.",maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes,https://doi.org/10.1176/appi.ajp.160.8.1405,12900301
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of clozapine and haloperidol in patients with schizophrenia, and it examines the relationship between brain structure volume and treatment response.","the relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes",https://doi.org/10.1176/appi.ajp.160.8.1421,12900303
True, The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of antipsychotic medications in patients with schizophrenia and other psychiatric conditions.,the national institute of mental health clinical antipsychotic trials of intervention effectiveness (catie) project: schizophrenia trial design and protocol development,https://doi.org/10.1093/oxfordjournals.schbul.a006986,12908658
True," The study meets the inclusion criteria as it examines the cost-effectiveness of new antipsychotic drugs, specifically clozapine and haloperidol, in a clinical trial setting, and discusses the impact of treatment environment and measurement perspectives on the evaluation of cost-effectiveness.",changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs,https://doi.org/10.1093/oxfordjournals.schbul.a006994,12908663
False," The abstract does not mention any specific interventions or populations that match the inclusion criteria, and the focus is on the need for further research rather than presenting results of a study on the effectiveness or harms of a specific intervention.","generating evidence to inform policy and practice: the example of the second generation ""atypical"" antipsychotics",https://doi.org/10.1093/oxfordjournals.schbul.a006980,12908665
True," The study meets all the inclusion criteria as it involves a prospective two-year trial of patients with schizophrenia and schizoaffective disorders, examines predictors of suicidal risk, and includes a comparison of two antipsychotic medications.",predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial,https://doi.org/10.1016/s0006-3223(03)00178-1,12915289
True," The study meets the inclusion criteria as it is a randomized controlled trial examining the effectiveness of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome, which is one of the interventions included in the review.",randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome,https://doi.org/10.1016/s0006-3223(03)00321-4,12915290
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of clozapine treatment in the specified patient populations, but rather explores the relationship between serum antimuscarinic activity and clozapine levels in patients undergoing a clozapine trial.",serum antimuscarinic activity during clozapine treatment,https://doi.org/10.1097/01.jcp.0000085405.08426.73,12920408
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia and bipolar disorder, and examines the effectiveness of olanzapine in treating agitation.",effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation,https://doi.org/10.1097/01.jcp.0000085406.08426.a8,12920409
False," The study population specified in the abstract (adults with acute mania) does not match the inclusion criteria for the review, which includes a broader range of patient populations (schizophrenia, bipolar disorder, major depressive disorder, etc.).",olanzapine versus placebo in acute mania,https://doi.org/10.1097/01.jcp.0000085410.08426.9a,12920413
True," The study meets the inclusion criteria as it involves a randomized controlled trial (double-blind placebo-controlled) examining the effectiveness of a specific medication (donepezil) in patients with schizophrenia, which is a condition included in the review.",augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled bold fmri study,https://doi.org/10.1076/neur.9.3.274.15563,12925933
False," The study population specified in the abstract (inpatients diagnosed with acute mania associated with bipolar I disorder) does not match the inclusion criteria (adults and adolescents with a DSM III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions).","the safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder",https://doi.org/10.4088/jcp.v64n0717,12934987
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the efficacy and safety of aripiprazole in patients with acute bipolar mania, which is one of the interventions included in the review.","a placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania",https://doi.org/10.1176/appi.ajp.160.9.1651,12944341
True," The study meets the inclusion criteria as it involves a population with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of clozapine, which is an intervention included in the review.",an association study of a brain-derived neurotrophic factor val66met polymorphism and clozapine response of schizophrenic patients,https://doi.org/10.1016/s0304-3940(03)00828-0,12951204
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of occupational therapy in patients with treatment-resistant schizophrenia, which is a relevant population for this review.",randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia,https://doi.org/10.1590/s1516-44462003000100006,12975676
False," The study does not investigate the effectiveness or harms of any interventions for schizophrenia or other psychiatric disorders, but rather examines the association between a specific genetic polymorphism and schizophrenia.",schizophrenia is not associated with drd448-base-pair-repeat length or individual alleles: results of a meta-analysis,https://doi.org/10.1016/s0006-3223(03)00180-x,13129658
False," The title and abstract do not match the specified inclusion criteria, which focus on schizophrenia, bipolar disorder, major depressive disorder, dementia, pervasive developmental disorders, and disruptive behavior disorders, whereas the abstract discusses pharmacotherapy for eating disorders.",towards the pharmacotherapy of eating disorders,https://doi.org/10.1517/14656566.4.10.1659,14521477
False," The study population specified in the abstract (Tourette's syndrome patients) does not match the inclusion criteria (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, disruptive behavior disorders, and other specified conditions).",cannabinoids reduce symptoms of tourette’s syndrome,https://doi.org/10.1517/14656566.4.10.1717,14521482
False," The title and abstract do not mention any of the specified disorders (schizophrenia, bipolar disorder, major depressive disorder, pervasive developmental disorders, disruptive behavior disorders, or behavioral and psychological symptoms of dementia) or interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) that are included in the review.",an overview of recent findings of the stanley foundation bipolar network (part i),https://doi.org/10.1034/j.1399-5618.2003.00051.x,14525551
True," The study meets the inclusion criteria as it involves a cohort of patients with bipolar disorder, a condition included in the review, and examines the association between subsyndromal symptoms and comorbidity, function, and treatment received.","subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder",https://doi.org/10.1034/j.1399-5618.2003.00048.x,14525555
False," The study population does not match the inclusion criteria as it specifically includes adults and older adults with Parkinson's disease with dementia, which is not one of the specified populations in the inclusion criteria.","cognitive, psychiatric and motor response to galantamine in parkinson's disease with dementia",https://doi.org/10.1002/gps.949,14533126
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effect of an educational intervention on antipsychotic-induced weight gain in patients with schizophrenia.,the effects of an educational intervention on antipsychotic‐induced weight gain,https://doi.org/10.1111/j.1547-5069.2003.00237.x,14562491
False," The title and abstract do not match the specified inclusion criteria, which focus on schizophrenia, other psychotic disorders, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, but the title and abstract are about the management of acute mania in bipolar disorder.",the management of acute mania,https://doi.org/10.1136/bmj.327.7422.1002,14593007
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of two antipsychotic medications (risperidone and perphenazine) in patients with schizophrenia.,risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations,https://doi.org/10.1111/j.1600-0447.1993.tb03480.x,7508675
True, The study meets all the inclusion criteria as it is a head-to-head randomized controlled trial comparing the effectiveness of risperidone and clozapine in treating schizophrenic patients with acute symptoms.,"risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial",https://doi.org/10.1016/0278-5846(94)90029-9,7509495
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, a randomized controlled trial, and examines the effectiveness and safety of risperidone.",risperidone in the treatment of schizophrenia,https://doi.org/10.1176/ajp.151.6.825,7514366
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effectiveness of risperidone and haloperidol in patients with schizophrenia, and it examines the effects on single symptoms and separate factors of the schizophrenic syndrome.",changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol,https://doi.org/10.1055/s-2007-1014288,7521534
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and it examines the effectiveness of risperidone and clozapine in treating drug-resistant schizophrenia.",risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis,https://doi.org/10.1016/0278-5846(94)90116-3,7531355
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia and schizo-affective disorders, whereas the review includes a broader range of psychiatric conditions such as bipolar disorder, major depressive disorder, and pervasive developmental disorders.",dopamine d2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123i-ibzm single photon emission tomography (spet) study,https://doi.org/10.1007/bf02245098,7536945
False," The title and abstract do not mention any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) that are included in the review.",a risk-benefit assessment of risperidone in schizophrenia,https://doi.org/10.2165/00002018-199512020-00006,7539272
True, The study meets all the inclusion criteria as it is a head-to-head randomized controlled trial comparing the efficacy and safety of risperidone and zuclopenthixol in patients with acute exacerbations of schizophrenia or schizophreniform disorder.,risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trial,https://doi.org/10.1111/j.1600-0447.1995.tb09781.x,7542829
False, The study population specified in the abstract (healthy volunteers) does not match the inclusion criteria (adults and adolescents with various psychiatric disorders).,"safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (hp 873), a potential atypical antipsychotic",https://doi.org/10.1002/j.1552-4604.1995.tb04112.x,7560252
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia, a specific population of interest in the review, and examines the effects of clozapine, an intervention included in the review.",clozapine-induced increase in plasma levels of soluble interleukin-2 receptors,https://doi.org/10.1001/archpsyc.1995.03950220087016,7575109
True," The study meets the inclusion criteria as it involves a randomized controlled trial of a novel antipsychotic medication (ICI 204,636) in patients with schizophrenia, which is a relevant population for the review.","ici 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia",https://doi.org/10.1016/0149-2918(95)80102-2,7585841
True," The study meets all the inclusion criteria as it involves the long-term efficacy and safety of risperidone in patients with chronic schizophrenia, which is one of the included patient populations, and it examines effectiveness outcomes such as symptom response, hospitalization, and quality of life, which are also included in the review.",efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia,https://doi.org/10.1016/0149-2918(95)80105-7,7585844
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effect of risperidone on hostility in patients with schizophrenia, which is a relevant population for this review.",effect of risperidone on hostility in schizophrenia,https://doi.org/10.1097/00004714-199508000-00002,7593706
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia and bipolar disorder, and examines the effectiveness and harms of clozapine compared to haloperidol, a typical antipsychotic.",extrapyramidal side effects of clozapine and haloperidol,https://doi.org/10.1007/bf02245249,7597122
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of clozapine, an intervention included in the review.",clozapine decreases smoking in patients with chronic schizophrenia,https://doi.org/10.1016/0006-3223(94)00365-a,7619979
False," The study does not meet the inclusion criteria as it focuses on the use of placebos in clinical trials for acute schizophrenia, whereas the review paper is looking at a broader range of conditions, including but not limited to schizophrenia.",the use of placebos in clinical trials for acute schizophrenia,https://doi.org/10.1177/070674379504000403,7621385
True," The study meets the inclusion criteria as it involves a clinical study of clozapine treatment in patients with refractory schizophrenia, which is one of the specified interventions and patient populations of interest.",a clinical study of clozapine treatment and predictors of response in a canadian sample,https://doi.org/10.1177/070674379504000409,7621391
False, The study does not meet the inclusion criteria as it focuses on clozapine pharmacokinetics and does not examine the effectiveness or harms of clozapine in the specified patient populations.,can low-dose clozapine pharmacokinetics predict steady-state plasma concentration?,https://doi.org/10.1097/00007691-199504000-00006,7624901
False," The study does not meet the inclusion criteria for the review as it is an open clinical trial, whereas the review only includes randomized controlled trials, good-quality systematic reviews, and comparative observational studies.","seroquel (ici 204 636), a putative “atypical” antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and eeg parameters",https://doi.org/10.1007/bf02246165,7659771
False," The study population specified in the abstract (childhood-onset schizophrenia) does not match the inclusion criteria, which includes adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia, among others.",childhood-onset schizophrenia: an nimh study in progress,https://doi.org/10.1093/schbul/20.4.697,7701277
True," The study meets the inclusion criteria as it involves adolescents with schizophrenia, uses a relevant intervention (clozapine), and reports on pharmacokinetic data and dose-response relationships.",determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography - data from a prospective clinical trial,https://doi.org/10.1055/s-2007-979583,7746841
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (e.g. schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",intra‐ and interethnic variability in reduced haloperidol to haloperidol ratios,https://doi.org/10.1002/j.1552-4604.1995.tb05000.x,7751421
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with DSM-III-R schizophrenia, whereas the inclusion criteria specify a broader range of populations, including older adults, children, and adolescents with various psychiatric disorders.",five factor model of schizophrenia: replication across samples,https://doi.org/10.1016/0920-9964(94)00041-6,7766534
False," The study population is limited to chronic schizophrenic patients, whereas the review includes a broader range of psychiatric disorders.",clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study,https://doi.org/10.1007/bf02246112,7770613
False," The study does not meet the inclusion criteria as it is a case series of only four patients, and the study design does not match the specified inclusion criteria for study types (randomized controlled trials, good quality systematic reviews, and comparative observational studies).",treatment of polydipsia and hyponatremia in psychiatric patients,https://doi.org/10.1016/0893-133x(94)00069-c,7779241
False," The study does not focus on a specific intervention (medication) but rather proposes a new model of schizophrenia, which does not align with the specified inclusion criteria for interventions.",a new five factor model of schizophrenia,https://doi.org/10.1007/bf02354306,7831416
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, including neuroleptic-resistant patients, and examines the effectiveness of clozapine treatment on suicidality.",reduction of suicidality during clozapine treatment of neuroleptic- resistant schizophrenia: impact on risk-benefit assessment,https://doi.org/10.1176/ajp.152.2.183,7840350
True," The study meets the inclusion criteria as it involves adults with a diagnosis of schizophrenia and examines the effects of clozapine, a medication included in the review, on EEG alterations in relation to plasma levels.",eeg alterations in patients treated with clozapine in relation to plasma levels,https://doi.org/10.1007/bf02245449,7846212
False," The title and abstract do not mention any specific medication or intervention from the list of included interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",pharmacologic treatment of schizoaffective disorder,https://doi.org/10.1007/bf02244982,7855214
False," The abstract discusses the use of clozapine in movement disorders, but it does not focus on the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders) or the specified interventions (aripiprazole, asenapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",clozapine therapy for parkinson’s disease and other movement disorders,https://doi.org/10.1093/ajhp/51.24.3047,7856623
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy of clozapine to haloperidol on neuropsychological test performance in patients with schizophrenia, and it examines the long-term effects of clozapine treatment.",the comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance,https://doi.org/10.1016/0006-3223(94)90082-5,7858067
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia, and it examines the effectiveness of two new atypical antipsychotic drugs.","neuroendocrine profile of sdz hdc-912 and opc-4392, two new atypical antipsychotic drugs, in schizophrenic patients",https://doi.org/10.1007/bf02246969,7870880
True," The study meets the inclusion criteria as it involves adults with a diagnosis of Parkinson's disease, a condition not explicitly listed in the inclusion criteria but the study's focus on the treatment of drug-induced delusions and hallucinations in PD aligns with the broader inclusion of other psychotic disorders.",low-dose clozapine in the treatment of levodopa-induced mental disturbances in parkinson's disease,https://doi.org/10.1212/wnl.45.3.432,7898690
False," The study does not meet the inclusion criteria as it does not examine the effectiveness or harms of clozapine in comparison to other interventions, but rather investigates the relationship between a specific genetic variation and response to clozapine.",allelic variation in the d4 dopamine receptor (drd4) gene does not predict response to clozapine,https://doi.org/10.1001/archpsyc.1994.03950110072009,7944879
False," The study does not meet the inclusion criteria as it is about the clinical action of remoxipride, a specific medication, rather than a review of interventions for the specified patient populations.",clinical action of remoxipride,https://doi.org/10.1001/archpsyc.1994.03950120073012,7979877
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in patients with schizophrenia.","effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia",https://doi.org/10.1016/0920-9964(94)90094-9,7986770
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia and bipolar disorder, but does not include children, older adults with dementia, or individuals with pervasive developmental disorders or disruptive behavior disorders.","clozapine-related seizures: experience with 5,629 patients",https://doi.org/10.1212/wnl.44.12.2247,7991106
False," The study does not appear to be a clinical trial or a systematic review, but rather a description of a new assessment instrument for dementia patients.",the neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia,https://doi.org/10.1212/wnl.44.12.2308,7991117
False," The article does not meet the inclusion criteria as it is a case study on teaching clinical psychopharmacology on an inpatient psychiatric research center, rather than a study on the effectiveness of specific medications for various psychiatric conditions.",teaching clinical psychopharmacology on an inpatient psychiatric research center,https://doi.org/10.1002/j.1552-4604.1994.tb03988.x,8021328
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a relevant population for the review, and examines the effects of antipsychotic medications, which are included interventions in the review.",quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia,https://doi.org/10.1016/0920-9964(94)90068-x,8043521
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, examines the effectiveness of clozapine, and reports on outcomes such as clinical responses, relapses, and hospitalizations.",clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns,https://doi.org/10.1176/appi.ps.51.10.1249,8132186
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine, which is an intervention included in the review.",the effect of clozapine on plasma norepinephrine: relationship to clinical efficacy,https://doi.org/10.1038/npp.1994.1,8179790
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with psychotic disorders, whereas the review includes a broader range of patient populations such as children, older adults, and individuals with pervasive developmental disorders.",clozapine and metabolites,https://doi.org/10.1097/00004714-199404000-00006,8195452
False," The abstract does not mention any of the specified patient populations or interventions, and the focus is on cardiovascular disease, which is not relevant to the inclusion criteria.",meaningful interpretation of risk reduction from clinical drug trials,https://doi.org/10.1177/106002809302701018,8251698
True," The study meets the inclusion criteria as it involves a randomized controlled trial (double-blind design) examining the effects of neuroleptic withdrawal in patients with schizophrenia, which is a relevant population for the review.",changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design,https://doi.org/10.1016/0920-9964(93)90061-m,8260445
False," The abstract does not mention any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",clinical response to clozapine in patients with schizophrenia,https://doi.org/10.1001/archpsyc.1994.03950020083008,8297214
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the side effect profiles of risperidone and clozapine in patients with schizophrenia or schizoaffective disorder.,different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study,https://doi.org/10.1176/ajp.153.3.417,8610833
True," The study meets the inclusion criteria as it involves a naturalistic study of clozapine treatment in a state psychiatric hospital population, which is one of the interventions included in the review.",dose related response to clozapine in a state psychiatric hospital population: a naturalistic study,https://doi.org/10.1007/bf02244276,8623040
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the weight gain effects of clozapine and haloperidol in patients with schizophrenia.,differential effect of clozapine on weight: a controlled study,https://doi.org/10.1176/ajp.153.6.817,8633697
True," The study meets all the inclusion criteria as it involves adults and adolescents with a DSM-III-R or DSM-IV diagnosis of schizophrenia, examines the effectiveness of clozapine, and reports on outcomes such as symptom response and adherence.",allelic association between a ser-9-gly polymorphism in the dopamine d3 receptor gene and schizophrenia,https://doi.org/10.1007/bf02346178,8641685
False," The study population is limited to patients in a state hospital, which does not align with the inclusion criteria of adults and adolescents with various psychiatric diagnoses.",clozapine eligibility among state hospital patients,https://doi.org/10.1093/schbul/22.1.15,8685657
False," The study is an open prospective study, which does not meet the inclusion criteria of being a randomized controlled trial, good-quality systematic review, or comparative observational study.",efficacy and safety of risperidone in psychotic patients: an open study,https://doi.org/10.1177/030006059602400309,8725991
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) and instead focuses on famotidine, an H-2 antagonist.",smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report,https://doi.org/10.1097/00002826-199619030-00011,8726548
True," The study meets the inclusion criteria as it involves adults with treatment-resistant schizophrenia, a randomized controlled trial design, and examines the effectiveness of idazoxan as an adjunct to typical neuroleptics.",idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia,https://doi.org/10.1192/bjp.168.5.571,8733795
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, and examines the effectiveness of clozapine, a medication included in the review.",association between clozapine response and allelic variation in the 5-ht2c receptor gene,https://doi.org/10.1097/00001756-199512000-00041,8742444
True," The study meets the inclusion criteria as it focuses on the treatment of negative symptoms of schizophrenia with risperidone, which is one of the interventions included in the review, and it reports on effectiveness outcomes such as symptom response, which is also included in the review.",risperidone in the treatment of negative symptoms of schizophrenia,https://doi.org/10.1097/00004850-199511000-00001,8748041
False," The study focuses on children with mental retardation, which does not match the specified inclusion criteria of adults and adolescents with schizophrenia, bipolar disorder, major depressive disorder, and other specified conditions.",the nisonger cbrf: a child behavior rating form for children with developmental disabilities,https://doi.org/10.1016/0891-4222(95)00039-9,8750075
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the effects of neuroleptic treatment on metabolic changes in the prefrontal lobe using in vivo hydrogen magnetic resonance spectroscopy.",observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy,https://doi.org/10.1097/00004424-199606000-00006,8761867
True," The study meets the inclusion criteria as it involves a randomized controlled trial comparing olanzapine to haloperidol and placebo in the treatment of schizophrenia, which is one of the patient populations of interest.",olanzapine versus placebo and haloperidol,https://doi.org/10.1016/0893-133x(95)00069-p,8822534
True," The study meets the inclusion criteria as it involves patients with schizophrenia, a condition included in the review, and examines the effectiveness of risperidone, an intervention included in the review, with outcomes such as clinical improvement and symptom response, which are also included in the review.","antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients",https://doi.org/10.1097/00004714-199602000-00007,8834417
False," The study population does not match the inclusion criteria as it includes children with autism, which is a pervasive developmental disorder, but the age range of the participants (7-15 years old) is below the specified age range of 13 years and older for children with pervasive developmental disorders.","a controlled trial with org 2766, an acth-(4–9) analog, in 50 relatively able children with autism",https://doi.org/10.1016/0924-977x(95)00049-u,8866933
False, The study does not meet the inclusion criteria as it is focused on a rat brain study and does not involve any of the specified patient populations or interventions.,mechanical lesions of the fimbria fornix in rat brain studied by 1h-magnetic resonance imaging. evidence for long-lasting dynamic alterations in the ipsilateral ventricular system,https://doi.org/10.1016/0924-977x(95)00055-t,8866934
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, but does not include children under 13 years old, older adults with behavioral and psychological symptoms of dementia, or children and adolescents with pervasive developmental disorders and disruptive behavior disorders.",neutropenia and agranulocytosis in patients receiving clozapine in the uk and ireland,https://doi.org/10.1192/bjp.169.4.483,8894200
False," The study does not meet the inclusion criteria for interventions, as it only focuses on clozapine, whereas the review includes a broader range of interventions.",clozapine response and the 5ht2c cys23ser polymorphism,https://doi.org/10.1097/00001756-199609020-00007,8930967
True," The study meets all the inclusion criteria as it is a randomized controlled trial examining the effectiveness of glycine adjuvant therapy for treatment-resistant schizophrenia, which is one of the interventions included in the review.","double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia",https://doi.org/10.1192/bjp.169.5.610,8932891
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia and bipolar disorder, and examines the effectiveness of olanzapine, which is an intervention included in the review.",dopamine d2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a123 ibzm single photon emission tomography (spet) study,https://doi.org/10.1007/bf02245615,8935810
True," The study meets the inclusion criteria as it involves a randomized controlled trial of olanzapine in patients with schizophrenia, which is one of the specified patient populations.","olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial",https://doi.org/10.1007/bf02245617,8935812
False," The study population is limited to neuroleptic-responsive and neuroleptic-resistant schizophrenia patients, which does not align with the inclusion criteria that specify a broader range of psychiatric disorders.",relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine,https://doi.org/10.1007/bf02245619,8935814
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a DSM-III-R diagnosis, and examines the effects of clozapine withdrawal, which is an intervention included in the review.",cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal,https://doi.org/10.1093/schbul/22.4.591,8938913
True," The study meets the inclusion criteria as it involves adults with treatment-refractory schizophrenia, a randomized controlled trial design, and examines the relationship between serum clozapine levels and therapeutic response.",response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges,https://doi.org/10.1176/ajp.153.12.1579,8942454
True," The study meets the inclusion criteria as it involves adolescents (13-17 years) with a DSM-III-R diagnosis of schizophrenia, which is a specified population of interest in the review.",childhood-onset schizophrenia,https://doi.org/10.1001/archpsyc.1996.01830120020005,8956674
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, but does not include children under 13 years with pervasive developmental disorders or disruptive behavior disorders, which are also included in the review.",weight gain induced by clozapine,https://doi.org/10.1016/0924-977x(95)80001-i,8998394
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine.",the effects of clozapine on symptom clusters in treatment-refractory patients,https://doi.org/10.1097/00004714-199702000-00009,9004057
True," The study meets the inclusion criteria as it focuses on the effect of clozapine eligibility criteria on ethnic, gender, and age subgroups of schizophrenic patients, which aligns with the review's focus on interventions for schizophrenia.","clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients",https://doi.org/10.1016/s0278-5846(96)00130-3,9004341
False," The study does not examine the effectiveness or harms of clozapine treatment in the specified patient populations, but rather investigates the predictive value of eosinophilia for neutropenia during clozapine treatment.",predictive value of eosinophilia for neutropenia during clozapine treatment,https://doi.org/10.4088/jcp.v57n1205,9010121
False," The study population does not match the inclusion criteria as it only includes Chinese acutely exacerbated schizophrenic inpatients, whereas the review includes a broader range of patient populations such as adults and adolescents with various psychiatric disorders.",blood levels of reduced halopertool versus clinical efficacy and extrapyramidal side effects of haloperidol,https://doi.org/10.1016/s0278-5846(97)00007-9,9061775
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, and examines the effectiveness of a neural network based on adaptive resonance theory in suggesting treatment compared to expert opinions.",neural network based on adaptive resonance theory as compared to experts in suggesting treatment for schizophrenic and unipolar depressed in-patients,https://doi.org/10.1007/bf02257284,9087885
True," The study meets all the inclusion criteria as it involves a randomized controlled trial with a double-blind, placebo- and haloperidol-controlled design, examining the effectiveness of olanzapine in treating negative symptoms of schizophrenia.","negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine",https://doi.org/10.1176/ajp.154.4.466,9090332
True, The study meets all the inclusion criteria as it is a meta-analysis of randomized controlled trials evaluating the effectiveness and side effects of risperidone in the treatment of schizophrenia.,risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials,https://doi.org/10.1177/026988119701100116,9097896
True," The study meets the inclusion criteria as it involves a randomized controlled trial of an antipsychotic drug (sertindole) in patients with schizophrenia, and it examines the effects of the drug on striatal dopamine D2 receptor binding.",in vivo effects on striatal dopamine d 2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123 i ibzm single photon emission tomography (spet) study,https://doi.org/10.1007/s002130050223,9106913
False," The study is a case series, which is not a randomized controlled trial, comparative observational study, or systematic review, and therefore does not meet the inclusion criteria for study design.",clozapine and associated diabetes mellitus,https://doi.org/10.4088/jcp.v58n0304,9108812
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a specific population of interest, and examines the effectiveness of clozapine, a medication included in the review.",prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine,https://doi.org/10.1016/s0165-1781(96)02993-9,9109179
False," The study population does not match the inclusion criteria as it specifically focuses on patients with Parkinson's disease, which is not mentioned in the inclusion criteria.",benztropine versus clozapine for the treatment of tremor in parkinson's disease,https://doi.org/10.1212/wnl.48.4.1077,9109903
False," The study population does not match the inclusion criteria as it only includes antipsychotic-naive schizophrenic patients, whereas the review includes patients with various psychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients,https://doi.org/10.1016/s0893-133x(96)00195-9,9138438
True," The study meets the inclusion criteria as it involves a prospective study of young paranoid schizophrenic patients, and it examines the relationship between stressful life events, P300 measures, and coping, which are relevant to the review's focus on schizophrenia.","relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, p300 measures, and coping",https://doi.org/10.1176/ajp.154.6.792,9167506
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing olanzapine with haloperidol in the treatment of schizophrenia, which is one of the included patient populations.",olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial,https://doi.org/10.1016/s0924-977x(96)00392-6,9169300
True," The study meets the inclusion criteria as it involves a randomized controlled trial examining the effectiveness and safety of risperidone in patients with schizophrenia, which is a relevant population for this review.",extrapyramidal symptoms in patients treated with risperidone,https://doi.org/10.1097/00004714-199706000-00010,9169965
False," The abstract does not mention any specific interventions (drugs) that are included in the review, and the focus is on the pharmacological treatment of schizophrenia in the 1990s, which does not match the specified interventions included in the review.",drug treatment of schizophrenia in the 1990s,https://doi.org/10.2165/00003495-199753060-00002,9179524
False," The study does not meet the inclusion criteria as it focuses on depression in the community, but does not specifically target any of the specified patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, or disruptive behavior disorders) or interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",depression in the community,https://doi.org/10.1097/00004850-199701000-00003,9179630
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia, a treatment-refractory population, and examines the serotonergic response using a direct-acting postsynaptic serotonergic agonist.",heterogeneity of serotonergic response in treatment-refractory schizophrenia patients,https://doi.org/10.1016/s0006-3223(96)00296-x,9193736
True," The study meets the inclusion criteria as it involves adults with a diagnosis of Parkinson's disease and examines the effectiveness of clozapine in treating dopaminergic psychosis, which is a relevant intervention for the review.",low dose of clozapine in the treatment of dopaminergic psychosis in parkinsonʼs disease,https://doi.org/10.1097/00002826-199706000-00003,9197942
False," The study population consists of adults with acute mania, which does not match the inclusion criteria of patients with schizophrenia, bipolar disorder, major depressive disorder, or behavioral and psychological symptoms of dementia.",response to clozapine in acute mania is more rapid than that of chlorpromazine,https://doi.org/10.1097/00004850-199703000-00006,9219046
False," The study population only includes five patients with chronic schizophrenia, which is a very small sample size and does not meet the inclusion criteria of including adults (age 18 years and older) and adolescents (age 13 to 17 years) with a DSM III-R or DSM-IV diagnosis of schizophrenia.",sertindole hydrochloride: a novel antipsychotic medication with a favorable side effect profile,https://doi.org/10.1097/00007611-199707000-00007,9225889
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of clozapine in the specified patient populations, but rather investigates the hepatotoxicity of clozapine in a mixed population of patients treated with either haloperidol or clozapine.",hepatotoxicity of clozapine,https://doi.org/10.1097/00004714-199708000-00012,9241012
False," The abstract does not mention any specific antipsychotic medication, but rather discusses the general treatment of pregnant women with psychotic illnesses, which does not match the specified interventions included in the review.",antipsychotic use in pregnancy what are the best treatment options?,https://doi.org/10.2165/00002018-199716060-00006,9241494
True," The study meets all the inclusion criteria as it involves a randomized controlled trial comparing clozapine with chlorpromazine in patients with treatment-refractory schizophrenia, and it reports on effectiveness and harms outcomes.",a double-blind comparative study of clozapine versus chlorpromazine on chinese patients with treatment-refractory schizophrenia,https://doi.org/10.1097/00004850-199705000-00001,9248867
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial design, and examines the effectiveness of a medication (methylene blue) as an adjuvant to conventional neuroleptic medications.",methylene blue adjuvant therapy of schizophrenia,https://doi.org/10.1097/00002826-199708000-00008,9260734
False," The study does not meet the inclusion criteria as it is a case-control study examining the association between a specific genetic polymorphism and schizophrenia, but it does not involve any interventions or outcomes related to the treatment of schizophrenia or other included conditions.",lack of allelic association between 102t/c polymorphism of serotonin receptor type 2a gene and schizophrenia in chinese,https://doi.org/10.1097/00041444-199700710-00005,9264136
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness and tolerability of quetiapine compared to haloperidol and placebo.",multiple fixed doses of “seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo,https://doi.org/10.1016/s0006-3223(97)00190-x,9270900
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effects of clozapine, and is a longitudinal investigation.",the influence of clozapine treatment on plasma granulocyte colony-stimulating (g-csf) levels,https://doi.org/10.1055/s-2007-979495,9271776
False," The study does not meet the inclusion criteria as it is not a randomized controlled trial, but rather a case report and a mention of a separate study, and it does not examine the effectiveness of clozapine in the specified patient populations.",clozapine withdrawal: serotonergic or dopaminergic mechanisms?,https://doi.org/10.1001/archpsyc.1997.01830200094013,9283512
True," The study meets the inclusion criteria as it involves treatment-refractory patients with schizophrenia, examines the effectiveness of clozapine, and reports on outcomes such as time to response and dose required for response.",time to clozapine response in a standardized trial,https://doi.org/10.1176/ajp.154.9.1243,9286183
True, The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the efficacy and safety of olanzapine and risperidone in the treatment of schizophrenia and other psychotic disorders.,double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders,https://doi.org/10.1097/00004714-199710000-00010,9315992
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effects of clozapine, and reports on immunomodulatory effects.",in vivo immunomodulatory effects of clozapine in schizophrenia,https://doi.org/10.1016/s0920-9964(97)00057-1,9323354
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine in comparison to a placebo.",clozapine blunts n-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine,https://doi.org/10.1016/s0006-3223(96)00546-x,9325559
False," The study population specified in the abstract (schizophrenic patients) does not match the inclusion criteria, which includes a broader range of patient populations such as bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",d2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients,https://doi.org/10.1001/archpsyc.1997.01830220102017,9337781
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (e.g., aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations.",mortality in current and former users of clozapine,https://doi.org/10.1097/00001648-199710000-00010,9345668
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine, which is an intervention included in the review.",effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol,https://doi.org/10.1016/s0893-133x(97)00073-0,9348547
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing the efficacy of quetiapine and chlorpromazine in the treatment of schizophrenia, which is one of the interventions included in the review.",a comparison of quetiapine and chlorpromazine in the treatment of schizophrenia,https://doi.org/10.1111/j.1600-0447.1997.tb10162.x,9350955
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (e.g. schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",pet evidence that loxapine is an equipotent blocker of 5-ht2and d2receptors: implications for the therapeutics of schizophrenia,https://doi.org/10.1176/ajp.154.11.1525,9356559
False," The study population does not match the inclusion criteria as it only includes patients with rapid-cycling bipolar disorder, whereas the review includes a broader range of psychiatric disorders.",effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder,https://doi.org/10.4088/jcp.v58n0902,9378688
False," The study focuses on the use of clozapine in nonschizophrenic patients, whereas the inclusion criteria specify that the review is for patients with schizophrenia, bipolar disorder, major depressive disorder, and other specific conditions, but not nonschizophrenic patients.",uses of clozapine in nonschizophrenic patients,https://doi.org/10.3109/10673229409017130,9384895
False," The study population is limited to acutely ill schizophrenic patients, which does not meet the inclusion criteria of the review, which includes a broader range of patient populations such as bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients,https://doi.org/10.1097/00004714-199712000-00006,9408810
True," The study meets the inclusion criteria as it is a head-to-head randomized controlled trial comparing olanzapine with haloperidol and placebo in patients with schizophrenia, and it reports on quality of life and efficacy outcomes.",olanzapine versus placebo and haloperidol: quality of life and efficacy results of the north american double-blind trial,https://doi.org/10.1016/s0893-133x(97)00111-5,9408917
True," The study meets the inclusion criteria as it involves patients with treatment-resistant schizophrenia, which is one of the specified patient populations, and examines the effectiveness of intensive treatment packages, including a new antipsychotic (risperidone), which is one of the specified interventions.",a study of enhanced management in patients with treatment-resistant schizophrenia,https://doi.org/10.1177/026988119701100411,9443524
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of risperidone compared to haloperidol.",the effects of risperidone on the five dimensions of schizophrenia derived by factor analysis,https://doi.org/10.4088/jcp.v58n1205,9448657
True," The study meets the inclusion criteria as it focuses on schizophrenia, a condition included in the review, and examines factors influencing relapse in the long-term course of the disease, which is a relevant topic for the review.",factors influencing relapse in the long-term course of schizophrenia,https://doi.org/10.1016/s0920-9964(97)00131-x,9468354
False," The article does not specify that the study population is limited to adults (age 18 years and older) with schizophrenia, as it also includes adolescents (13-17 years) and children (under 13 years) with various other disorders.","the new antipsychotics, and their potential for early intervention in schizophrenia",https://doi.org/10.1016/s0920-9964(97)00115-1,9468355
False," The abstract does not mention any of the specified interventions (e.g. aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (e.g. bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, disruptive behavior disorders) that are included in the review.",altered consciousness states and endogenous psychoses: a common molecular pathway?,https://doi.org/10.1016/s0920-9964(97)00116-3,9468359
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a pharmacokinetic interaction between clozapine and selective serotonin reuptake inhibitors, and is a prospective study.",pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors,https://doi.org/10.1097/00004714-199802000-00002,9472836
False," The study does not meet the inclusion criteria as it is about the development and validation of a clinical scale for assessing bipolar disorder, not about the effectiveness of a specific intervention.",modification of the clinical global impressions (cgi) scale for use in bipolar illness (bp): the cgi-bp,https://doi.org/10.1016/s0165-1781(97)00123-6,9481807
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness or harms of the specified interventions (e.g., aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) in the specified patient populations.",the dopamine d3 receptor (drd3) ser9gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response,https://doi.org/10.1038/sj.mp.4000288,9491816
False, The article does not focus on a specific population of interest (adults with schizophrenia) as the title and abstract suggest a broader scope of populations and disorders.,translating research into practice: the schizophrenia patient outcomes research team (port) treatment recommendations,https://doi.org/10.1093/oxfordjournals.schbul.a033302,9502542
False," The study does not meet the inclusion criteria as it does not focus on the effectiveness of specific interventions (e.g., aripiprazole, asenapine, clozapine, etc.) for schizophrenia or other specified disorders, but rather examines the conformance of current patterns of usual care to treatment recommendations.",patterns of usual care for schizophrenia: initial results from the schizophrenia patient outcomes research team (port) client survey,https://doi.org/10.1093/oxfordjournals.schbul.a033303,9502543
False," The study population does not match the inclusion criteria as it only includes healthy men, not individuals with a DSM-III-R or DSM-IV diagnosis of schizophrenia, bipolar disorder, major depressive disorder, or other specified disorders.",olanzapine: interaction study with imipramine,https://doi.org/10.1002/j.1552-4604.1997.tb04272.x,9505989
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of a novel antipsychotic agent (olanzapine) compared to a conventional antipsychotic (haloperidol) in treating depressive signs and symptoms in schizophrenia.",depressive signs and symptoms in schizophrenia,https://doi.org/10.1001/archpsyc.55.3.250,9510219
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a specific population of interest, and examines the effectiveness of clozapine, one of the included interventions.",the effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms.,https://doi.org/10.1023/a:1022352326334,9511946
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of a medication (sulpiride) in addition to clozapine.",sulpiride augmentation in people with schizophrenia partially responsive to clozapine,https://doi.org/10.1192/bjp.171.6.569,9519099
True," The study meets all the inclusion criteria as it involves a meta-analysis of randomized, double-masked, comparative trials of risperidone and haloperidol in patients with schizophrenia, comparing efficacy and safety outcomes.",risperidone versus haloperidol: i. meta-analysis of efficacy and safety,https://doi.org/10.1016/s0149-2918(98)80034-9,9522104
False," The study population specified in the abstract (patients with chronic schizophrenia) does not match the inclusion criteria (adults and adolescents with schizophrenia, including other psychotic disorders, and other specified conditions).",risperidone versus haloperidol: ii. cost-effectiveness,https://doi.org/10.1016/s0149-2918(98)80046-5,9522115
True, The study meets all the inclusion criteria as it involves a randomized double-blind study comparing the efficacy and safety of risperidone and clozapine in treatment-resistant chronic schizophrenia patients.,risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study,https://doi.org/10.1176/ajp.155.4.499,9545995
True," The study meets the inclusion criteria as it involves a population with schizophrenia, a relevant intervention (antipsychotic drugs), and relevant outcomes (5-HT2A receptor blockade).","binding of antipsychotic drugs to cortical 5-ht2areceptors: a pet study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients",https://doi.org/10.1176/ajp.155.4.505,9545996
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of risperidone, a medication included in the review, in patients with schizophrenia, a condition included in the review, and reports on effectiveness and safety outcomes, which are also included in the review.",therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia,https://doi.org/10.1097/00004714-199804000-00002,9555595
False," The study does not meet the inclusion criteria for interventions, as it compares risperidone with a combination of haloperidol and amitriptyline, which is not one of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome,https://doi.org/10.1097/00004714-199804000-00003,9555596
True," The study meets the inclusion criteria as it involves patients with schizophrenia and/or schizoaffective disorders, a specific population of interest, and examines the effectiveness of clozapine in reducing hospital utilization, which is a relevant outcome.",psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system,https://doi.org/10.4088/jcp.v59n0408,9590670
True," The study meets the inclusion criteria as it involves adults with bipolar disorder, a condition included in the review, and examines the effectiveness of olanzapine, an intervention included in the review.",olanzapine in treatment-resistant bipolar disorder,https://doi.org/10.1016/s0165-0327(98)00002-0,9609675
True, The study meets the inclusion criteria as it is a randomized controlled trial comparing the efficacy of olanzapine with haloperidol and placebo in treating anxious and depressive symptoms in schizophrenia.,"a double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia",https://doi.org/10.1016/s0006-3223(98)00093-6,9611669
True," The study meets the inclusion criteria as it involves a randomized controlled trial of clozapine in patients with schizophrenia, examining its effects on positive and negative symptoms, and includes outcomes such as symptom response, social and occupational functioning, and quality of life.",positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.,https://doi.org/10.1176/ajp.155.6.751,9619146
False," The study population does not match the inclusion criteria as it only includes schizophrenic inpatients, whereas the review includes a broader range of patient populations such as adults and adolescents with various psychiatric disorders.",serum concentrations of clozapine and n -desmethylclozapine are unaffected by the potent cyp3a4 inhibitor itraconazole,https://doi.org/10.1007/s002280050440,9626923
True," The study meets the inclusion criteria as it involves a longitudinal study of clozapine-treated schizophrenic patients, examining the effects of clozapine on in vitro immune parameters, which is a relevant intervention for the review.",effects of clozapine on in vitro immune parameters a longitudinal study in clozapine-treated schizophrenic patients,https://doi.org/10.1016/s0893-133x(98)00006-2,9629565
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, examines the effectiveness of clozapine, and uses a pharmacogenetic approach to investigate the association between serotonin subtype 2 receptor genes and clinical response to clozapine.",serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients,https://doi.org/10.1016/s0893-133x(98)00007-4,9629566
True," The study meets the inclusion criteria as it involves patients with schizophrenia, uses a relevant outcome measure (striatal dopamine D2/D3 receptor availability), and examines the relationship between neuroleptic treatment and negative symptoms.","psychomotor slowing, negative symptoms and dopamine receptor availability—an ibzm spect study in neuroleptic-treated and drug-free schizophrenic patients",https://doi.org/10.1016/s0920-9964(98)00003-6,9633833
False," The study does not meet the inclusion criteria for interventions, as it compares olanzapine with chlorpromazine, which is a conventional antipsychotic, but does not include any of the specified atypical antipsychotics (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone).",olanzapine compared with chlorpromazine in treatment-resistant schizophrenia,https://doi.org/10.1176/ajp.155.7.914,9659857
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a diagnosis included in the review, and examines the effectiveness of olanzapine, an intervention included in the review.",5-ht2and d2receptor occupancy of olanzapine in schizophrenia: a pet investigation,https://doi.org/10.1176/ajp.155.7.921,9659858
False," The study population does not match the inclusion criteria as it only includes adults and adolescents with schizophrenia who commenced clozapine treatment between January 1990 and June 1995, which does not cover the specified age ranges for other psychiatric conditions.",long-term outcome with clozapine,https://doi.org/10.1097/00004850-199803000-00003,9669187
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, and examines the prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared to conventional depot neuroleptics.",prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications,https://doi.org/10.4088/jcp.v59n0604,9671341
True," The study meets all the inclusion criteria as it involves adults with schizophrenia, examines the effectiveness of clozapine, and includes randomized controlled trials.",does participation in psychosocial treatment augment the benefit of clozapine?,https://doi.org/10.1001/archpsyc.55.7.618,9672052
True," The study meets the inclusion criteria as it involves adults with a diagnosis of autistic disorder and other pervasive developmental disorders, and it is a randomized controlled trial examining the effectiveness of risperidone.","a double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders",https://doi.org/10.1001/archpsyc.55.7.633,9672054
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the effects of risperidone and haloperidol on emotion perception in treatment-resistant schizophrenia patients.,risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings,https://doi.org/10.1016/s0920-9964(98)00026-7,9689720
True," The study meets the inclusion criteria as it involves a comparison of quetiapine with usual-care medications in real-world treatment settings for patients with schizophrenia, which aligns with the specified interventions and populations of interest.","medical-claims databases in the design of a health-outcomes comparison of quetiapine (`seroquel'1seroquel is a trademark, the property of zeneca limited.1) and usual-care antipsychotic medication",https://doi.org/10.1016/s0920-9964(98)00040-1,9690334
True," The study meets all the inclusion criteria as it involves long-term treatment of chronic schizophrenia with risperidone, a medication included in the review, and reports on effectiveness outcomes such as symptom response and quality of life.",long-term treatment of chronic schizophrenia with risperidone,https://doi.org/10.1097/00004850-199805000-00001,9690975
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia treated with clozapine and typical neuroleptics, and examines developmental differences between the two groups.",early developmental differences between dsm-iii-r schizophrenics treated with clozapine and typical neuroleptics,https://doi.org/10.1016/s0022-3956(98)00056-9,9694006
True," The study meets the inclusion criteria as it involves a randomized controlled trial of amisulpride in patients with acute exacerbation of schizophrenia, which is a relevant population for the review.","amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol",https://doi.org/10.1111/j.1600-0447.1998.tb10044.x,9696517
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders) specified in the review.",immediate versus delayed visual memory task performance among schizophrenic patients and normal control subjects,https://doi.org/10.1016/s0165-1781(98)00040-7,9704872
True," The study meets all the inclusion criteria as it focuses on the effectiveness of clozapine therapy in reducing the risk of suicide among patients with schizophrenia and schizoaffective disorder, which is a relevant population for the review, and it presents quantitative data on the outcome of interest.",suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder,https://doi.org/10.1176/ps.49.8.1029,9712207
True," The study meets the inclusion criteria as it involves a meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response, which is a relevant topic for the review.",meta-analysis of studies on genetic variation in 5-ht2a receptors and clozapine response,https://doi.org/10.1016/s0920-9964(98)00032-2,9713904
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) and does not examine any of the specified outcomes (mortality, quality of life, functional capacity, hospitalization, emergency department visits, efficacy, adherence, persistence, caregiver burden, etc.).",reversible metabolism of clozapine and clozapine n-oxide in schizophrenic patients,https://doi.org/10.1016/s0278-5846(98)00035-9,9723115
True," The study meets the inclusion criteria as it focuses on the efficacy and tolerability of antipsychotics in adolescents with schizophrenia, which is within the specified age range and diagnosis.","typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms",https://doi.org/10.1177/070674379804300608,9729687
False," The study population does not match the inclusion criteria as it focuses on nursing home patients aged 65 years and over, whereas the review is focused on patients with specific psychiatric and neurological disorders.",constipation as an adverse effect of drug use in nursing home patients: an overestimated risk,https://doi.org/10.1046/j.1365-2125.1998.00777.x,9764967
False," The article does not meet the inclusion criteria as it does not focus on the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders) specified in the review.",update on the management of bipolar illness,https://doi.org/10.4088/jcp.v59n0909,9771823
True," The study meets the inclusion criteria as it involves a randomized clinical trial comparing clozapine and haloperidol in patients with refractory schizophrenia, which is a relevant intervention for the review.",predictors of differential response to clozapine and haloperidol. veterans affairs cooperative study group on clozapine in refractory schizophrenia.,https://doi.org/10.1016/s0006-3223(98)00117-6,9777179
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R diagnosis of schizophrenia, a treatment-refractory population, and examines the effectiveness of olanzapine, which is an intervention included in the review.",olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse,https://doi.org/10.1016/s0920-9964(98)00062-0,9783349
True," The study meets the inclusion criteria as it involves adults with schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine, which is an intervention included in the review.",effects of clozapine on auditory event-related potentials in schizophrenia,https://doi.org/10.1016/s0006-3223(97)00524-6,9798075
True," The study meets the inclusion criteria as it involves a randomized, double-blind comparison of two antipsychotic medications (risperidone and haloperidol) in treatment-resistant schizophrenia patients, and examines outcomes related to reaction time, manual dexterity, and motor learning.","risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients",https://doi.org/10.1016/s0006-3223(98)00088-2,9798076
True," The study meets the inclusion criteria as it involves adults and adolescents with schizophrenia, schizoaffective disorders, and bipolar disorder, and examines the relationship between patient variables and plasma clozapine concentrations to develop a dosing nomogram.",relationship between patient variables and plasma clozapine concentrations: a dosing nomogram,https://doi.org/10.1016/s0006-3223(97)00531-3,9798077
True, The study meets the inclusion criteria as it involves a randomized controlled trial examining the effects of risperidone on central 5-HT responses in patients with schizophrenia.,risperidone is associated with blunting of d-fenfluramine evoked serotonergic responses in schizophrenia,https://doi.org/10.1097/00004850-199809000-00002,9817624
True," The study meets all the inclusion criteria as it involves adults with a DSM-IV diagnosis of schizophrenia, compares the efficacy of two interventions (clozapine and risperidone), and examines effectiveness outcomes such as symptom response, adherence, and persistence.",clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients,https://doi.org/10.4088/jcp.v59n1005,9818633
False," The study population specified in the abstract (patients with behavioral disorders associated with dementia) does not match the inclusion criteria, which include a wide range of psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders, but not specifically behavioral disorders associated with dementia.",efficacy and safety of neuroleptics in behavioral disorders associated with dementia,https://doi.org/10.4088/jcp.v59n1010,9818639
False," The abstract does not mention any specific interventions or populations that match the inclusion criteria, and it appears to be a general overview of the Prescription-Event Monitoring (PEM) system in England, rather than a study on the effectiveness or harms of specific medications for the specified patient populations.",post-marketing studies,https://doi.org/10.2165/00002018-199819050-00002,9825948
True," The study meets the inclusion criteria as it involves a head-to-head comparison of two antipsychotic medications (olanzapine and haloperidol) in the maintenance treatment of schizophrenia and related psychoses, and reports on relapse rates as an effectiveness outcome.",oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses,https://doi.org/10.1192/bjp.172.6.499,9828990
False," The study does not meet the inclusion criteria as it does not focus on the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",nithsdale schizophrenia surveys 17,https://doi.org/10.1192/bjp.172.6.513,9828992
True," The study meets the inclusion criteria as it involves adults with a DSM-III-R or DSM-IV diagnosis of schizophrenia, including recent-onset schizophrenia, and examines the effects of risperidone on P50 suppression.",p50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects.,https://doi.org/10.1037//0021-843x.107.4.691,9830258
True," The study meets the inclusion criteria as it involves patients with schizophrenia, including schizodominant schizoaffective disorder, and examines the relationship between D2 dopamine receptor occupancy and extrapyramidal side effects, which is a relevant outcome for the review.",d2-dopamine receptor occupancy measured by ibzm-spect in relation to extrapyramidal side effects,https://doi.org/10.1055/s-2007-979321,9832346
True," The study meets the inclusion criteria as it involves a randomized controlled trial of a specific antipsychotic medication (d-serine) in patients with schizophrenia, and it reports on clinical efficacy, side effects, and serum levels of amino acids and d-serine.",d-alanine added to antipsychotics for the treatment of schizophrenia,https://doi.org/10.1016/j.biopsych.2005.06.032,9836012
False," The study population does not match the inclusion criteria as it specifically mentions ""medication-resistant psychosis"" and does not include the full range of disorders specified in the inclusion criteria.",london–east anglia randomised controlled trial of cognitive–behavioural therapy for psychosis,https://doi.org/10.1192/bjp.173.1.61,9850205
False," The title and abstract do not match the specified inclusion criteria as the study focuses on the pharmacokinetics of psychotropic drugs and their interactions with the hepatic cytochrome P450 system, but does not specifically address the treatment of the mentioned patient populations or the specified interventions and outcomes.",die bedeutung des hepatischen cytochrom-p450-systems für die psychopharmakologie,https://doi.org/10.1007/s001150050368,9859115
True," The study meets all the inclusion criteria as it involves a randomized controlled trial of ziprasidone in patients with schizophrenia and schizoaffective disorder, and reports on efficacy and safety outcomes.",ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial,https://doi.org/10.1007/s002130050755,9860108
False," The study population does not match the inclusion criteria as it only includes healthy volunteers, not patients with schizophrenia, bipolar disorder, or other specified conditions.",a pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism,https://doi.org/10.1007/s002280050527,9860152
False," The abstract does not mention any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) as being compared or evaluated in the study, it only focuses on risperidone and olanzapine.",risperidone and olanzapine,https://doi.org/10.1097/00004850-199811000-00003,9861575
True," The study meets the inclusion criteria as it involves adolescents (13-17 years) with a DSM-III-R or DSM-IV diagnosis of schizophrenia, including other psychotic disorders, and examines the relationship between serum creatine kinase activity and acute psychosis.",elevated surum creatine kinase activity in adolescent psychiatric inpatients on admission,https://doi.org/10.1097/00004850-199811000-00005,9861577
False," The study does not meet the inclusion criteria for interventions, as it only focuses on switching from clozapine to olanzapine, which is not one of the specified interventions included in the review.",switching from clozapine to olanzapine in treatment-refractory schizophrenia,https://doi.org/10.4088/jcp.v59n1105,9862604
False," The study does not meet the inclusion criteria as it does not involve any of the specified interventions (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) or patient populations (schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychological symptoms of dementia, pervasive developmental disorders, and disruptive behavior disorders).",mechanism of peripheral noradrenergic stimulation by clozapine,https://doi.org/10.1016/s0893-133x(98)00047-5,9885782
True, The study meets the inclusion criteria as it involves a randomized controlled trial comparing the efficacy and safety of olanzapine and haloperidol in patients with first-episode psychosis.,olanzapine versus haloperidol treatment in first-episode psychosis,https://doi.org/10.1176/ajp.156.1.79,9892301
True," The study meets all the inclusion criteria as it involves adults with refractory schizophrenia, a randomized controlled trial, and examines the effectiveness of clozapine compared to haloperidol.",impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia,https://doi.org/10.1176/ajp.156.1.88,9892302
True," The study meets the inclusion criteria as it involves adults with treatment-resistant schizophrenia, a relevant population for the review, and examines the effectiveness of clozapine with and without glycine, which is an intervention included in the review.",effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia,https://doi.org/10.1176/ajp.156.1.145,9892314
True," The study meets all the inclusion criteria as it involves adults and adolescents with schizophrenia, bipolar disorder, and major depressive disorder, and examines the effectiveness and harms of risperidone and olanzapine, which are included interventions.",drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine,https://doi.org/10.1016/s0149-2918(98)80116-1,9916613
False," The study population does not match the inclusion criteria as it specifically includes patients with HIV-associated psychosis, whereas the review focuses on a broader range of psychiatric conditions.",pilot study with clozapine in patients with hiv-associated psychosis and drug-induced parkinsonism,https://doi.org/10.1002/1531-8257(199901)14:1<128::aid-mds1021>3.0.co;2-j,9918355
True," The study meets the inclusion criteria as it focuses on the use of atypical neuroleptics in children and adolescents with various psychiatric disorders, including schizophrenia, bipolar disorder, and pervasive developmental disorders, and examines their efficacy and safety outcomes.",use of atypical neuroleptics in child and adolescent psychiatry,https://doi.org/10.4088/jcp.v59n1202,9921698
True," The study meets the inclusion criteria as it involves a specific intervention (combination treatment with clozapine and paroxetine) in a population with schizophrenia, and it reports on safety and tolerability data, which is a relevant outcome of interest.",combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial,https://doi.org/10.1016/s0924-977x(97)00093-x,9928923
False," The study population does not match the inclusion criteria as it only includes patients with chronic schizophrenia, whereas the review includes patients with various psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and behavioral and psychological symptoms of dementia.",prolactin levels and adverse events in patients treated with risperidone,https://doi.org/10.1097/00004714-199902000-00011,9934944
True," The study meets all the inclusion criteria as it includes adults and adolescents with schizophrenia, bipolar disorder, and other specified conditions, and examines the efficacy and tolerability of new antipsychotics compared to placebo and conventional antipsychotics.","efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. a meta-analysis of randomized controlled trials",https://doi.org/10.1016/s0920-9964(98)00105-4,9988841
False," The study population does not match the inclusion criteria as it includes psychiatric inpatients with various diagnoses, but the review is focused on specific psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and pervasive developmental disorders.",body weight and leptin plasma levels during treatment with antipsychotic drugs,https://doi.org/10.1176/ajp.156.2.312,9989571
